WO2024044755A2 - Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof - Google Patents
Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof Download PDFInfo
- Publication number
- WO2024044755A2 WO2024044755A2 PCT/US2023/072918 US2023072918W WO2024044755A2 WO 2024044755 A2 WO2024044755 A2 WO 2024044755A2 US 2023072918 W US2023072918 W US 2023072918W WO 2024044755 A2 WO2024044755 A2 WO 2024044755A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- alkyl
- hplc
- equiv
- formula
- Prior art date
Links
- 239000012217 radiopharmaceutical Substances 0.000 title description 26
- 229940121896 radiopharmaceutical Drugs 0.000 title description 26
- 230000002799 radiopharmaceutical effect Effects 0.000 title description 25
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 title 1
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 title 1
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 250
- 238000000034 method Methods 0.000 claims abstract description 79
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 55
- 201000011510 cancer Diseases 0.000 claims abstract description 33
- 101710113864 Heat shock protein 90 Proteins 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims abstract 4
- -1 DOTAGA Chemical compound 0.000 claims description 57
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 39
- OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 claims description 31
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 150000001413 amino acids Chemical group 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 15
- 239000002738 chelating agent Substances 0.000 claims description 15
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 13
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 12
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 11
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 9
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 8
- 206010039491 Sarcoma Diseases 0.000 claims description 7
- 235000013922 glutamic acid Nutrition 0.000 claims description 7
- 239000004220 glutamic acid Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 230000008685 targeting Effects 0.000 abstract description 12
- 239000000543 intermediate Substances 0.000 description 184
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 140
- 238000006243 chemical reaction Methods 0.000 description 131
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 107
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 105
- 238000010828 elution Methods 0.000 description 105
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 88
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 84
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 84
- 230000015572 biosynthetic process Effects 0.000 description 68
- 238000003786 synthesis reaction Methods 0.000 description 68
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 58
- 239000007787 solid Substances 0.000 description 56
- 238000003756 stirring Methods 0.000 description 54
- 230000014759 maintenance of location Effects 0.000 description 51
- 239000012043 crude product Substances 0.000 description 50
- 239000000243 solution Substances 0.000 description 49
- 238000005160 1H NMR spectroscopy Methods 0.000 description 44
- 239000002904 solvent Substances 0.000 description 43
- 239000011541 reaction mixture Substances 0.000 description 38
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 38
- 229910052739 hydrogen Inorganic materials 0.000 description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 35
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 35
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 33
- 239000001257 hydrogen Substances 0.000 description 33
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 32
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 31
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- 125000003275 alpha amino acid group Chemical group 0.000 description 25
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 24
- 239000003643 water by type Substances 0.000 description 23
- 239000002202 Polyethylene glycol Substances 0.000 description 21
- 229920001223 polyethylene glycol Polymers 0.000 description 21
- 125000000623 heterocyclic group Chemical group 0.000 description 20
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 19
- 238000004587 chromatography analysis Methods 0.000 description 19
- 238000011282 treatment Methods 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 125000001424 substituent group Chemical group 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 239000002253 acid Chemical group 0.000 description 17
- 239000003921 oil Substances 0.000 description 17
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 16
- 230000002441 reversible effect Effects 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 13
- 238000004007 reversed phase HPLC Methods 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000007821 HATU Substances 0.000 description 12
- 239000007822 coupling agent Substances 0.000 description 12
- 125000001072 heteroaryl group Chemical group 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000010511 deprotection reaction Methods 0.000 description 11
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 10
- 229940126062 Compound A Drugs 0.000 description 10
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 229940125666 actinium-225 Drugs 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 8
- 125000002947 alkylene group Chemical group 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- PSCMQHVBLHHWTO-UHFFFAOYSA-K indium(iii) chloride Chemical compound Cl[In](Cl)Cl PSCMQHVBLHHWTO-UHFFFAOYSA-K 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 229940006114 lithium hydroxide anhydrous Drugs 0.000 description 7
- 125000004043 oxo group Chemical group O=* 0.000 description 7
- 238000000163 radioactive labelling Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 125000005309 thioalkoxy group Chemical group 0.000 description 6
- 150000003573 thiols Chemical class 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 235000009697 arginine Nutrition 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- AYFCVLSUPGCQKD-UHFFFAOYSA-I calcium;trisodium;2-[bis[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate Chemical compound [Na+].[Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)CC([O-])=O AYFCVLSUPGCQKD-UHFFFAOYSA-I 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000007974 sodium acetate buffer Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 4
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 4
- RVUXZXMKYMSWOM-UHFFFAOYSA-N 2-[4,7,10-tris[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound CC(C)(C)OC(=O)CN1CCN(CC(O)=O)CCN(CC(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CC1 RVUXZXMKYMSWOM-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- JVHROZDXPAUZFK-UHFFFAOYSA-N TETA Chemical compound OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CCCN(CC(O)=O)CC1 JVHROZDXPAUZFK-UHFFFAOYSA-N 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 4
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 125000001475 halogen functional group Chemical group 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- AEDROEGYZIARPU-UHFFFAOYSA-K lutetium(iii) chloride Chemical compound Cl[Lu](Cl)Cl AEDROEGYZIARPU-UHFFFAOYSA-K 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- QQINRWTZWGJFDB-YPZZEJLDSA-N actinium-225 Chemical compound [225Ac] QQINRWTZWGJFDB-YPZZEJLDSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 125000004181 carboxyalkyl group Chemical group 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 125000006501 nitrophenyl group Chemical group 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- SUAUFMLRKFUOID-AREMUKBSSA-N (4r)-5-[(2-methylpropan-2-yl)oxy]-5-oxo-4-[4,7,10-tris[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-1,4,7,10-tetrazacyclododec-1-yl]pentanoic acid Chemical compound CC(C)(C)OC(=O)CN1CCN(CC(=O)OC(C)(C)C)CCN([C@H](CCC(O)=O)C(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CC1 SUAUFMLRKFUOID-AREMUKBSSA-N 0.000 description 2
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KIUIVKNVSSLOAG-UHFFFAOYSA-N 1,4,7,10-tetrazacyclotridecan-11-one Chemical compound O=C1CCNCCNCCNCCN1 KIUIVKNVSSLOAG-UHFFFAOYSA-N 0.000 description 2
- BYBCIVKIWIFVFD-UHFFFAOYSA-N 2-[4,10-bis(carboxymethyl)-7-(2,6-dioxooxan-3-yl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound C1CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CCN1C1C(=O)OC(=O)CC1 BYBCIVKIWIFVFD-UHFFFAOYSA-N 0.000 description 2
- FQIHLPGWBOBPSG-UHFFFAOYSA-N 2-[4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetamide Chemical compound NC(=O)CN1CCN(CC(N)=O)CCN(CC(N)=O)CCN(CC(N)=O)CC1 FQIHLPGWBOBPSG-UHFFFAOYSA-N 0.000 description 2
- DFPHZEYJGWLQJE-UHFFFAOYSA-N 2-[4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound NC(=O)CN1CCN(CC(N)=O)CCN(CC(O)=O)CCN(CC(N)=O)CC1 DFPHZEYJGWLQJE-UHFFFAOYSA-N 0.000 description 2
- SYFGLWDDLZQFNI-UHFFFAOYSA-N 2-[4-(carboxymethyl)-1,4,8,11-tetrazabicyclo[6.6.2]hexadecan-11-yl]acetic acid Chemical compound C1CN(CC(O)=O)CCCN2CCN(CC(=O)O)CCCN1CC2 SYFGLWDDLZQFNI-UHFFFAOYSA-N 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 125000003860 C1-C20 alkoxy group Chemical group 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229920001410 Microfiber Polymers 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229920001774 Perfluoroether Polymers 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 229920002536 Scavenger resin Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 2
- RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000001118 alkylidene group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 description 2
- 238000012801 analytical assay Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229960000958 deferoxamine Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
- 229940055742 indium-111 Drugs 0.000 description 2
- 229940060367 inert ingredients Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000003658 microfiber Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 102000027450 oncoproteins Human genes 0.000 description 2
- 108091008819 oncoproteins Proteins 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000005258 radioactive decay Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 230000003007 single stranded DNA break Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000004964 sulfoalkyl group Chemical group 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 1
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 1
- OZAANHMXYLCEGN-BYPYZUCNSA-N (2s)-2-(hydroxyamino)pentanoic acid Chemical compound CCC[C@H](NO)C(O)=O OZAANHMXYLCEGN-BYPYZUCNSA-N 0.000 description 1
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 1
- GOPWHXPXSPIIQZ-FQEVSTJZSA-N (4s)-4-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(O)=O)C(=O)OC(C)(C)C)C3=CC=CC=C3C2=C1 GOPWHXPXSPIIQZ-FQEVSTJZSA-N 0.000 description 1
- ITWBWJFEJCHKSN-UHFFFAOYSA-N 1,4,7-triazonane Chemical compound C1CNCCNCCN1 ITWBWJFEJCHKSN-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- ZYVYEJXMYBUCMN-UHFFFAOYSA-N 1-methoxy-2-methylpropane Chemical compound COCC(C)C ZYVYEJXMYBUCMN-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 1
- UURYASDYOGIDRX-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)ethylazanium;chloride Chemical compound Cl.C1=CC=C2C(COC(=O)NCCN)C3=CC=CC=C3C2=C1 UURYASDYOGIDRX-UHFFFAOYSA-N 0.000 description 1
- OLOMBAYFBVCLCE-UHFFFAOYSA-N 2-[1,2,5,11,14-pentakis(carboxymethyl)-1,2,5,8,11,14-hexazacyclohexadec-8-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)N(CC(O)=O)CCN(CC(O)=O)CC1 OLOMBAYFBVCLCE-UHFFFAOYSA-N 0.000 description 1
- FHQWIXXRHHMBQL-UHFFFAOYSA-N 2-[1,3,10-tris(carboxymethyl)-1,3,6,10-tetrazacyclododec-6-yl]acetic acid Chemical compound OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CN(CC(O)=O)CC1 FHQWIXXRHHMBQL-UHFFFAOYSA-N 0.000 description 1
- IFZOPNLVYZYSMQ-UHFFFAOYSA-N 2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethanamine Chemical compound NCCOCCOCCOCCOCCN IFZOPNLVYZYSMQ-UHFFFAOYSA-N 0.000 description 1
- RAEOEMDZDMCHJA-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O RAEOEMDZDMCHJA-UHFFFAOYSA-N 0.000 description 1
- GTACSIONMHMRPD-UHFFFAOYSA-N 2-[4-[2-(benzenesulfonamido)ethylsulfanyl]-2,6-difluorophenoxy]acetamide Chemical compound C1=C(F)C(OCC(=O)N)=C(F)C=C1SCCNS(=O)(=O)C1=CC=CC=C1 GTACSIONMHMRPD-UHFFFAOYSA-N 0.000 description 1
- RZESKRXOCXWCFX-UHFFFAOYSA-N 2-[bis[2-[carboxymethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetic acid Chemical compound CNC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NC RZESKRXOCXWCFX-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- PVRGRRPCHFTMMD-UHFFFAOYSA-N 3-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid Chemical compound NCCOCCOCCOCCOCCOCCOCCC(O)=O PVRGRRPCHFTMMD-UHFFFAOYSA-N 0.000 description 1
- NLXRBQLQDLAFIM-UHFFFAOYSA-N 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid Chemical compound NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(O)=O NLXRBQLQDLAFIM-UHFFFAOYSA-N 0.000 description 1
- SOUJYUTZZAWCOV-UHFFFAOYSA-N 3-[4,8,11-tris(2-carboxyethyl)-1,4,8,11-tetrazacyclotetradec-1-yl]propanoic acid Chemical compound OC(=O)CCN1CCCN(CCC(O)=O)CCN(CCC(O)=O)CCCN(CCC(O)=O)CC1 SOUJYUTZZAWCOV-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- SFYKWYAIJZEDNG-RGMNGODLSA-N 4-o-tert-butyl 1-o-methyl (2s)-2-aminobutanedioate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC(=O)OC(C)(C)C SFYKWYAIJZEDNG-RGMNGODLSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- JKIPBZRGKFRHKQ-ZETCQYMHSA-N 5-o-tert-butyl 1-o-methyl (2s)-2-aminopentanedioate Chemical compound COC(=O)[C@@H](N)CCC(=O)OC(C)(C)C JKIPBZRGKFRHKQ-ZETCQYMHSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101710130081 Aspergillopepsin-1 Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102100031007 Cytosolic non-specific dipeptidase Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- IQUHNCOJRJBMSU-UHFFFAOYSA-N H3HP-DO3A Chemical compound CC(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 IQUHNCOJRJBMSU-UHFFFAOYSA-N 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- LDCHYBFLHSZQKG-UHFFFAOYSA-N OCCCN1NNCCCCCCCC(CC(O)=O)(CC(O)=O)N1CC(O)=O Chemical compound OCCCN1NNCCCCCCCC(CC(O)=O)(CC(O)=O)N1CC(O)=O LDCHYBFLHSZQKG-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- CYJYKTMBMMYRHR-UHFFFAOYSA-N acetic acid;1,4,7-triazonane Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.C1CNCCNCCN1 CYJYKTMBMMYRHR-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- MNJPPZOECOMFQW-UHFFFAOYSA-N benzyl 3-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]propanoate Chemical compound NCCOCCOCCOCCOCCC(=O)OCC1=CC=CC=C1 MNJPPZOECOMFQW-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 125000005242 carbamoyl alkyl group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000000633 chiral stationary phase gas chromatography Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000007748 combinatorial effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940099217 desferal Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- BJAJDJDODCWPNS-UHFFFAOYSA-N dotp Chemical compound O=C1N2CCOC2=NC2=C1SC=C2 BJAJDJDODCWPNS-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000005658 nuclear physics Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229940124553 radioprotectant Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- VEMKTZHHVJILDY-UHFFFAOYSA-N resmethrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-UHFFFAOYSA-N 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Definitions
- HSP90 EXTRACELLULAR HSP90 (eHSP90)-TARGETED RADIOPHARMACEUTICALS AND USE THEREOF RELATED APPLICATION
- the present application claims priority to U.S. Provisional Application No.63/401,227, filed on August 26, 2022, the entire contents of which are hereby incorporated by reference for all purposes.
- Heat shock protein 90 (HSP90) is a molecular chaperone that regulates protein folding to ensure correct conformation and translocation and to avoid protein aggregation.
- HSP90 client proteins such as epidermal growth factor receptor (EGFR) mutant, cyclin dependent kinase 4 (CDK4), hypoxia-inducible factor (HIF)-1 ⁇ , and matrix metallopeptidase 2 (MMP2).
- EGFR epidermal growth factor receptor
- CDK4 cyclin dependent kinase 4
- HIF hypoxia-inducible factor-1 ⁇
- MMP2 matrix metallopeptidase 2
- HSP90 inhibition has been shown to have a significant direct impact on cell cycle and DNA repair mechanisms, thus offering great promise in the treatment of a wide variety of solid and hematological malignancies.
- early clinical trials have demonstrated that certain HSP90 inhibitors exhibited limited efficacy and various side effects.
- eHSP90 e.g., eHSP90.
- RLT radioligand therapy
- Radioactive decay can cause direct physical damage (such as single or double-stranded DNA breaks) or indirect damage (such as by-stander or crossfire effects) to the biomolecules that constitute a cell.
- Drugs that deliver radionuclides to cancer cells i.e., radiopharmaceuticals, provide a mechanism to generate DNA damage with anti-cancer therapeutic effect.
- the present disclosure provides certain radiopharmaceuticals, specifically, small molecule-based radiopharmaceuticals targeting HSP90- overexpressing tumors and using actinium-225 ( 225 Ac), lutetium-177 ( 177 Lu) or other suitable therapeutic radionuclides to target cancer cells to treat or ameliorate cancers such as lung cancer, sarcoma, pancreatic cancer, breast cancer, or colon cancer.
- the compounds of this disclosure specifically bound to extracellular HSP90 (eHSP90).
- the compounds of this disclosure have the structure of Formula II: O HO O N N HO O Z 1 OH X N N N Y Z 2 n O O OH HO HN N O N N OH (II), wherein each of X, Y, n, Z 1 , and Z 2 is as defined above.
- the compounds of Formula I or Formula II feature that at least one of Z 1 and Z 2 is an amino acid unit.
- the compounds of Formula I or Formula II feature that the amino acid unit is formed from glycine (Gly), aspartic acid (Asp), glutamic acid (Glu), 2,4- diaminobutyric acid (Dab), 2,3-diaminopropionic acid (Dap), lysine (Lys), or arginine (Arg).
- Gly glycine
- Asp aspartic acid
- Glu glutamic acid
- Dab 2,4- diaminobutyric acid
- Dap 2,3-diaminopropionic acid
- lysine Lysine
- Arg arginine
- the compounds of Formula I or Formula II feature that the amino acid unit is formed from glycine (Gly), aspartic acid (Asp), glutamic acid (Glu), 2,4- diaminobutyric acid (Dab), 2,3-diaminopropionic acid (Dap), lysine (Lys), arginine (Arg), or combination thereof.
- the compounds of Formula I or Formula II feature that the amino acid unit comprises an organic moiety formed from Asp.
- the compounds of Formula I or Formula II feature that the amino acid unit is formed from Gly.
- the compounds of Formula I or Formula II feature that the amino acid unit is formed from Glu.
- the compounds of Formula I or Formula II feature that n is 4 or 5. [23] In some embodiments, the compounds of Formula I or Formula II feature that n is 4. [24] In some embodiments, the compounds of Formula I or Formula II feature that n is 5. [25] In some embodiments, the compounds of Formula I or Formula II feature that Y is each independently O, NH, or N(C1-6 alkyl). In some embodiments, the compounds of Formula I or Formula II feature that Y is each independently O. In some embodiments, the compounds of Formula I or Formula II feature that Y is each independently NH. [26] In some embodiments, the compounds of Formula I or Formula II feature that each of Z 1 and Z 2 is absent.
- the amino acid unit is selected from the group consisting of HO O O OH O H N N O H H O N O H N N H , O , HO O , H2N O , HO O O OH O H O O H O H N H N N N N N H N H O H O HN HO O HN H 2 N NH , NH 2 , H 2 N NH and HO O O O H H N N N H O H 2 N O HN H 2 N NH .
- the compounds of Formula I or Formula II are selected from the group consisting of: O HO O N N HO O O OH O O N N N O O N H O O OH HO HN N O N N OH , HO O O N N HO O H O OH (S) N O O N N N O N H O O CO 2 H O OH HO HN N O OH N N , O HO O N N HO O H O OH (S) N O O N N N O N H O O CO 2 H HO HN N O OH N ,
- the compounds of Formula I or Formula II feature that each compound comprises a radionuclide selected from the group consisting of 43 Sc, 44 Sc, 47 Sc, 55 Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 67 Cu, 66 Ga, 67 Ga, 68 Ga, 82 Rb, 86 Y, 87 Y, 89 Zr, 90 Y, 97 Ru, 99 Tc, 99m Tc, 105 Rh, 109 Pd, 111 In, 117m Sn, 133 La, 134 Ce, 149 Pm, 149 Tb, 153 Sm, 152 Tb, 155 Tb, 161 Tb, 166 Ho, 177 Lu, 186 Re, 188 Re, 198 Au, 199 Au, 201
- the radionuclide is selected from the group consisting of 68 Ga, 89 Zr, 90 Y, 111 In, 177 Lu, and 225 Ac. [45] In certain embodiments, the radionuclide is 177 Lu or 225 Ac. [46] In certain embodiments, the radionuclide is 177 Lu. [47] In certain embodiments, the radionuclide is 225 Ac. [48] In another aspect, the present disclosure also covers a pharmaceutical composition comprising one of the compounds set forth above and a pharmaceutically acceptable excipient. [49] Still within the scope of this disclosure is a method of treating cancer, the method comprising administering to a subject in need thereof one of the compounds set forth above or the above-described pharmaceutical composition.
- the method of treating cancer comprises administering to the subject in need thereof a first dose of one of the compounds or the composition described above in an amount effective for radiation treatment planning, followed by administering subsequent doses of one of the compounds or the composition described above in a therapeutically effective amount.
- the cancer is small-cell lung cancer, non-small-cell lung cancer, sarcoma, pancreatic cancer, breast cancer, or colon cancer.
- FIG.1 Tumor growth of HSP90 expressing xenograft tumors in response to treatment with 225Ac-Compound D.
- Radio-labelled targeting molecules are designed to target a protein or receptor (e.g., eHSP90) that is upregulated in a disease state and/or specific to diseased cells (e.g., tumor cells) to deliver a radioactive payload to damage and kill cells of interest.
- Radiopharmaceuticals targeting eHSP90 can be used for treating various cancers including, but not limited to, small-cell lung cancer, non-small-cell lung cancer, sarcoma, pancreatic cancer, breast cancer, and colon cancer.
- alkyl is inclusive of both straight chain and branched chain saturated groups from 1 to 20 carbons (e.g., from 1 to 10 or from 1 to 6), unless otherwise specified.
- Alkyl groups are exemplified by methyl, ethyl, n- and iso-propyl, n-, sec-, iso- and tert-butyl, neopentyl, and the like, and may be optionally substituted with one, two, three, or, in the case of alkyl groups of two carbons or more, four substituents independently selected from the group consisting of: (1) C 1-6 alkoxy; (2) C 1-6 alkylsulfinyl; (3) amino, as defined herein (e.g., unsubstituted amino (i.e., -NH 2 ) or a substituted amino (i.e., -N(R N1 ) 2 , where R N1 is as defined for amino); (4) C 6-10 aryl-C 1-6 alkoxy; (5) azido; (6) halo; (7) (C 2-9 heterocyclyl)oxy; (8) hydroxy, optionally substituted with an O-protecting group; (9)
- each of these groups can be further substituted as described herein.
- the alkylene group of a C1-alkaryl can be further substituted with an oxo group to afford the respective aryloyl substituent.
- alkylene alkylidene
- alk- alk-
- Cx-y alkyl Cx-y alkylene
- Cx-y alkylidene Cx-y alk- represent alkyl or alkylene groups having between x and y carbons.
- Exemplary values for x are 1, 2, 3, 4, 5, and 6, and exemplary values for y are 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or 20 (e.g., C1-6, C1-10, C2-5, C2-8, C2-10, or C2-20 alkyl or alkylene).
- the alkylene can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for an alkyl group.
- alkenyl represents monovalent straight or branched chain groups of, unless otherwise specified, from 2 to 20 carbons (e.g., from 2 to 6 or from 2 to 10 carbons) containing one or more carbon-carbon double bonds and is exemplified by ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, and the like. Alkenyls include both cis and trans isomers.
- Alkenyl groups may be optionally substituted with 1, 2, 3, or 4 substituent groups that are selected, independently, from amino, aryl, cycloalkyl, or heterocyclyl (e.g., heteroaryl), as defined herein, or any of the exemplary alkyl substituent groups described herein.
- alkynyl represents monovalent straight or branched chain groups from 2 to 20 carbon atoms (e.g., from 2 to 4, from 2 to 6, or from 2 to 10 carbons) containing a carbon-carbon triple bond and is exemplified by ethynyl, 1-propynyl, and the like.
- Alkynyl groups may be optionally substituted with 1, 2, 3, or 4 substituent groups that are selected, independently, from aryl, cycloalkyl, or heterocyclyl (e.g., heteroaryl), as defined herein, or any of the exemplary alkyl substituent groups described herein.
- amino represents –N(R N1 ) 2 , wherein each R N1 is, independently, H, OH, NO 2 , N(R N2 ) 2 , SO 2 OR N2 , SO 2 R N2 , SOR N2 , an N-protecting group, alkyl, alkenyl, alkynyl, alkoxy, aryl, alkaryl, cycloalkyl, alkcycloalkyl, carboxyalkyl (e.g., optionally substituted with an O-protecting group, such as optionally substituted arylalkoxycarbonyl groups or any described herein), sulfoalkyl, acyl (e.g., acetyl, trifluoroacetyl, or others described herein), alkoxycarbonylalkyl (e.g., optionally substituted with an O-protecting group, such as optionally substituted arylalkoxycarbonyl groups or any
- Amino groups can be unsubstituted amino (i.e., –NH 2 ) or substituted amino (i.e., –N(R N1 ) 2 ) groups.
- amino is –NH2 or –NHR N1 , wherein R N1 is, independently, OH, NO2, NH2, NR N2 2, SO2OR N2 , SO2R N2 , SOR N2 , alkyl, carboxyalkyl, sulfoalkyl, acyl (e.g., acetyl, trifluoroacetyl, or others described herein), alkoxycarbonylalkyl (e.g., t-butoxycarbonylalkyl) or aryl, and each R N2 can be H, C1-20 alkyl (e.g., C1-6 alkyl), or C6-10 aryl.
- amino acid refers to a molecule having a side chain, an amino group, and an acid group (e.g., a carboxy group of –CO 2 H or a sulfo group of –SO 3 H), wherein the amino acid is attached to the parent molecular group by the side chain, amino group, or acid group (e.g., the side chain).
- the amino acid is attached to the parent molecular group by a carbonyl group, where the side chain or amino group is attached to the carbonyl group.
- Exemplary side chains include an optionally substituted alkyl, aryl, heterocyclyl, alkaryl, alkheterocyclyl, aminoalkyl, carbamoylalkyl, and carboxyalkyl.
- Exemplary amino acids include alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, hydroxynorvaline, isoleucine, leucine, lysine, methionine, norvaline, ornithine, phenylalanine, proline, pyrrolysine, selenocysteine, serine, taurine, threonine, tryptophan, tyrosine, and valine.
- Amino acid groups may be optionally substituted with one, two, three, or, in the case of amino acid groups of two carbons or more, four substituents independently selected from the group consisting of: (1) C1-6 alkoxy; (2) C1-6 alkylsulfinyl; (3) amino, as defined herein (e.g., unsubstituted amino (i.e., -NH2) or a substituted amino (i.e., -N(R N1 )2, where R N1 is as defined for amino); (4) C6-10 aryl-C1-6 alkoxy; (5) azido; (6) halo; (7) (C 2-9 heterocyclyl)oxy; (8) hydroxy; (9) nitro; (10) oxo (e.g., carboxyaldehyde or acyl); (11) C 1-7 spirocyclyl; (12) thioalkoxy; (13) thiol; (14) -CO 2 R A’ , where R A’ is selected from the group consisting
- each of these groups can be further substituted as described herein.
- aryl represents a mono-, bicyclic, or multicyclic carbocyclic ring system having one or two aromatic rings and is exemplified by phenyl, naphthyl, 1,2- dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, anthracenyl, phenanthrenyl, fluorenyl, indanyl, indenyl, and the like, and may be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of: (1) C1-7 acyl (e.g., carboxyaldehyde); (2) C1-20 alkyl (e.g., C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C1-6 alkylsulfinyl-C1-6 alkyl, amino-C1-6 alkyl, azido-C1-6 alkyl
- each of these groups can be further substituted as described herein.
- the alkylene group of a C1-alkaryl or a C1- alkheterocyclyl can be further substituted with an oxo group to afford the respective aryloyl and (heterocyclyl)oyl substituent group.
- acyl represents an a radical of general formula –C(O)R, where R is an alkyl or aryl group. Examples of an “acyl” group include, but are not limited to, – C(O)CH3, –C(O)C2H5, and –C(O)Ph.
- carboxy as used herein, means –CO2H.
- cycloalkyl represents a monovalent saturated or unsaturated non- aromatic cyclic hydrocarbon group from three to eight carbons, unless otherwise specified, and is exemplified by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicycle heptyl, and the like.
- the cycloalkyl group when the cycloalkyl group includes one carbon-carbon double bond or one carbon- carbon triple bond, the cycloalkyl group can be referred to as a “cycloalkenyl” or “cycloalkynyl” group respectively.
- exemplary cycloalkenyl and cycloalkynyl groups include cyclopentenyl, cyclohexenyl, cyclohexynyl, and the like.
- Cycloalkyl groups can be optionally substituted with: (1) C1-7 acyl (e.g., carboxyaldehyde); (2) C1-20 alkyl (e.g., C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C1-6 alkylsulfinyl-C 1-6 alkyl, amino-C 1-6 alkyl, azido-C 1-6 alkyl, (carboxyaldehyde)-C 1-6 alkyl, halo- C 1-6 alkyl (e.g., perfluoroalkyl), hydroxy-C 1-6 alkyl, nitro-C 1-6 alkyl, or C 1-6 thioalkoxy-C 1-6 alkyl); (3) C 1-20 alkoxy (e.g., C 1-6 alkoxy, such as perfluoroalkoxy); (4) C 1-6 alkylsulfinyl; (5) C 6- 10 aryl; (6) amino; (7) C1-6 alk-C6-10
- each of these groups can be further substituted as described herein.
- the alkylene group of a C 1 -alkaryl or a C 1 -alkheterocyclyl can be further substituted with an oxo group to afford the respective aryloyl and (heterocyclyl)oyl substituent group.
- halogen represents a halogen selected from bromine, chlorine, iodine, or fluorine.
- heteroalkyl and “heteroalkylidene,” as used herein, each refer to an alkyl group, as defined herein, in which one or two of the constituent carbon atoms have each been replaced by nitrogen, oxygen, or sulfur.
- the heteroalkyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkyl groups.
- heteroalkenyl and heteroalkynyl refer to alkenyl and alkynyl groups, as defined herein, respectively, in which one or two of the constituent carbon atoms have each been replaced by nitrogen, oxygen, or sulfur.
- heteroalkenyl and heteroalkynyl groups can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkyl groups.
- heteroaryl represents that subset of heterocyclyls, as defined herein, which are aromatic: i.e., they contain 4n+2 pi electrons within the mono- or multicyclic ring system.
- Exemplary unsubstituted heteroaryl groups are of 1 to 12 (e.g., 1 to 11, 1 to 10, 1 to 9, 2 to 12, 2 to 11, 2 to 10, or 2 to 9) carbons.
- the heteroaryl is substituted with 1, 2, 3, or 4 substituents groups as defined for a heterocyclyl group.
- polyethylene glycol represents an alkoxy chain comprised of one or more monomer units, each monomer unit consisting of –OCH 2 CH 2 -.
- Polyethyelene glycol (PEG) is also sometimes referred to as polyethylene oxide (PEO) or polyoxyethylene (POE), and these terms may be considered interchangeable for the purpose of this disclosure.
- a polyethylene glycol may have the structure, -(CH 2 ) s2 (OCH 2 CH 2 ) s1 (CH 2 ) s3 O-, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), and each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10).
- Polyethylene glycol may also be considered to include an amino-polyethylene glycol of - NR N1 (CH2)s2(CH2CH2O)s1(CH2)s3NR N1 -, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each R N1 is, independently, hydrogen or optionally substituted C 1-6 alkyl.
- isomer means any tautomer, stereoisomer, enantiomer, or diastereomer of any compound.
- the compounds can have one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as double-bond isomers (i.e., geometric E/Z isomers) or diastereomers, enantiomers (i.e., (+) or (-)) or cis/trans isomers).
- stereoisomers such as double-bond isomers (i.e., geometric E/Z isomers) or diastereomers, enantiomers (i.e., (+) or (-)) or cis/trans isomers).
- stereoisomers such as double-bond isomers (i.e., geometric E/Z isomers) or diastereomers
- enantiomers i.e., (+) or (-)
- cis/trans isomers i.e., (+) or (-)
- chemical structures depicted herein encompass all of the corresponding stereoisomers, that is, both the stereomerically pure form (e
- Enantiomeric and stereoisomeric mixtures of compounds can typically be resolved into their component enantiomers or stereoisomers by well-known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent.
- Enantiomers and stereoisomers can also be obtained from stereomerically or enantiomerically pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods.
- stereoisomer refers to all possible different isomeric as well as conformational forms which a compound may possess (e.g., a compound of any formula described herein), in particular all possible stereochemically and conformationally isomeric forms, all diastereomers, enantiomers and/or conformers of the basic molecular structure. Some compounds may exist in different tautomeric forms, all of the latter being included within the scope of the present disclosure.
- diastereomer as used herein means stereoisomers that are not mirror images of one another and are non-superimposable on one another.
- enantiomer means each individual optically active form of a compound, having an optical purity or enantiomeric excess (as determined by methods standard in the art) of at least 80% (i.e., at least 90% of one enantiomer and at most 10% of the other enantiomer), preferably at least 90% and more preferably at least 98%.
- optical purity or enantiomeric excess as determined by methods standard in the art
- other terms preferably at least 90% and more preferably at least 98%.
- the term “about” or “approximately” refers to a ⁇ 10% variation from the recited quantitative value (and includes the recited quantitative value itself) unless otherwise indicated or inferred from the context.
- a dose of about 100 kBq/kg indicates a dose range of 100 ⁇ 10% kBq/kg, i.e., from 90 kBq/kg to 110 kBq/kg, inclusive.
- the term “administered in combination,” “combined administration,” or “co- administered” means that two or more agents are administered to a subject at the same time or within an interval such that there may be an overlap of an effect of each agent on the patient. Thus, two or more agents that are administered in combination need not be administered together.
- administering an agent to a subject includes contacting cells of said subject with the agent.
- cancer refers to any cancer caused by the proliferation of malignant neoplastic cells, such as tumors, neoplasms, carcinomas, sarcomas, leukemias, and lymphomas.
- a “solid tumor cancer” is a cancer comprising an abnormal mass of tissue, e.g., sarcomas, carcinomas, and lymphomas.
- a “hematological cancer” or “liquid cancer,” as used interchangeably herein, is a cancer present in a body fluid, e.g., lymphomas and leukemias.
- chelate as used herein, refers to an organic compound or portion thereof that can be bonded to a central metal or radiometal atom at two or more points.
- conjugate refers to a molecule that contains a chelating group or metal complex thereof, a linker group, and which optionally contains a therapeutic moiety or a targeting moiety.
- therapeutic moiety refers to any molecule or any part of a molecule that confers a therapeutic benefit.
- the therapeutic moiety is a protein or polypeptide, e.g., an antibody, an antigen-binding fragment thereof.
- the therapeutic moiety is a small molecule.
- targeting moiety refers to any molecule or any part of a molecule that binds to a given target.
- the targeting moiety is a protein or polypeptide such as an antibody or antigen binding fragment thereof, a nanobody, an affibody, or a consensus sequence from a Fibronectin type III domain. In some embodiments, the targeting moiety is a peptide or a small molecule.
- the term “compound,” is meant to include all stereoisomers, geometric isomers, and tautomers of the structures depicted.
- the compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
- Tautomeric forms result from the swapping of a single bond with an adjacent double bond and the concomitant migration of a proton.
- Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Examples prototropic tautomers include ketone – enol pairs, amide – imidic acid pairs, lactam – lactim pairs, amide – imidic acid pairs, enamine – imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, such as, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4- triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole.
- Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
- substituents of compounds of the present disclosure are disclosed in groups or in ranges. It is specifically intended that the present disclosure include each and every individual sub-combination of the members of such groups and ranges.
- C1-6 alkyl is specifically intended to individually disclose methyl, ethyl, C 3 alkyl, C 4 alkyl, C 5 alkyl, and C 6 alkyl.
- optionally substituted X e.g., optionally substituted alkyl
- X optionally substituted
- alkyl wherein said alkyl is optionally substituted
- the terms “decrease,” “decreased,” “increase,” “increased,” or “reduction,” “reduced,” have meanings relative to a reference level.
- the reference level is a level as determined by the use of said method with a control in an experimental animal model or clinical trial. In some embodiments, the reference level is a level in the same subject before or at the beginning of treatment. In some embodiments, the reference level is the average level in a population not being treated by said method of treatment.
- an “effective amount” of an agent e.g., any of the foregoing compounds or conjugates, as used herein, is that amount sufficient to effect beneficial or desired results, such as clinical results, and, as such, an “effective amount” depends upon the context in which it is being applied.
- composition represents a composition containing a compound described herein formulated with a pharmaceutically acceptable excipient.
- the pharmaceutical composition is manufactured or sold with the approval of a governmental regulatory agency as part of a therapeutic regimen for the treatment of disease in a mammal.
- compositions can be formulated, for example, for oral administration in unit dosage form (e.g., a tablet, capsule, caplet, gelcap, or syrup); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); or in any other formulation described herein.
- Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, radioprotectants, sorbents, suspending or dispersing agents, sweeteners, or waters of hydration.
- excipients include, but are not limited to: ascorbic acid, histidine, phosphate buffer, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearic acid,
- salts of the compounds described here that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, or allergic response.
- Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J. Pharmaceutical Sciences 66:1-19, 1977 and in Pharmaceutical Salts: Properties, Selection, and Use, (Eds. P.H. Stahl and C.G. Wermuth), Wiley-VCH, 2008.
- the salts can be prepared in situ during the final isolation and purification of the compounds described herein or separately by reacting the free base group with a suitable organic acid.
- Compounds may have ionizable groups so as to be capable of preparation as pharmaceutically acceptable salts.
- These salts may be acid addition salts involving inorganic or organic acids or the salts may, in the case of acidic forms of compounds, be prepared from inorganic or organic bases.
- the compounds are prepared or used as pharmaceutically acceptable salts prepared as addition products of pharmaceutically acceptable acids or bases.
- Suitable pharmaceutically acceptable acids and bases are well-known in the art, such as hydrochloric, sulphuric, hydrobromic, acetic, lactic, citric, or tartaric acids for forming acid addition salts, and potassium hydroxide, sodium hydroxide, ammonium hydroxide, caffeine, various amines for forming basic salts.
- Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
- Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine.
- the term “radionuclide,” refers to an atom capable of undergoing radioactive decay (e.g., 3 H, 14 C, 15 N, 18 F, 35 S, 47 Sc, 55 Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 67 Cu, 75 Br, 76 Br , 77 Br , 89 Zr, 86 Y, 87 Y, 90 Y, 97 Ru, 99 Tc, 99m Tc, 105 Rh, 109 Pd, 111 In, 123 I, 124 I, 125 I, 131 I, 149 Pm, 149 Tb, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 198 Au, 199 Au, 203 Pb, 211 At, 212 Pb , 212 Bi, 213 Bi, 223 Ra, 225 Ac, 227 Th, 229Th , 66 Ga, 67 Ga, 68 Ga, 82 Rb, 117m Sn, or 201 T
- radioactive nuclide may also be used to describe a radionuclide.
- Radionuclides may be used as detection agents.
- Exemplary radionuclides used in this disclosure include, but are not limited to, 43 Sc, 44 Sc, 47 Sc, 55 Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 67 Cu, 66 Ga, 67 Ga, 68 Ga, 82 Rb, 86 Y, 87 Y, 89 Zr, 90 Y, 97 Ru, 99 Tc, 99m Tc, 105 Rh, 109 Pd, 111 In, 117m Sn, 133 La, 134 Ce, 149 Pm, 149 Tb, 153 Sm, 152 Tb, 155 Tb, 161 Tb, 166 Ho, 177 Lu, 186 Re, 188 Re, 198 Au, 199 Au, 201 Tl, 203 Pb, 211 At, 212 Pb, 212 Bi, 213 Bi, 223
- beneficial or desired results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions; diminishment of extent of disease, disorder, or condition; stabilized (i.e., not worsening) state of disease, disorder, or condition; preventing spread of disease, disorder, or condition; delay or slowing the progress of the disease, disorder, or condition; amelioration or palliation of the disease, disorder, or condition; and remission (whether partial or total), whether detectable or undetectable.
- “ameliorating” may include, for example, reducing incidence of metastases, reducing tumor volume, reducing tumor vascularization and/or reducing the rate of tumor growth.
- “Palliating” a disease, disorder, or condition means that the extent and/or undesirable clinical manifestations of the disease, disorder, or condition are lessened and/or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment.
- Compounds [97] The disclosure is directed to, in part, compounds that are radiopharmaceuticals. In some embodiments, a disclosed compound is selected from the group consisting of the compounds identified in Table 1. Table 1.
- the chelator can be selected from the group consisting of DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), DOTMA (1R,4R,7R,10R)- ⁇ ⁇ ⁇ ⁇ -tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, DOTAM (1,4,7,10- tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane), DOTPA (1,4,7,10- tetraazacyclododecane-1,4,7,10-tetra propionic acid), DO3AM-acetic acid (2-(4,7,10-tris(2- amino-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid), DOTA-
- the chelator is selected from DOTA, DOTA-GA, NOTA, NODA-GA, NODA-SA, DTPA, TETA, EDTA, TRITA, CDTA, and DFO, which are defined as below:
- DOTA stands for 1,4,7,10-tetrazacyclododecane-1,4,7,10-tetraacetic acid, DOTA-GA, or DOTAGA as used herein, stands for 1,4,7,10-tetraazacyclododececane,1- (glutaric acid)-4,7,10-triacetic acid
- NOTA stands for 1,4,7-triazacyclononanetriacetic acid
- NODA-GA or NODAGA as used herein, stands for 1,4,7-triazacyclononane-N-glutaric acid-N',N"-diacetic acid
- NODA-SA stands for 1,4,7- triazacyclononane -1-succinic acid-4,7-diacetic acid
- DOTA stands
- the chelator is represented by the variable W.
- W is selected from the group consisting of O , O HO O OH OH N N O HO O O N OH N N N N O N N O O O OH , O O OH , and O OH O OH .
- Radionuclides each comprising a radionuclide.
- suitable radionuclides include, but are not limited to, 43 Sc, 44 Sc, 47 Sc, 55 Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 67 Cu, 66 Ga, 67 Ga, 68 Ga, 82 Rb, 86 Y, 87 Y, 89 Zr, 90 Y, 97 Ru, 99 Tc, 99m Tc, 105 Rh, 109 Pd, 111 In, 117m Sn, 133 La, 134 Ce, 149 Pm, 149 Tb, 153 Sm, 152 Tb, 155 Tb, 161 Tb, 166 Ho, 177 Lu, 186 Re, 188 Re, 198 Au, 199 Au, 201 Tl, 203 Pb, 211 At, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 225 Ac, 227 Th, and 229 Th.
- the radionuclide is selected from the group consisting of 64 Cu, 67 Cu, 68 Ga, 90 Y, 111 In, 149 Tb, 153 Sm, 177 Lu, 211 At, 212 Bi, 212 Pb, 213 Bi, 223 Ra, 225 Ac, and 227 Th.
- the radionuclide is 68 Ga, 89 Zr, 90 Y, 111 In, 177 Lu, or 225 Ac.
- the radionuclide is 177 Lu or 225 Ac.
- the radionuclide used herein is a beta-emitting radionuclide such as 177 Lu.
- the radionuclide used herein is an alpha-emitting radionuclide such as 225 Ac.
- the term “amino acid unit” described herein refers to one or more organic moieties each formed from an amino acid (e.g., a natural amino acid or an unnatural amino acid).
- an amino acid unit is formed as shown below: O O H N NH HO 2 2 2 R R a mino acid amino acid unit where R 2 represents an alkyl, cycloalkyl, aryl, or heteroaryl, each of which can be optionally substituted with a suitable substituent described herein (e.g., -C(O)OH, -NH 2 , -NH 3 +, - NH(CNH2 + )NH2); alternatively, R 2 together with the -NH2 group within the amino acid form a heterocycle.
- a suitable substituent described herein e.g., -C(O)OH, -NH 2 , -NH 3 +, - NH(CNH2 + )NH2
- an amino acid unit refers to an organic moiety formed from aspartic acid (Asp), glutamic acid (Glu), 2,4-diaminobutyric acid (Dab), 2,3-diaminopropionic acid (Dap), lysine (Lys), or arginine (Arg), with their structures shown below:
- the compounds of Formula I or Formula II feature that the amino acid unit comprises an organic moiety formed from aspartic acid (Asp), for example, with the OH O N H structure shown as (including its stereoisomers) O .
- the compounds of Formula I or Formula II feature that the amino O H N acid unit is formed from glycine (Gly), for example, with the structure .
- the compounds of Formula I or Formula II feature that the amino acid unit is formed from glutamic acid (Glu), for example, with the structure shown below O H N (including its stereoisomers) HO O .
- an amino acid unit refers to a fragment comprising multiple organic moieties formed from glutamine, glutamic acid, and arginine, with their structures shown below, including all their stereoisomers: HO O HO O HO O O O O O H H H H H H N N N N N N N N H H H H O O O O H H 2 N O HN H N O N 2 H 2 N NH H 2 N NH NH .
- Exemplary linkers include, but are not limited to, the following: O O O H O N O N , , O O N H , H , O O H O N O O O O O N , and H , each of which can be optionally substituted with a suitable substituent described herein.
- a representative exemplary compound is one of the following: O HO O N N HO O H O OH (S) N O O N N N O N H O O CO 2 H O OH HO HN N O N N OH , and O HO O N N HO O H O OH (S) N O O N N N O N H O O C O 2 H HO HN N O OH N N .
- a representative exemplary compound is one of the following: O HO O N N H O HO O 2C O H OH O N N N N O O (S) N H O O O OH HO HN N O N N OH , and
- a representative exemplary compound is one of the following: O OH O H O N O N N O O O N N H O OH HO N N O HO O HO HN N O OH N , and O H O N O N O O O O H O N N O H HO N N O HO O HO HN N O OH N N .
- a representative exemplary compound is one of the following: HO O O N N HO O H H O OH O N N N N O O N O H O O OH HO HN N O OH N N , and HO O O N N HO O H H O OH O N N O N N N O N O H O HO HN N O N OH .
- the compounds of Formula I or Formula II feature that X is absent, n is 0, Z 1 is absent, and Z 2 is an amino acid unit.
- linker of such compounds O H N would be: R2 , wherein R 2 represents an alkyl, cycloalkyl, aryl, or heteroaryl, each of which can be optionally substituted with a suitable substituent described herein; alternatively, R 2 together with the -NH2 group within the amino acid form a heterocycle.
- a representative exemplary compound is one of the following: O O OH H O (S) N N N N O OH C O2 H HO N N O HO O HO HN N O N N OH , and O O H N OH (S) N N N O N CO H HO N 2 HO O O HO HN N O N N OH .
- the compounds of Formula I or Formula II feature that X is absent, n is 0, each of Z 1 and Z 2 is absent.
- a representative exemplary compound is one of the following: O O HO HO O O N N N N N HO HO O OH O OH N N N N N O N O O OH HO HN HO HN N N O O N N N N OH , and OH .
- a therapy e.g., comprising a therapeutic agent
- the subject is a mammal, e.g., a human.
- the subject has cancer or is at risk of developing cancer.
- the subject may have been diagnosed with cancer.
- the cancer may be a primary cancer or a metastatic cancer.
- Subjects may have any stage of cancer, e.g., stage I, stage II, stage III, or stage IV with or without lymph node involvement and with or without metastases.
- Provided compositions may prevent or reduce further growth of the cancer and/or otherwise ameliorate the cancer (e.g., prevent or reduce metastases).
- the subject does not have cancer but has been determined to be at risk of developing cancer, e.g., because of the presence of one or more risk factors such as environmental exposure, presence of one or more genetic mutations or variants, family history, etc.
- the subject has not been diagnosed with cancer.
- the cancer is small-cell lung cancer, non-small-cell lung cancer, sarcoma, pancreatic cancer, breast cancer, or colon cancer.
- Administration and dosage Effective doses [129]
- the present disclosure provides methods of using a compound of Formula I for treating clinical indications expressing HSP90, with the compound administered to a subject (e.g., a human) in an amount therapeutically effective for such treatment.
- a subject e.g., a human
- This disclosure also covers combination therapies in which the amounts of each therapeutic may or may not be, on their own, therapeutically effective.
- therapeutic combinations as disclosed herein are administered to a subject in a manner (e.g., dosing amount and timing) sufficient to cure or at least partially arrest the symptoms of the disorder and its complications.
- an amount adequate to accomplish this purpose is defined as a “therapeutically effective amount,” an amount of a compound sufficient to substantially improve at least one symptom associated with the disease or a medical condition.
- the “therapeutically effective amount” typically varies depending on the therapeutic. For known therapeutic agents, the relevant therapeutically effective amounts may be known to or readily determined by those of skill in the art. [131] For example, in the treatment of cancer, an agent or compound that decreases, prevents, delays, suppresses, or arrests any symptom of the disease or condition would be therapeutically effective.
- a therapeutically effective amount of an agent or compound is not required to cure a disease or condition but will provide a treatment for a disease or condition such that the onset of the disease or condition is delayed, hindered, or prevented, or the disease or condition symptoms are ameliorated, or the term of the disease or condition is changed or, for example, is less severe or recovery is accelerated in an individual.
- a treatment may be therapeutically effective if it causes a cancer to regress or to slow the cancer’s growth.
- the dosage regimen e.g., amounts of each therapeutic, relative timing of therapies, etc.
- that is effective for these uses may depend on the severity of the disease or condition and the weight and general state of the subject.
- the therapeutically effective amount of a particular composition comprising a therapeutic agent applied to mammals can be determined by the person of ordinary skill in the art with consideration of individual differences in age, weight, and the condition of the mammal. Because certain conjugates of the present disclosure exhibit an enhanced ability to target cancer cells and residualize, the dosage of these compounds can be lower than (e.g., less than or equal to about 90%, 75%, 50%, 40%, 30%, 20%, 15%, 12%, 10%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1% of) the equivalent dose of required for a therapeutic effect of the unconjugated agent.
- Radiopharmaceutical or a composition e.g., a pharmaceutical composition comprising a therapeutic agent or a radiopharmaceutical
- Single or multiple administrations of a radiopharmaceutical or a composition can be carried out with dose levels and pattern being selected by the treating physician.
- the dose and administration schedule can be determined and adjusted based on the severity of the disease or condition in the subject, which may be monitored throughout the course of treatment according to the methods commonly practiced by clinicians or those described herein.
- a radiopharmaceutical compound of this disclosure may be administered in combination with another therapeutic agent.
- the first and second therapies may be administered sequentially or concurrently to a subject.
- a first composition comprising a first therapeutic agent and a second composition comprising a second therapeutic agent may be administered sequentially or concurrently to a subject.
- a composition comprising a combination of a first therapeutic agent and a second therapeutic agent may be administered to the subject.
- the radiopharmaceutical is administered in a single dose.
- the radiopharmaceutical is administered more than once, i.e., multiple doses. When the radiopharmaceutical is administered more than once, the dose of each administration may be the same or different.
- compositions are administered for radiation treatment planning or diagnostic purposes.
- compositions may be administered to a subject in a diagnostically effective dose and/or an amount effective to determine the therapeutically effective dose.
- a first dose of disclosed conjugate or a composition (e.g., pharmaceutical composition) thereof is administered in an amount effective for radiation treatment planning, followed administration of a combination therapy including a conjugate as disclosed herein and another therapeutic.
- Pharmaceutical compositions comprising one or more agents can be formulated for use in accordance with disclosed methods and systems in a variety of drug delivery systems.
- compositions may be formulated for parenteral, intranasal, topical, oral, or local administration, such as by a transdermal means, for prophylactic and/or therapeutic treatment.
- compositions can be administered parenterally (e.g., by intravenous, intramuscular, or subcutaneous injection), or by oral ingestion, or by topical application or intraarticular injection at areas affected by the vascular or cancer condition.
- parenterally e.g., by intravenous, intramuscular, or subcutaneous injection
- oral ingestion or by topical application or intraarticular injection at areas affected by the vascular or cancer condition.
- additional routes of administration include intravascular, intra-arterial, intratumor, intraperitoneal, intraventricular, intraepidural, as well as nasal, ophthalmic, intrascleral, intraorbital, rectal, topical, or aerosol inhalation administration.
- sustained release administration by such means as depot injections or erodible implants or components.
- compositions comprising include agents (e.g., compounds as disclosed herein) dissolved or suspended in an acceptable carrier, preferably an aqueous carrier, e.g., water, buffered water, saline, or PBS, among others, e.g., for parenteral administration.
- an acceptable carrier preferably an aqueous carrier, e.g., water, buffered water, saline, or PBS, among others, e.g., for parenteral administration.
- Compositions may contain pharmaceutically acceptable auxiliary substances to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents, or detergents, among others.
- compositions are formulated for oral delivery; for example, compositions may contain inert ingredients such as binders or fillers for the formulation of a unit dosage form, such as a tablet or a capsule.
- compositions are formulated for local administration; for example, compositions may contain inert ingredients such as solvents or emulsifiers for the formulation of a cream, an ointment, a gel, a paste, or an eye drop.
- Compositions may be sterilized, e.g., by conventional sterilization techniques, or sterile filtered.
- Aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
- the pH of the preparations typically will be between 3 and 11, more preferably between 5 and 9 or between 6 and 8, and most preferably between 6 and 7, such as 6 to 6.5.
- compositions in solid form are packaged in multiple single dose units, each containing a fixed amount of the above-mentioned agent or agents, such as in a sealed package of tablets or capsules.
- compositions in solid form are packaged in a container for a flexible quantity, such as in a squeezable tube designed for a topically applicable cream or ointment.
- Radiopharmaceuticals Comprising Compounds of Formula I
- Compounds of Formula I comprise conjugates targeting HSP90, which can be radiolabeled with a radionuclide such as Indium-111 ( 111 In), Lutetium-177 ( 177 Lu), or Actinium- 225 ( 225 Ac) to form radionuclide-chelated radiopharmaceuticals.
- a radionuclide such as Indium-111 ( 111 In), Lutetium-177 ( 177 Lu), or Actinium- 225 ( 225 Ac) to form radionuclide-chelated radiopharmaceuticals.
- the synthesis of compounds of Formula I, or their radionuclide-chelated radiopharmaceuticals can be referred to WO 2020/205948. Below are the synthetic schemes or protocols that can be followed to synthesize the corresponding compounds.
- Actinium-225 ( 225 Ac) was supplied by the U.S. Department of Energy Isotope Program in the Office of Science for Nuclear Physics. Lutetium-177 ( 177 Lu) was received from ITG Isotope Technologies Garching GmbH. Indium-111 ( 111 In) was supplied from BWXT. [149] RadioTLC was performed with Bioscan AR-2000 Imaging Scanner, carried out on iTLC- SG glass microfiber chromatography paper (Agilent Technologies, SGI0001) plates or iTLC-SA glass microfiber chromatography paper (Agilent Technologies, A120B12) plates.
- Radioactive HPLC was performed using a Waters system comprised of a Waters 1525 Binary HPLC pump, a Waters 2489 UV/Visible Detector (monitoring at 254 and 214 nm), and a Bioscan Flow Count radiodetector (FC-3300) and a reverse phase (C18) column.
- a Waters system comprised of a Waters 1525 Binary HPLC pump, a Waters 2489 UV/Visible Detector (monitoring at 254 and 214 nm), and a Bioscan Flow Count radiodetector (FC-3300) and a reverse phase (C18) column.
- a Waters Acquity UPLC system comprised of a Waters Acquity Binary Solvent Manager, a Waters Acquity Sample Manager, a Waters Acquity Column Manager (column temperature 30 °C), a Water Acquity Photodiode Array Detector (monitoring 254 nm and 214 nm), a Bioscan Flow Count radiodetector (FC-3300), and a reverse phase (C18) column.
- a Waters Acquity UPLC system comprised of a Waters Acquity Binary Solvent Manager, a Waters Acquity Sample Manager, a Waters Acquity Column Manager (column temperature 30 °C), a Water Acquity Photodiode Array Detector (monitoring 254 nm and 214 nm), a Bioscan Flow Count radiodetector (FC-3300), and a reverse phase (C18) column.
- Analytical HPLC-MS was performed using a Waters Acquity HPLC-MS system comprised of a Waters Acquity Binary Solvent Manager, a Waters Acquity Sample Manager, a Waters Acquity Column Manager (column temperature 30 °C), a Waters Acquity Photodiode Array Detector (monitoring at 254 nm and 214 nm), a Waters Acquity TQD with electrospray ionization and a Waters Acquity BEH C18, 2.1 x 50 mm (1.7 ⁇ m) column.
- a Waters Acquity HPLC-MS system comprised of a Waters Acquity Binary Solvent Manager, a Waters Acquity Sample Manager, a Waters Acquity Column Manager (column temperature 30 °C), a Waters Acquity Photodiode Array Detector (monitoring at 254 nm and 214 nm), a Waters Acquity TQD with electrospray
- Preparative HPLC was performed using a Waters HPLC system comprised of a Waters 1525 Binary HPLC pump, a Waters 2489 UV/Visible Detector (monitoring at 254 nm and 214 nm) and a Waters XBridge Prep C1819 x 100 mm (5 ⁇ m) column.
- the reaction was monitored by HPLC-MS and after 3h ⁇ 29% conversion to product was found with the remainder being DOTAGA(tBu)4 by HPLC-MS.
- the reaction was worked up by concentration under vacuum and then resubjected to the reaction conditions by adding the following reagents: anhydrous THF (4.6 mL) and HBTU (803 mg, 2.12 mmol, 3 equiv.), at which point the reaction was stirred for 5 minutes before adding DIPEA (0.62 mL) and stirring over the weekend at RT (22.5 °C). After 88 h,the reaction had gone to completion and was worked up by concentration under vacuum.
- Step 2 Synthesis of (R)-2,2-Dimethyl-4,8-dioxo-5-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)- 1,4,7,10-tetraazacyclododecan-1-yl)-3,12,15,18,21-pentaoxa-9-azatetracosan-24-oic acid (Intermediate 1 - B) To a solution of Intermediate 1 - A (396 mg, 0.30 mmol, 1 equiv.) in anhydrous MeOH (4 mL) in a 20 mL vial was added a stir bar and Pd/C, 10% Pd basis (32 mg, 0.03 mmol, 0.1 equiv.).
- reaction mixture was degassed and subjected to H2 atmosphere via a balloon (3X).
- the reaction was then left to stir at RT (22 deg °C) and monitored by HPLC-MS.
- RT 22 deg °C
- HPLC-MS HPLC-MS.
- the reaction was filtered through an Acrodisc One (0.2 ⁇ m PTFE) syringe filter into a 20 mL scintillation vial.
- the reaction vial was then rinsed with MeOH (4 mL), and this was also filtered into the scintillation vial.
- the crude reaction was then concentrated under vacuum to afford 387 mg of a clear film.
- the crude product was purified by reverse phase-C18 column chromatography to afford Intermediate 1 - B (237 mg, 66%, purity: 99%) as a clear film, TFA salt.
- Step 3 Synthesis of tri-tert-Butyl 2,2',2''-(10-(24-(4-(4-(3-(2,4-Dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,2-dimethyl-4,8,24-trioxo- 3,12,15,18,21-pentaoxa-9-azatetracosan-5-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)(R)- triacetate (Intermediate 1 - D) To a 20 mL vial was added Intermediate 1 - B (14 mg, 15 ⁇ mol, 1 equiv.) followed by 1 anhydrous DMF (1 mL) and stir bar.
- the vessel was then loaded with HBTU (5.6 mg, 15 ⁇ mol, 1 equiv.) and lastly DIPEA (12.4 ⁇ L, 71 ⁇ mol, 5 equiv.) and stirred at RT (22 °C) for 5 min.
- a solution of Intermediate 1 - C (8 mg, 1 equiv.) in anhydrous DMF (1 mL) was then added, and an additional 1 mL of anhydrous DMF was used to rinse the vial containing the Intermediate and added to the reaction vessel.
- the resulting solution was stirred at RT (22 °C) and monitored by HPLC-MS. After 1 h the reaction was worked up by concentration under vacuum.
- Step 4 Synthesis of (R)-2,2',2''-(10-(21-Carboxy-1-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)- 5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-1,18-dioxo-5,8,11,14-tetraoxa- 2,17-diazahenicosan-21-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound A) To a 20 mL vial was added Intermediate 1 - D (10.4 mg, 6.4 ⁇ mol, 1 equiv.) and a stir bar, followed by 2 mL of TFA/TIPS/H2O (95:2.5:2.5 v/v/v).
- the reaction mixture was stirred RT (22.5 °C) and monitored by HPLC-MS. After 70 min ⁇ 80% starting material was remaining, so the reaction was dosed with HBTU (34 mg, 0.09 mmol, 1 equiv.) and stirred for 10 min at RT. The reaction mixture was then transferred to a second vial containing Amino-PEG6-acid (64 mg, 0.17 mmol, 2 equiv.) in anhydrous DMF (1 mL, limited solubility) and stirred at RT. The reaction was monitored by HPLC-MS and worked up after 64 hours by concentration under vacuum to afford a clear oil.
- Step 2 Synthesis of tri-tert-Butyl 2,2',2''-(10-(24-(4-(4-(3-(2,4-bis(benzyloxy)-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,24-dioxo- 6,9,12,15,18,21-hexaoxa-3-azatetracosyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (Intermediate 2 - C) To a solution of Intermediate 2 - A (30 mg, 26 ⁇ mol, 1 equiv.) in MeCN (2 mL) was added HBTU (12 mg, 32 ⁇ mol, 1.2 equiv.), and DIPEA (18 ⁇ L, 0.11 mmol, 4 equiv.).
- Step 3 Synthesis of tri-tert-Butyl 2,2',2''-(10-(24-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,24-dioxo-6,9,12,15,18,21- hexaoxa-3-azatetracosyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (Intermediate 2 - D) To a solution of Intermediate 2 - C (28.3 mg, 16.1 ⁇ mol, 1 equiv.) in MeOH (2.5 mL) in a microwave vial was added a stir bar and Pd/C, 10% Pd basis (7 mg, 6 ⁇ mol 0.4 equiv.).
- the reaction mixture was degassed and subjected to H 2 atmosphere via a balloon (3X).
- the reaction was then left to stir at RT (23 °C) and monitored by HPLC-MS.
- the reaction was filtered through an Acrodisc PSF syringe filter into a 20 mL scintillation vial.
- the reaction vial was rinsed with MeOH (2 x1.5 mL), and this was also filtered into the scintillation vial.
- the crude reaction was then concentrated crude under vacuum to afford a 23 mg of a yellow film.
- Step 4 Synthesis of 2,2',2''-(10-(24-(4-(4-(3-(2,4-Dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,24-dioxo-6,9,12,15,18,21- hexaoxa-3-azatetracosyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound B) To a 20 mL vial was added Intermediate 2 - D (18.0 mg, 11.4 ⁇ mol, 1 equiv.), and a stir bar followed by 2 mL of TFA/TIPS/H2O (95:2.5:2.5 v/v/v).
- Example 3 Synthesis of 2,2',2''-(10-(42-(4-(4-(3-(2,4-Dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,42-dioxo- 6,9,12,15,18,21,24,27,30,33,36,39-dodecaoxa-3-azadotetracontyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound C) CO 2 t Bu i) DSC, pyridine, MeCN CO 2 t Bu ii) HBTU, DMF C O t CO t N N 2 Bu N N 2 Bu HO 2 C O O O O O NH 2 O HO 2 C N N 9 HO2C O O N N O O O
- the reaction mixture was stirred at RT (22.5 °C) and monitored by HPLC-MS. After 70 min, ⁇ 80% starting material remained, so the reaction was dosed with HBTU (34 mg, 0.09 mmol, 1 equiv.) and stirred for 10 min at RT. The reaction mixture was then transferred to a second vial containing Amino-PEG12-acid (81 mg, 0.13 mmol, 1.5 equiv.) in anhydrous DMF (1 mL, limited solubility) and stirred at RT. The reaction was monitored by HPLC-MS and worked up after 64 hours by concentration under vacuum to afford a clear oil.
- Step 2 Synthesis of tri-tert-Butyl 2,2',2''-(10-(42-(4-(4-(3-(2,4-bis(benzyloxy)-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,42-dioxo- 6,9,12,15,18,21,24,27,30,33,36,39-dodecaoxa-3-azadotetracontyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetate (Intermediate 3 - B) To a solution of Intermediate 3 - A (49 mg, 35 ⁇ mol, 1 equiv.) in MeCN (2 mL) was added HBTU (14 mg, 46 ⁇ mol, 1.3 equiv.), DIPEA (24 ⁇
- Step 3 Synthesis of tri-tert-Butyl 2,2',2''-(10-(42-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,42-dioxo- 6,9,12,15,18,21,24,27,30,33,36,39-dodecaoxa-3-azadotetracontyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetate (Intermediate 3 - C) To a solution of Intermediate 3 - B (33 mg, 0.02 mmol, 1 equiv.) in MeOH (2.5 mL) in a microwave vial was added a stir bar and Pd/C, 10% Pd basis (7 mg, 6 ⁇ mol 0.4
- the reaction mixture was degassed and subjected to H2 atmosphere via a balloon (3X).
- the reaction was then left to stir at RT (23 °C) and monitored by HPLC-MS.
- the reaction was filtered through an Acrodisc PSF syringe filter into a 20 mL scintillation vial.
- the reaction vial was rinsed with MeOH (2 x1.5 mL), and this was also filtered into the scintillation vial.
- the crude reaction was then concentrated under vacuum to afford 30 mg of a pale-yellow film.
- Step 4 Synthesis of 2,2',2''-(10-(42-(4-(4-(3-(2,4-Dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,42-dioxo- 6,9,12,15,18,21,24,27,30,33,36,39-dodecaoxa-3-azadotetracontyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound C) To a 20 mL vial was added Intermediate 3 - C (18.0 mg, 9.8 ⁇ mol, 1 equiv.) and a stir bar, followed by 2 mL of TFA/TIPS/H 2 O (95:2.5:2.5 v/v/v).
- the resulting clear solution was placed in a 37 °C oil bath and the reaction was monitored by HPLC-MS. After 2.5 h the reaction appeared complete and was worked up by transferring to a 50 mL Falcon tube. The reaction vial was washed with TFA (2x0.5 mL), and this was also added to the Falcon tube. The Falcon tube was cooled in an ice bath and thenEt2O (pre-chilled in the ice bath) was added up to the 45 mL mark. After 5 min in the ice bath the flask was centrifuged (5 min, 4 ⁇ C, 3700 rpm) to afford an off-white pellet.
- the Et2O layer was decanted into a round bottomed flask, and the pellet was dissolved in ACN/H2O (2 mL, 1:1 v/v) and transferred to a tared 20 mL scintillation vial.
- the Falcon tube was rinsed with additional ACN/H 2 O (2x2 mL, 1:1 v/v), which was added to the scintillation vial and concentrated under vacuum to afford 9 mg of crude product as a clear film.
- the crude product was purified by reverse phase-C18 column chromatography to afford Compound C (6.6 mg, 40%, purity: 97%) as a white solid, TFA salt.
- Step 2 Synthesis of tri-tert-Butyl 2,2',2''-(10-(1-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-24,24-dimethyl-1,18,22-trioxo- 5,8,11,14,23-pentaoxa-2,17-diazapentacosan-21-yl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)(R)-triacetate (Intermediate 4 - B) To a solution of Intermediate 4 – A (50 mg, 41 ⁇ mol, 1 equiv) in anhydrous THF (1 mL) and stir bar was added DIPEA (28.7 ⁇ L, 164 ⁇ mol, 4 equiv) and
- Step 3 Synthesis of (R)-2,2',2''-(10-(21-Carboxy-1-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)- 5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-1,18-dioxo-5,8,11,14-tetraoxa- 2,17-diazahenicosan-21-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound D) To a 20 mL vial was added Intermediate 4 - B (16.2 mg, 9.7 ⁇ mol, 1 equiv), stir bar followed by 2 mL of TFA/TIPS/H 2 O (95:2.5:2.5 v/v/v).
- Step 2 Synthesis of 23-(tert-Butyl) 1-methyl (R)-14,19-dioxo-22-(4,7,10-tris(2-(tert-butoxy)-2- oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)-4,7,10-trioxa-13,15,18-triazatricosanedioate (Intermediate 5-B) To a solution of tri-tert-butyl 2,2',2''-(10-(5-((2-aminoethyl)amino)-1-(tert-butoxy)-1,5- dioxopentan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)(R)-triacetate (Intermediate 5-A) (50 mg, 0.07 mmol, 1 equiv.) in anhydrous THF (3 mL) and stir bar was
- Step 3 Synthesis of (R)-2,2-Dimethyl-4,8,13-trioxo-5-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)- 1,4,7,10-tetraazacyclododecan-1-yl)-3,17,20,23-tetraoxa-9,12,14-triazahexacosan-26-oic acid (Intermediate 5-C) To a flask containing Intermediate 5-B (32 mg, 0.03 mmol, 1 equiv.) was added THF (2 mL) and water (1 mL) and placed in an ice bath and stirred for 10 min.
- Step 4 Synthesis of tri-tert-Butyl 2,2',2''-(10-(26-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,2-dimethyl-4,8,13,26-tetraoxo- 3,17,20,23-tetraoxa-9,12,14-triazahexacosan-5-yl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)(R)-triacetate (Intermediate 5-D) To a 20 mL scintillation vial with a stir bar was added Intermediate 5-C, (19.9 mg, 0.02 mmol, 1 equiv.) and DMF (2 mL).
- Step 5 (R)-2,2',2''-(10-(22-Carboxy-1-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-1,14,19-trioxo-4,7,10-trioxa- 13,15,18-triazadocosan-22-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound E) To a 20 mL scintillation vial with a stir bar was added Intermediate 5-D (37 mg, 0.03 mmol) and 4.5 mL of deprotection cocktail TFA:TIPS:H2O - 95:2.5:2.5 at RT.
- the reaction mixture was cooled to 0 °C and DIPEA (650 ⁇ L, 18.7 mg, 0.14 mmol, 3 equiv.), followed by HBTU, (719 mg, 0.04 mmol, 1.5 equiv.) was added and stirred for 5 min at 0 °C.
- the solution was brought to RT and stirred for 15 min and then 4-(tert-butyl) 1-methyl L-aspartate hydrochloride (300 mg, 0.04 mmol, 1 equiv.) was added as solid.
- the reaction was stirred at RT and was monitored by HPLC-MS.
- Step 2 Synthesis of (S)-4-(tert-Butoxy)-2-((R)-5-(tert-butoxy)-5-oxo-4-(4,7,10-tris(2-(tert- butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanamido)-4-oxobutanoic acid
- Intermediate 6-B A flask containing Intermediate 6-A, (400.00 mg, 0.45 mmol, 1 equiv.) was dissolved in THF (6 mL) and water (3 mL) and placed in an ice bath and stirred for 15 min.
- Lithium hydroxide anhydrous (LiOH), (64.87 mg, 2.71 mmol, 6 equiv.) was added as a solid in one portion, and the reaction was continued in an ice-water bath. The reaction was monitored by HPLC-MS, after 30 min the major product was observed. After 1h, the reaction solution was acidified with Amberlite IR120 [H], ⁇ 600 mg by stirring for 15 min at rt, then filtered to remove the resin. The resin was further washed with acetonitrile, MeOH and the solvent was evaporated under vacuum. The crude product was lyophilized to give Intermediate 6-B as a white solid (394 mg, 95%, purity: 95%) and used for the next step without further purification.
- LiOH Lithium hydroxide anhydrous
- Step 3 Synthesis of (5R,10S)-10-(2-(tert-Butoxy)-2-oxoethyl)-2,2-dimethyl-4,8,11-trioxo-5- (4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)-3,15,18,21- tetraoxa-9,12-diazatetracosan-24-oic acid (Intermediate 6-C) To a 20 mL scintillation vial with a stir bar was added Intermediate 6-B, (70 mg, 0.08 mmol, 1 equiv.) and DMF (3 mL).
- the reaction mixture was cooled to 0 °C and DIPEA, (42 ⁇ L, 31.1 mg, 0.24 mmol, 3 equiv.), followed by HBTU, (31.1 mg, 0.08 mmol, 1.0 equiv.) was added and stirred for 10 min at 0 °C.
- the solution was brought to RT and stirred for 15 min and then 4- (tert-butyl) 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoic acid (19.7 mg, 0.08 mmol, 1 equiv.) was added as solid.
- the reaction was stirred at RT and was monitored by HPLC-MS.
- Step 4 Synthesis of (5R,10S)-10-(2-(tert-Butoxy)-2-oxoethyl)-2,2-dimethyl-4,8,11-trioxo-5- (4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)-3,15,18,21- tetraoxa-9,12-diazatetracosan-24-oic acid (Intermediate 6-D) To a 20 mL scintillation vial with a stir bar was added Intermediate 6-C (40 mg , 0.04 mmol, 1 equiv.) and 2.5 mL DMF.
- Step 5 Synthesis of 2,2',2''-(10-((15S,20R)-20-Carboxy-15-(carboxymethyl)-1-(4-(4-(3-(2,4- dihydroxy-5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)- 1,14,17-trioxo-4,7,10-trioxa-13,16-diazaicosan-20-yl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)triacetic acid (Compound F) To a 20 mL scintillation vial with a stir bar was added Intermediate 6-D (46 mg, 0.03 mmol, 1 equiv.) and 2.5 mL of deprotection cocktail TFA:TIPS:H 2 O - 95:2.5:2.5 (v/v/v) at
- reaction was brought to 37 °C by placing on a pre-heated oil bath at 37 °C and monitored by HPLC-MS. The reaction was stopped after 4h and reaction mixture placed under stream of air to remove TFA. The crude product was purified by preparative RP HPLC to afford Compound F (10.3 mg, 26 %, purity: 99%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 3.07 min; MS (positive ESI): found m/z 1240.3 [M+H] + ; C58H86N11O19 (calc.1240.6).
- the reaction mixture was cooled to 0 °C and DIPEA, (345 ⁇ L, 256 mg, 1.98 mmol, 3 equiv.), followed by HBTU, (255mg, 0.66 mmol, 1 equiv.) was added and stirred for 10 min at 0 °C.
- the solution was brought to RT and stirred for 30 min and then glycine (50 mg, 0.66 mmol, 1 equiv.) was added as a solid.
- Glycine solubility was poor in reaction mixture, therefore TFA (0.3 mL) and pyridine (0.6 mL) were added to the reaction mixture and continued stirring at RT, pH ⁇ 5.
- the reaction was monitored by HPLC-MS.
- Step 2 Synthesis of tri-tert-Butyl 2,2’,2’’-(10-(1-(tert-butoxy)-5-((2-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2- oxoethyl)amino)-1,5-dioxopentan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)®-triacetate (Intermediate 7-B) To a 20 mL scintillation vial with a stir bar was added Intermediate 7-A (66.2 mg, 0.08 mmol, 1.4 equiv.) and DMF (3 mL).
- reaction mixture was cooled to 0 °C and DIPEA, (51.7 ⁇ L, 38.4 mg, 0.3 mmol, 5 equiv.), followed by HBTU, (23 mg, 0.06 mmol, 1 equiv.) was added and stirred for 10 min at 0 °C.
- the solution was brought to RT and stirred for 15 min and then Intermediate 1-C (30 mg, 0.06 mmol, 1 equiv.) was added as a solid.
- the reaction was stirred at RT and monitored by HPLC-MS.
- Step 3 Synthesis of (R)-2,2',2''-(10-(1-Carboxy-4-((2-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2- oxoethyl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound G) To a 20 mL scintillation vial with a stir bar was added Intermediate 7-B (35 mg, 0.03 mmol) and 4 mL of deprotection cocktail TFA:TIPS:H 2 O - 95:2.5:2.5 (v/v/v) at RT.
- reaction was brought to 37 °C by placing on a pre-heated oil bath at 37 °C and monitored by HPLC-MS. The reaction was stopped after 3h and reaction mixture was placed under stream of air to remove TFA.
- the crude product was purified by preparative RP HPLC to afford Compound G (20 mg, 57 %, purity: 99%) as a white solid as the TFA salt.
- An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 1.70 min; MS (positive ESI): found m/z 979.3 [M+H] + ; C44H62N10O11 (calc.979.4).
- Example 8 Synthesis of 2,2',2''-(10-((R)-1-Carboxy-4-(((S)-1-carboxy-4-(4-(4-(3-(2,4- dihydroxy-5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)- 4-oxobutyl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound H)
- reaction mixture was cooled to 0 °C and DIPEA, (70 ⁇ L, 51.7 mg, 0. 40 mmol, 4 equiv.), followed by HBTU, (38.7 mg, 0.10 mmol, 1 equiv.) was added and stirred for 15 min at 0 °C.
- the solution was brought to RT and stirred for 20 min and then Intermediate 1- C (50 mg, 0.10 mmol, 1 equiv.) was added as solid.
- the reaction was stirred at RT and monitored by HPLC-MS. The reaction was stopped after 2 h and solvent was evaporated under vacuum to give the crude product.
- Step 2 Synthesis of tert-Butyl (S)-2-amino-5-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-5-oxopentanoate (Intermediate 8- B) To a 20 mL scintillation vial with a stir bar was added Intermediate 8-A, (60 mg, 0.07 mmol, 1 equiv.), followed by 6 mL of 15% piperidine solution in DMF at RT. The reaction was monitored by HPLC-MS.
- Step 3 Synthesis of tri-tert-Butyl 2,2',2''-(10-((R)-1-(tert-butoxy)-5-(((S)-1-(tert-butoxy)-5-(4-(4- (3-(2,4-dihydroxy-5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4- yl)benzyl)piperidin-1-yl)-1,5-dioxopentan-2-yl)amino)-1,5-dioxopentan-2-yl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetate (Intermediate 8-C): To a 20 mL scintillation vial with a stir bar was added (R)-5-(tert-butoxy)-5-oxo-4-(4,7,10-tris(2-(tert-but
- Reaction mixture was cooled to 0 °C and DIPEA, (16.2 ⁇ L, 12 mg, 0.09 mmol, 4 equiv.), followed by HBTU, (9.2 mg, 0.02 mmol, 1 equiv.) was added and stirred for 15 min at 0 °C.
- the solution was brought to RT and stirred for 20 min and then Intermediate 8-B (18.5 mg, 0.02 mmol, 1 equiv.) was added as solution in DMF (0.5 mL). The reaction was stirred at RT and monitored by HPLC-MS.
- Step 3 Synthesis of 2,2',2''-(10-((R)-1-Carboxy-4-(((S)-1-carboxy-4-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-4- oxobutyl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound H) To a 20 mL scintillation vial with a stir bar was added Intermediate 8-C (17 mg, 9.3 ⁇ mol, 1 equiv.) and 2.5 mL of deprotection cocktail TFA:TIPS:H2O - 95:2.5:2.5 (v/v)
- the reaction was brought to 37 °C by placing on a pre-heated oil bath at 37 °C and monitored by HPLC-MS. The reaction was stopped after 2h30 min and the reaction mixture was placed under stream of air to remove TFA.
- the crude product was purified by preparative RP HPLC to afford Compound H (10.5 mg, 87 %, purity: 99%) as a white solid as the TFA salt.
- An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 1.71 min; MS (positive ESI): found m/z 1051.6 [M+H] + ; C 50 H 71 N 10 O 15 (calc.1051.5).
- the reaction mixture was cooled to 0 °C and DIPEA, (348 ⁇ L, 258 mg, 2 mmol, 4 equiv.), followed by HBTU, (208mg, 0.55 mmol, 1.1 equiv.) was added and stirred for 10 min at 0 °C.
- the solution was brought to RT and was stirred for 15 min and then 5- (tert-butyl) 1-methyl L-glutamate HCl (127 mg, 0.5 mmol, 1 equiv.) was added as a solid.
- the reaction was stirred at RT and was monitored by HPLC-MS.
- Step 2 Synthesis of (S)-5-(tert-Butoxy)-2-((R)-5-(tert-butoxy)-5-oxo-4-(4,7,10-tris(2-(tert- butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanamido)-5-oxopentanoic acid (Intermediate 9-B) To a flask containing 5-(tert-Butyl) 1-methyl ((R)-5-(tert-butoxy)-5-oxo-4-(4,7,10-tris(2-(tert- butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanoyl)-L-glutamate (Intermediate 9-A) (164mg, 0.18 mmol, 1 equiv.) was dissolved in THF (5 mL) and water (
- Lithium hydroxide anhydrous (21.8 mg, 0.91 mmol, 5 equiv.) was added as a solid in one portion and thereaction was stirredin an ice-water bath.
- the reaction was monitored by HPLC-MS, after 1h was worked up by acidification with Amberlite IR120 [H], at rt to pH ⁇ 5, then filtered via a 0.2 ⁇ M filter disk to remove resin. The resin was further washed with ACN, MeOH and the solvent was evaporated under vacuum. The crude product was dissolved in acetonitrile/water and lyophilised to give Intermediate 9-B (159 mg, 94%, purity: 95%) as a white solid.
- Step 3 Synthesis of (9H-Fluoren-9-yl)methyl (2-(4-(4-(3-(2,4-bis(benzyloxy)-5-isopropylphenyl)- 5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2-oxoethyl)carbamate (Intermediate 9-C) To a 20 mL scintillation vial with a stir bar was added (((9H-fluoren-9- yl)methoxy)carbonyl)glycine, (24.4 mg, 0.08 mmol, 1 equiv.) and DMF (1.5 mL).
- reaction mixture was cooled to 0 °C and DIPEA, (28 ⁇ L, 0.16 mmol, 2 equiv.), followed by HBTU, (31.4 mg, 0.08 mmol, 1 equiv.) was added and stirred for 5 min at 0 °C.
- the solution was brought to RT and stirred for 20 min and then solution of Intermediate 2-B (55 mg, 0.08 mmol, 1 equiv.) in DMF (1.5 mL) containing DIPEA, (53 ⁇ L, 0.24 mmol, 3 equiv.) was added.
- the reaction was stirred at RT and was monitored by HPLC-MS.
- Step 4 Synthesis of 5-(2,4-bis(Benzyloxy)-5-isopropylphenyl)-N-ethyl-4-(4-((1-glycylpiperidin-4- yl)methyl)phenyl)-4H-1,2,4-triazole-3-carboxamide
- Piperidine (0.45 mL) was added to a solution of (9H-fluoren-9-yl)methyl (2-(4-(4-(3-(2,4- bis(benzyloxy)-5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1- yl)-2-oxoethyl)carbamate (Intermediate 9-C), ( 50 mg, 0.05 mmol, 1 equiv) in DMF (2.55 mL) and the mixture stirred at RT.
- Step 5 Synthesis of tri-tert-Butyl 2,2',2''-(10-((R)-5-(((S)-1-((2-(4-(4-(3-(2,4-bis(benzyloxy)-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2- oxoethyl)amino)-5-(tert-butoxy)-1,5-dioxopentan-2-yl)amino)-1-(tert-butoxy)-1,5-dioxopentan-2- yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (Intermediate 9-E) To a 20 mL scintillation vial with a stir bar was added Intermediate 9-B (22.8 mg, 0.02 mmol
- Step 6 Synthesis of tri-tert-Butyl 2,2',2''-(10-((R)-1-(tert-butoxy)-5-(((S)-5-(tert-butoxy)-1-((2-(4- (4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4- yl)benzyl)piperidin-1-yl)-2-oxoethyl)amino)-1,5-dioxopentan-2-yl)amino)-1,5-dioxopentan-2-yl)- 1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (Intermediate 9-F) To a flask containing Intermediate 9-E (26 mg, 16.6 ⁇ mol, 1
- Step 7 Synthesis of 2,2',2''-(10-((R)-1-Carboxy-4-(((S)-4-carboxy-1-((2-(4-(4-(3-(2,4-dihydroxy- 5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2- oxoethyl)amino)-1-oxobutan-2-yl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)triacetic acid (Compound I) To a 20 mL scintillation vial with a stir bar was added Intermediate 9-F (22 mg, 15.68 ⁇ mol) and 2.5 mL of deprotection cocktail TFA:TIPS:H2O - 95:2.5:2.5 (v/v/v
- Fmoc-Gln(Trt)-OH (305 mg, 0.5 mmol) was dissolved in DMF (4 mL) with potassium iodide (16 mg, 0.1 mmol) and DIPEA (174 ⁇ L, 1.0 mmol). The resulting solution was combined with the resin and stirred at room temperature overnight. Fmoc deprotection was performed for 5 and 15 minutes with 20% piperidine in DMF. Subsequent couplings were performed using 0.3 mmol of protected amino acids (Fmoc-Glu(OtBu)-OH, Fmoc-Arg(Pbf)-OH and DOTA(OtBu)3) 0.3 mmol of HBTU and 0.6 mmol of DIPEA in DMF for 1 hour.
- Step 2 Synthesis of tri-tert-Butyl 2,2',2''-(10-((6S,9S,12S)-6-(4-(4-(3-(2,4-bis(benzyloxy)-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidine-1-carbonyl)-9-(3- (tert-butoxy)-3-oxopropyl)-3,8,11,14-tetraoxo-12-(3-(3-((2,2,4,6,7-pentamethyl-2,3- dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-1,1,1-triphenyl-2,7,10,13- tetraazapentadecan-15-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl
- Step 3 Synthesis of 2,2',2''-(10-(2-(((S)-1-(((S)-1-(((S)-5-Amino-1-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-1,5- dioxopentan-2-yl)amino)-4-carboxy-1-oxobutan-2-yl)amino)-5-guanidino-1-oxopentan-2- yl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound J) 10% w/w Palladium on carbon (30% w/w, 3.5 mg) was added to a 5 mL microwave vial
- the vial was purged with nitrogen, followed by the addition of Intermediate 10-B (23 mg, 10.8 ⁇ mol) dissolved in methanol (2 mL). The vial was then purged with hydrogen and a hydrogen balloon attached to the vial. After stirring for 2 hours at room temperature, the vial was purged with nitrogen and the vial unsealed. The reaction mixture was filtered through a 0.2 ⁇ m syringe filter and the solvent evaporated under reduced pressure. The resulting product was dissolved in 2 mL of 95:2.5:2.5 TFA/ /TIPS/H2O (v/v/v) and stirred at 37 °C in a heating block for 90 minutes.
- Example 11 Synthesis of (S)-2,2',2''-(10-(1-Carboxy-4-((2-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidine-1- carboxamido)ethyl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound K) O O t Bu O H O t BuO O N O N N N N N O t Bu -NO-Phenyl chl H O tBuO N N 1.
- Step 2 Synthesis of tri-tert-Butyl 2,2',2''-(10-(1-(tert-butoxy)-5-((2-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidine-1- carboxamido)ethyl)amino)-1,5-dioxopentan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)(S)-triacetate (Intermediate 11-B) To a flask containing Intermediate 11-A (30 mg, 19.11 ⁇ mol) and methanol (4.5 mL) was added 10% Pd/C (8 mg, 7.64 ⁇ mol, 0.4 equiv.) at room temperature.
- reaction mixture was degassed under vacuum and subjected to hydrogen gas via a balloon.
- the reaction was stirred overnight and was monitored by HPLC-MS.
- the reaction was stopped after 15 hours, filtered through a 0.2 ⁇ M filter disk and solvent evaporated under vacuum to give the crude product, which was purified by RP chromatography to afford Intermediate 11-B (18.4 mg, 66 %, purity: 98%) as a white solid as the TFA salt.
- An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 4.78 min; MS (positive ESI): found m/z 1232.5 [M+H] + ; C64H102N11O13 (calc.1232.8).
- Step 3 Synthesis of (S)-2,2',2''-(10-(1-Carboxy-4-((2-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidine-1- carboxamido)ethyl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound K) To a 20 mL scintillation vial with a stir bar was added Intermediate 11-B (18 mg, 10.73 ⁇ mol, 1 equiv.) and 2.5 mL of deprotection cocktail TFA:TIPS:H 2 O - 95:2.5:2.5 (v/v/v) at RT.
- the reaction was brought to 37 °C by placing on a pre-heated oil bath at 37 °C and monitored by HPLC-MS. The reaction was stopped after 4h and reaction mixture placed under stream of air to remove TFA.
- the crude product was purified by preparative RP HPLC to afford Compound K (13 mg, 97 %, purity: 99%) as a white solid as the TFA salt.
- An aliquot was analyzed by HPLC- MS elution using elution method 1; retention time: 2.89 min; MS (positive ESI): found m/z 1009.0 [M+H] + ; C48H70N11O13 (calc. 1008.5).
- Example 12 Synthesis of 2,2',2''-(10-((R)-1-Carboxy-4-(((S)-4-carboxy-1-((2-(4-(4-(3-(2,4- dihydroxy-5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)- 2-oxoethyl)amino)-1-oxobutan-2-yl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)triacetic acid (Compound L) O O t Bu N O N O NH•HCl O N N O t Bu O t N Bu BuO t N O N O O O N HBTU, DIPEA, DMF HO O HO N O t Bu HO O N N BuO t Step 1 OH
- Step 2 Synthesis of 2,2',2''-(10-(2-(4-(4-(3-(2,4-Dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2-oxoethyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound L) To a 20 mL scintillation vial with a stir bar was added Intermediate 12-A (25 mg, 21 ⁇ mol) and 2.5 mL of deprotection cocktail TFA:TIPS:H2O - 95:2.5:2.5 (v/v/v) at RT.
- the reaction was brought to 37 °C by placing on a pre-heated oil bath at 37 °C and monitored by HPLC-MS. The reaction was stopped after 2h 30min and the reaction mixture was placed under stream of air to remove TFA.
- the crude product was purified by preparative RP HPLC to afford Compound L (11 mg, 48 %, purity: 99%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC- MS elution using elution method 1; retention time: 2.78 min; MS (positive ESI): found m/z 850.0 [M+H] + ; C42H60N9O10 (calc.850.4).
- reaction mixture was cooled to 0 °C and DIPEA, (11.3 ⁇ L, 8.4 mg, 0.06 mmol, 3 equiv.) and HBTU, (11 mg, 0.03 mmol, 1.3 equiv.) were added and stirred for 10 min at 0 °C.
- the solution was brought to RT and stirred for 15 min and then Intermediate 1-C (12 mg, 0.02 mmol, 1 equiv.) was added as solution in THF (0.4 mL) and DMF (0.3 mL) along with 5 ⁇ L DIPEA.
- the reaction was stirred at RT and was monitored by HPLC-MS.
- Step 2 Synthesis of (R)-2,2',2''-(10-(1-Carboxy-4-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-4-oxobutyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound M) To a 20 mL scintillation vial with a stir bar was added Intermediate 13-A (7 mg, 0.01 ⁇ mol) and 0.6 mL of deprotection cocktail TFA:TIPS:H2O - 95:2.5:2.5 (v/v/v) DW ⁇ After 5 min the reaction was brought to
- Step 2 Synthesis of (R)-2,2',2''-(10-(4-(4-(4-(3-(2,4-bis(Benzyloxy)-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-1-carboxy-4-oxobutyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound N) To a 20 mL scintillation vial with a stir bar was added Intermediate 14-A (25 mg, 18.65 ⁇ mol, 1 equiv.) and 2.5 mL of deprotection cocktail TFA:TIPS:H 2 O - 95:2.5:2.5 (v/v/v) at RT.
- the reaction was brought to 37 °C by placing on a pre-heated oil bath at 37 °C and monitored by HPLC-MS. The reaction was stopped after 2h30min and the reaction mixture was placed under stream of air to remove TFA.
- the crude product was purified by preparative RP HPLC to afford Compound N (15 mg, 60%, purity: 99%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 4.37 min; MS (positive ESI): found m/z 1102.2 [M+H] + ; C59H76N9O12 (calc. 1102.6).
- Example 15 Method for Radiolabeling Disclosed Compounds Prior to radiolabeling, a stock solution of each Compound was made by dissolving the appropriate quantity of Compound in sodium acetate buffer. Ethanol may be added up to 10% by volume to improve solubility of the compounds. A 1.5 mL Eppendorf tube was charged with the desired Compound followed by sodium acetate buffer to raise the total volume as desired (0.05- 0.5 mL). Next, a solution of [177Lu]LuCl3 or [111In]InCl3 or [225Ac]AcNO3 (or [225Ac]AcCl3) in hydrochloric acid solution was added and the mixture was heated.
- Binding affinity (K d ) results are summarized in Table 4 ⁇ ZKHUH ⁇ Q0 ⁇ $ ⁇ 5 nM, ⁇ Q0 ⁇ % ⁇ Q0 ⁇ DQG ⁇ C > 100 nM.
- Table 4 Binding affinities (K d ⁇ RI ⁇ VHOHFWHG ⁇ FRPSRXQGV ⁇ WR ⁇ UHFRPELQDQW ⁇ +VS ⁇ RU ⁇ isoforms.
- mice implanted with HSP90 expressing xenograft tumors were treated with various concentrations and doses of the compounds of Formula I to evaluate in vivo efficacy.
- OTHER EMBODIMENTS [158] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described herein. Such equivalents are intended to be encompassed by the following claims.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Compounds comprising a targeting moiety that specifically binds to HSP90, in particular, extracellular HSP90. Also disclosed are pharmaceutical compositions and methods of treating cancer with the same.
Description
EXTRACELLULAR HSP90 (eHSP90)-TARGETED RADIOPHARMACEUTICALS AND USE THEREOF RELATED APPLICATION [1] The present application claims priority to U.S. Provisional Application No.63/401,227, filed on August 26, 2022, the entire contents of which are hereby incorporated by reference for all purposes. BACKGROUND [2] Heat shock protein 90 (HSP90) is a molecular chaperone that regulates protein folding to ensure correct conformation and translocation and to avoid protein aggregation. Many oncogenic proteins are HSP90 client proteins, such as epidermal growth factor receptor (EGFR) mutant, cyclin dependent kinase 4 (CDK4), hypoxia-inducible factor (HIF)-1Į, and matrix metallopeptidase 2 (MMP2). [3] There is a fraction of HSP90 identified at the surface of a number of cell types, i.e., extracellular HSP90 (eHSP90), which can be a useful tumor antigen for eliciting a host immune response. Studies show that eHSP90 plays a crucial role in maintaining oncogenic protein homoeostasis and participates in the invasion and metastatic processes of various cancers including breast cancer, which make eHSP90 an attractive target for developing cancer therapy. [4] HSP90 inhibition has been shown to have a significant direct impact on cell cycle and DNA repair mechanisms, thus offering great promise in the treatment of a wide variety of solid and hematological malignancies. However, early clinical trials have demonstrated that certain HSP90 inhibitors exhibited limited efficacy and various side effects. [5] Therefore, there is a need for improved treatment of cancers with good efficacy and acceptable safety profiles by targeting certain proteins, e.g., eHSP90. SUMMARY [6] The present disclosure encompasses the insight that certain radiopharmaceuticals comprising a targeting moiety that specifically binds to HSP90, in particular, eHSP90, can be effective as HSP90 radioligand therapy (RLT) for treating cancers. Radioactive decay can cause direct physical damage (such as single or double-stranded DNA breaks) or indirect damage (such as
by-stander or crossfire effects) to the biomolecules that constitute a cell. Drugs that deliver radionuclides to cancer cells, i.e., radiopharmaceuticals, provide a mechanism to generate DNA damage with anti-cancer therapeutic effect. The present disclosure provides certain radiopharmaceuticals, specifically, small molecule-based radiopharmaceuticals targeting HSP90- overexpressing tumors and using actinium-225 (225Ac), lutetium-177 (177Lu) or other suitable therapeutic radionuclides to target cancer cells to treat or ameliorate cancers such as lung cancer, sarcoma, pancreatic cancer, breast cancer, or colon cancer. [7] In one aspect, the present disclosure provides compounds of Formula I, or a pharmaceutically acceptable salt thereof: Z1 X N Y Z2 n W HO HN N O OH N N (I), wherein X is absent, C=O, or (C=O)NR1, R1 being H, alkyl, aryl, (C-CF3)R2 or (SO2)R2, R2 being alkyl or aryl; Y is each independently O or NR3, R3 being H, alkyl, aryl, or acyl; n is an integer of 0-5 (inclusive); Z1 and Z2 each are, independently, absent, an amino acid unit, (C=O)NR4(CH2CH2)O, or (C=O)NR4(CH2CH2)NR5, in which each of R4 and R5 independently is H or alkyl or (C-CF3)R6 or (SO2)R6, R6 being alkyl or aryl; and W is a chelator selected from the group consisting of DOTA, DOTAGA, NOTA, and NODAGA, each as defined in the DETAILED DESCRIPTION section below, wherein when W is DOTA, at least one of Z1 and Z2 is an amino acid unit, or each of Z1 and Z2 is absent and n is equal to or less than 4; wherein the compound binds to HSP90; and wherein the compound optionally further comprises a radionuclide chelated by the chelator.
[8] In some embodiments, the compounds of this disclosure specifically bound to extracellular HSP90 (eHSP90). [9] In some embodiments, the compounds of this disclosure have the structure of Formula II: O HO O N N HO O Z1 OH X N N N Y Z2 n O O OH HO HN N O N N OH (II), wherein each of X, Y, n, Z1, and Z2 is as defined above. [10] In some embodiments, the compounds of Formula I or Formula II feature that at least one of Z1 and Z2 is an amino acid unit. [11] In some embodiments, the compounds of Formula I or Formula II feature that the amino acid unit is formed from glycine (Gly), aspartic acid (Asp), glutamic acid (Glu), 2,4- diaminobutyric acid (Dab), 2,3-diaminopropionic acid (Dap), lysine (Lys), or arginine (Arg). [12] In some embodiments, the compounds of Formula I or Formula II feature that the amino acid unit is formed from glycine (Gly), aspartic acid (Asp), glutamic acid (Glu), 2,4- diaminobutyric acid (Dab), 2,3-diaminopropionic acid (Dap), lysine (Lys), arginine (Arg), or combination thereof. [13] In some embodiments, the compounds of Formula I or Formula II feature that the amino acid unit comprises an organic moiety formed from Asp. [14] In some embodiments, the compounds of Formula I or Formula II feature that the amino acid unit is formed from Gly. [15] In some embodiments, the compounds of Formula I or Formula II feature that the amino acid unit is formed from Glu. [16] In some embodiments, the compounds of Formula I or Formula II feature that X is absent.
[17] In some embodiments, the compounds of Formula I or Formula II feature that X is C=O. [18] In some embodiments, the compounds of Formula I or Formula II feature that X is (C=O)NR1, wherein R1 is H, alkyl, or aryl. [19] In some embodiments, the compounds of Formula I or Formula II feature that X is (C=O)NH. [20] In some embodiments, the compounds of Formula I or Formula II feature that n is 0. [21] In some embodiments, the compounds of Formula I or Formula II feature that n is 1, 2, or 3. [22] In some embodiments, the compounds of Formula I or Formula II feature that n is 4 or 5. [23] In some embodiments, the compounds of Formula I or Formula II feature that n is 4. [24] In some embodiments, the compounds of Formula I or Formula II feature that n is 5. [25] In some embodiments, the compounds of Formula I or Formula II feature that Y is each independently O, NH, or N(C1-6 alkyl). In some embodiments, the compounds of Formula I or Formula II feature that Y is each independently O. In some embodiments, the compounds of Formula I or Formula II feature that Y is each independently NH. [26] In some embodiments, the compounds of Formula I or Formula II feature that each of Z1 and Z2 is absent. [27] In some embodiments, the compounds of Formula I or Formula II feature that Z1 is absent. [28] In some embodiments, the compounds of Formula I or Formula II feature that Z2 is absent. [29] In some embodiments, the compounds of Formula I or Formula II feature that Z1 is an amino acid unit. [30] In some embodiments, the compounds of Formula I or Formula II feature that Z2 is an amino acid unit. [31] In some embodiments, the compounds of Formula I or Formula II feature that Z1 is (C=O)NH(CH2CH2)NH. In some embodiments, the compounds of Formula I or Formula II feature that Z2 is (C=O)NH(CH2CH2)NH. [32] In some embodiments, the compounds of Formula I or Formula II feature that Z1 is (C=O)NH(CH2CH2)N(C1-6 alkyl). In some embodiments, the compounds of Formula I or Formula II feature that Z2 is (C=O)NH(CH2CH2)N(C1-6 alkyl). [33] In some embodiments, the compounds of Formula I or Formula II feature that Z1 is (C=O)N(C1-6 alkyl)(CH2CH2)NH. In some embodiments, the compounds of Formula I or Formula II feature that Z2 is (C=O)N(C1-6 alkyl)(CH2CH2)NH.
[34] In some embodiments, the compounds of Formula I or Formula II feature that Z1 is (C=O)N(C1-6 alkyl)(CH2CH2)N(C1-6 alkyl). In some embodiments, the compounds of Formula I or Formula II feature that Z2 is (C=O)N(C1-6 alkyl)(CH2CH2)N(C1-6 alkyl). [35] In some embodiments, the compounds of Formula I or Formula II feature that X is absent, n is 0, Z1 is absent, and Z2 is an amino acid unit. [36] In some embodiments, the compounds of Formula I or Formula II feature that X is C=O, n is 4 or 5, Z1 is an amino acid unit, and Z2 is absent. [37] In some embodiments, the compounds of Formula I or Formula II feature that X is C=O, n is 4 or 5, Z1 is absent, and Z2 is an amino acid unit. [38] In some embodiments, the amino acid unit is selected from the group consisting of HO O O OH O H N N O H H O N O H N N H , O , HO O , H2N O , HO O O OH O H O O H O H N H N N N N N H N H O H O O HN HO O HN H2N NH , NH2 , H2N NH and HO O O O H H N N N H O H2N O HN H2N NH .
[39] In some embodiments, the compounds of Formula I or Formula II feature that X is (C=O)NH, n is 4 or 5, each of Z1 and Z2 is absent. [40] In some embodiments, the compounds of Formula I or Formula II feature that X is C=O, n is 4 or 5, Z1 is absent, and Z2 is (C=O)NH(CH2CH2)NH. [41] In some embodiments, the compounds of Formula I or Formula II feature that X is absent, n is 0, each of Z1 and Z2 is absent. [42] In some embodiments, the compounds of Formula I or Formula II are selected from the group consisting of: O HO O N N HO O O OH O O N N N O O N H O O OH HO HN N O N N OH , HO O O N N HO O H O OH (S) N O O N N N O N H O O CO2H O OH HO HN N O OH N N , O HO O N N HO O H O OH (S) N O O N N N O N H O O CO2H HO HN N O OH N N ,
O HO O N N HO HO O 2 C O H OH O N N N N O O (S) N H O O O OH HO HN N O N N OH , O HO O N N HO HO O 2C O H OH O N N N N O O (S) N H O O HO HN N O N N OH , O OH O H O N O N O O N O N N H O OH HO N N O HO O HO HN N O OH N N , O H O N O O O N N O H N N O OH HO N N O HO O HO HN N O OH N N ,
HO O O N N HO O H H O OH O N N N N N O O N O H O O OH HO HN N O OH N N , HO O O N N HO O H H O OH N N N N O O O N N O H O HO HN N O N N OH , O O OH H N O (S) N N N O OH CO2H HO N N O HO O HO HN N O N N OH , O O H N OH (S) N N N O N CO2H HO N HO O O HO HN N O N N OH ,
O O HO HO O O N N N N HO HO O OH O OH N N N N N O N O O OH HO HN HO HN N N O O N N N N OH , and OH . [43] In some embodiments, the compounds of Formula I or Formula II feature that each compound comprises a radionuclide selected from the group consisting of 43Sc, 44Sc, 47Sc, 55Co, 60Cu, 61Cu, 62Cu, 64Cu, 67Cu, 66Ga, 67Ga, 68Ga, 82Rb, 86Y, 87Y, 89Zr, 90Y, 97Ru, 99Tc, 99mTc, 105Rh, 109Pd, 111In, 117mSn, 133La, 134Ce, 149Pm, 149Tb, 153Sm, 152Tb, 155Tb, 161Tb, 166Ho, 177Lu, 186Re, 188Re, 198Au, 199Au, 201Tl, 203Pb, 211At, 212Pb, 212Bi, 213Bi, 223Ra, 225Ac, 227Th, and 229Th. [44] In certain embodiments, the radionuclide is selected from the group consisting of 68Ga, 89Zr, 90Y, 111In, 177Lu, and 225Ac. [45] In certain embodiments, the radionuclide is 177Lu or 225Ac. [46] In certain embodiments, the radionuclide is 177Lu. [47] In certain embodiments, the radionuclide is 225Ac. [48] In another aspect, the present disclosure also covers a pharmaceutical composition comprising one of the compounds set forth above and a pharmaceutically acceptable excipient. [49] Still within the scope of this disclosure is a method of treating cancer, the method comprising administering to a subject in need thereof one of the compounds set forth above or the above-described pharmaceutical composition. [50] In some embodiments, the method of treating cancer comprises administering to the subject in need thereof a first dose of one of the compounds or the composition described above in an amount effective for radiation treatment planning, followed by administering subsequent doses of one of the compounds or the composition described above in a therapeutically effective amount.
[51] In some embodiments, the cancer is small-cell lung cancer, non-small-cell lung cancer, sarcoma, pancreatic cancer, breast cancer, or colon cancer. BRIEF DESCRIPTION OF THE DRAWINGS [52] FIG.1. Tumor growth of HSP90 expressing xenograft tumors in response to treatment with 225Ac-Compound D. DETAILED DESCRIPTION [53] The present disclosure relates to radiopharmaceutical compounds comprising a targeting moiety that specifically binds to HSP90, in particular, extracellular HSP90 (eHSP90). [54] Radio-labelled targeting molecules (also known as radiopharmaceuticals) are designed to target a protein or receptor (e.g., eHSP90) that is upregulated in a disease state and/or specific to diseased cells (e.g., tumor cells) to deliver a radioactive payload to damage and kill cells of interest. Radiopharmaceuticals targeting eHSP90 provided in this disclosure can be used for treating various cancers including, but not limited to, small-cell lung cancer, non-small-cell lung cancer, sarcoma, pancreatic cancer, breast cancer, and colon cancer. Definitions Chemical Terms [55] The term “alkyl,” as used herein, is inclusive of both straight chain and branched chain saturated groups from 1 to 20 carbons (e.g., from 1 to 10 or from 1 to 6), unless otherwise specified. Alkyl groups are exemplified by methyl, ethyl, n- and iso-propyl, n-, sec-, iso- and tert-butyl, neopentyl, and the like, and may be optionally substituted with one, two, three, or, in the case of alkyl groups of two carbons or more, four substituents independently selected from the group consisting of: (1) C1-6 alkoxy; (2) C1-6 alkylsulfinyl; (3) amino, as defined herein (e.g., unsubstituted amino (i.e., -NH2) or a substituted amino (i.e., -N(RN1)2, where RN1 is as defined for amino); (4) C6-10 aryl-C1-6 alkoxy; (5) azido; (6) halo; (7) (C2-9 heterocyclyl)oxy; (8) hydroxy, optionally substituted with an O-protecting group; (9) nitro; (10) oxo (e.g., carboxyaldehyde or acyl); (11) C1-7 spirocyclyl; (12) thioalkoxy; (13) thiol; (14) -CO2RA’, optionally substituted with an O-protecting group and where RA’ is selected from the group consisting of (a) C1-20 alkyl (e.g., C1-6 alkyl), (b) C2-20 alkenyl (e.g., C2-6 alkenyl), (c) C6-10 aryl, (d) hydrogen, (e) C1-6 alk-C6-10
aryl, (f) amino-C1-20 alkyl, (g) polyethylene glycol of -(CH2)s2(OCH2CH2)s1(CH2)s3OR’, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R’ is H or C1-20 alkyl, and (h) amino-polyethylene glycol of - NRN1(CH2)s2(CH2CH2O)s1(CH2)s3NRN1, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted C1-6 alkyl; (15) -C(O)NRB’RC’, where each of RB’ and RC’ is, independently, selected from the group consisting of (a) hydrogen, (b) C1-6 alkyl, (c) C6-10 aryl, and (d) C1-6 alk-C6-10 aryl; (16) -SO2RD’, where RD’ is selected from the group consisting of (a) C1-6 alkyl, (b) C6-10 aryl, (c) C1-6 alk-C6-10 aryl, and (d) hydroxy; (17) -SO2NRE’RF’, where each of RE’ and RF’ is, independently, selected from the group consisting of (a) hydrogen, (b) C1-6 alkyl, (c) C6-10 aryl and (d) C1-6 alk-C6-10 aryl; (18) -C(O)RG’, where RG’ is selected from the group consisting of (a) C1-20 alkyl (e.g., C1-6 alkyl), (b) C2-20 alkenyl (e.g., C2-6 alkenyl), (c) C6-10 aryl, (d) hydrogen, (e) C1-6 alk-C6-10 aryl, (f) amino-C1-20 alkyl, (g) polyethylene glycol of - (CH2)s2(OCH2CH2)s1(CH2)s3OR’, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R’ is H or C1-20 alkyl, and (h) amino-polyethylene glycol of -NRN1(CH2)s2(CH2CH2O)s1(CH2)s3NRN1, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted C1-6 alkyl; (19) -NRH’C(O)RI’, wherein RH’ is selected from the group consisting of (a1) hydrogen and (b1) C1-6 alkyl, and RI’ is selected from the group consisting of (a2) C1-20 alkyl (e.g., C1-6 alkyl), (b2) C2-20 alkenyl (e.g., C2-6 alkenyl), (c2) C6-10 aryl, (d2) hydrogen, (e2) C1-6 alk-C6-10 aryl, (f2) amino-C1-20 alkyl, (g2) polyethylene glycol of -(CH2)s2(OCH2CH2)s1(CH2)s3OR’, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R’ is H or C1-20 alkyl, and (h2) amino- polyethylene glycol of -NRN1(CH2)s2(CH2CH2O)s1(CH2)s3NRN1, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is,
independently, hydrogen or optionally substituted C1-6 alkyl; (20) -NRJ’C(O)ORK’, wherein RJ’ is selected from the group consisting of (a1) hydrogen and (b1) C1-6 alkyl, and RK’ is selected from the group consisting of (a2) C1-20 alkyl (e.g., C1-6 alkyl), (b2) C2-20 alkenyl (e.g., C2-6 alkenyl), (c2) C6-10 aryl, (d2) hydrogen, (e2) C1-6 alk-C6-10 aryl, (f2) amino-C1-20 alkyl, (g2) polyethylene glycol of -(CH2)s2(OCH2CH2)s1(CH2)s3OR’, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R’ is H or C1-20 alkyl, and (h2) amino- polyethylene glycol of -NRN1(CH2)s2(CH2CH2O)s1(CH2)s3NRN1, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted C1-6 alkyl; and (21) amidine. In some embodiments, each of these groups can be further substituted as described herein. For example, the alkylene group of a C1-alkaryl can be further substituted with an oxo group to afford the respective aryloyl substituent. [56] The terms “alkylene”, “alkylidene”, and the prefix “alk-,” as used herein, represent a saturated divalent hydrocarbon group derived from a straight or branched chain saturated hydrocarbon by the removal of two hydrogen atoms, and is exemplified by methylene, ethylene, isopropylene, and the like. The terms “Cx-y alkyl,” “Cx-y alkylene,” “Cx-y alkylidene,” and the prefix “Cx-y alk-” represent alkyl or alkylene groups having between x and y carbons. Exemplary values for x are 1, 2, 3, 4, 5, and 6, and exemplary values for y are 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or 20 (e.g., C1-6, C1-10, C2-5, C2-8, C2-10, or C2-20 alkyl or alkylene). In some embodiments, the alkylene can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for an alkyl group. [57] The term “alkenyl,” as used herein, represents monovalent straight or branched chain groups of, unless otherwise specified, from 2 to 20 carbons (e.g., from 2 to 6 or from 2 to 10 carbons) containing one or more carbon-carbon double bonds and is exemplified by ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, and the like. Alkenyls include both cis and trans isomers. Alkenyl groups may be optionally substituted with 1, 2, 3, or 4 substituent groups that are selected, independently, from amino, aryl, cycloalkyl, or heterocyclyl (e.g., heteroaryl), as defined herein, or any of the exemplary alkyl substituent groups described herein.
[58] The term “alkynyl,” as used herein, represents monovalent straight or branched chain groups from 2 to 20 carbon atoms (e.g., from 2 to 4, from 2 to 6, or from 2 to 10 carbons) containing a carbon-carbon triple bond and is exemplified by ethynyl, 1-propynyl, and the like. Alkynyl groups may be optionally substituted with 1, 2, 3, or 4 substituent groups that are selected, independently, from aryl, cycloalkyl, or heterocyclyl (e.g., heteroaryl), as defined herein, or any of the exemplary alkyl substituent groups described herein. [59] The term “amino,” as used herein, represents –N(RN1)2, wherein each RN1 is, independently, H, OH, NO2, N(RN2)2, SO2ORN2, SO2RN2, SORN2, an N-protecting group, alkyl, alkenyl, alkynyl, alkoxy, aryl, alkaryl, cycloalkyl, alkcycloalkyl, carboxyalkyl (e.g., optionally substituted with an O-protecting group, such as optionally substituted arylalkoxycarbonyl groups or any described herein), sulfoalkyl, acyl (e.g., acetyl, trifluoroacetyl, or others described herein), alkoxycarbonylalkyl (e.g., optionally substituted with an O-protecting group, such as optionally substituted arylalkoxycarbonyl groups or any described herein), heterocyclyl (e.g., heteroaryl), or alkheterocyclyl (e.g., alkheteroaryl), wherein each of these recited RN1 groups can be optionally substituted, as defined herein for each group; or two RN1 combine to form a heterocyclyl or an N- protecting group, and wherein each RN2 is, independently, H, alkyl, or aryl. Amino groups can be unsubstituted amino (i.e., –NH2) or substituted amino (i.e., –N(RN1)2) groups. In a preferred embodiment, amino is –NH2 or –NHRN1, wherein RN1 is, independently, OH, NO2, NH2, NRN22, SO2ORN2, SO2RN2, SORN2, alkyl, carboxyalkyl, sulfoalkyl, acyl (e.g., acetyl, trifluoroacetyl, or others described herein), alkoxycarbonylalkyl (e.g., t-butoxycarbonylalkyl) or aryl, and each RN2 can be H, C1-20 alkyl (e.g., C1-6 alkyl), or C6-10 aryl. [60] The term “amino acid,” as described herein, refers to a molecule having a side chain, an amino group, and an acid group (e.g., a carboxy group of –CO2H or a sulfo group of –SO3H), wherein the amino acid is attached to the parent molecular group by the side chain, amino group, or acid group (e.g., the side chain). In some embodiments, the amino acid is attached to the parent molecular group by a carbonyl group, where the side chain or amino group is attached to the carbonyl group. Exemplary side chains include an optionally substituted alkyl, aryl, heterocyclyl, alkaryl, alkheterocyclyl, aminoalkyl, carbamoylalkyl, and carboxyalkyl. Exemplary amino acids include alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, hydroxynorvaline, isoleucine, leucine, lysine, methionine, norvaline, ornithine, phenylalanine, proline, pyrrolysine, selenocysteine, serine, taurine,
threonine, tryptophan, tyrosine, and valine. Amino acid groups may be optionally substituted with one, two, three, or, in the case of amino acid groups of two carbons or more, four substituents independently selected from the group consisting of: (1) C1-6 alkoxy; (2) C1-6 alkylsulfinyl; (3) amino, as defined herein (e.g., unsubstituted amino (i.e., -NH2) or a substituted amino (i.e., -N(RN1)2, where RN1 is as defined for amino); (4) C6-10 aryl-C1-6 alkoxy; (5) azido; (6) halo; (7) (C2-9 heterocyclyl)oxy; (8) hydroxy; (9) nitro; (10) oxo (e.g., carboxyaldehyde or acyl); (11) C1-7 spirocyclyl; (12) thioalkoxy; (13) thiol; (14) -CO2RA’, where RA’ is selected from the group consisting of (a) C1-20 alkyl (e.g., C1-6 alkyl), (b) C2-20 alkenyl (e.g., C2-6 alkenyl), (c) C6-10 aryl, (d) hydrogen, (e) C1-6 alk-C6-10 aryl, (f) amino-C1-20 alkyl, (g) polyethylene glycol of - (CH2)s2(OCH2CH2)s1(CH2)s3OR’, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R’ is H or C1-20 alkyl, and (h) amino-polyethylene glycol of -NRN1(CH2)s2(CH2CH2O)s1(CH2)s3NRN1, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted C1-6 alkyl; (15) -C(O)NRB’RC’, where each of RB’ and RC’ is, independently, selected from the group consisting of (a) hydrogen, (b) C1-6 alkyl, (c) C6-10 aryl, and (d) C1-6 alk-C6-10 aryl; (16) -SO2RD’, where RD’ is selected from the group consisting of (a) C1-6 alkyl, (b) C6-10 aryl, (c) C1-6 alk-C6-10 aryl, and (d) hydroxy; (17) - SO2NRE’RF’, where each of RE’ and RF’ is, independently, selected from the group consisting of (a) hydrogen, (b) C1-6 alkyl, (c) C6-10 aryl and (d) C1-6 alk-C6-10 aryl; (18) -C(O)RG’, where RG’ is selected from the group consisting of (a) C1-20 alkyl (e.g., C1-6 alkyl), (b) C2-20 alkenyl (e.g., C2-6 alkenyl), (c) C6-10 aryl, (d) hydrogen, (e) C1-6 alk-C6-10 aryl, (f) amino-C1-20 alkyl, (g) polyethylene glycol of -(CH2)s2(OCH2CH2)s1(CH2)s3OR’, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R’ is H or C1-20 alkyl, and (h) amino-polyethylene glycol of -NRN1(CH2)s2(CH2CH2O)s1(CH2)s3NRN1, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted C1-6 alkyl; (19) -NRH’C(O)RI’, wherein RH’ is selected from the group consisting of (a1) hydrogen and (b1) C1-6 alkyl, and RI’ is
selected from the group consisting of (a2) C1-20 alkyl (e.g., C1-6 alkyl), (b2) C2-20 alkenyl (e.g., C2-6 alkenyl), (c2) C6-10 aryl, (d2) hydrogen, (e2) C1-6 alk-C6-10 aryl, (f2) amino-C1-20 alkyl, (g2) polyethylene glycol of -(CH2)s2(OCH2CH2)s1(CH2)s3OR’, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R’ is H or C1-20 alkyl, and (h2) amino-polyethylene glycol of -NRN1(CH2)s2(CH2CH2O)s1(CH2)s3NRN1, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted C1-6 alkyl; (20) - NRJ’C(O)ORK’, wherein RJ’ is selected from the group consisting of (a1) hydrogen and (b1) C1-6 alkyl, and RK’ is selected from the group consisting of (a2) C1-20 alkyl (e.g., C1-6 alkyl), (b2) C2-20 alkenyl (e.g., C2-6 alkenyl), (c2) C6-10 aryl, (d2) hydrogen, (e2) C1-6 alk-C6-10 aryl, (f2) amino-C1- 20 alkyl, (g2) polyethylene glycol of -(CH2)s2(OCH2CH2)s1(CH2)s3OR’, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R’ is H or C1-20 alkyl, and (h2) amino-polyethylene glycol of -NRN1(CH2)s2(CH2CH2O)s1(CH2)s3NRN1, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted C1-6 alkyl; and (21) amidine. In some embodiments, each of these groups can be further substituted as described herein. [61] The term “aryl,” as used herein, represents a mono-, bicyclic, or multicyclic carbocyclic ring system having one or two aromatic rings and is exemplified by phenyl, naphthyl, 1,2- dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, anthracenyl, phenanthrenyl, fluorenyl, indanyl, indenyl, and the like, and may be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of: (1) C1-7 acyl (e.g., carboxyaldehyde); (2) C1-20 alkyl (e.g., C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C1-6 alkylsulfinyl-C1-6 alkyl, amino-C1-6 alkyl, azido-C1-6 alkyl, (carboxyaldehyde)-C1-6 alkyl, halo-C1-6 alkyl (e.g., perfluoroalkyl), hydroxy-C1- 6 alkyl, nitro-C1-6 alkyl, or C1-6 thioalkoxy-C1-6 alkyl); (3) C1-20 alkoxy (e.g., C1-6 alkoxy, such as perfluoroalkoxy); (4) C1-6 alkylsulfinyl; (5) C6-10 aryl; (6) amino; (7) C1-6 alk-C6-10 aryl; (8) azido; (9) C3-8 cycloalkyl; (10) C1-6 alk-C3-8 cycloalkyl; (11) halo; (12) C1-12 heterocyclyl (e.g.,
C1-12 heteroaryl); (13) (C1-12 heterocyclyl)oxy; (14) hydroxy; (15) nitro; (16) C1-20 thioalkoxy (e.g., C1-6 thioalkoxy); (17) –(CH2)qCO2RA’, where q is an integer from zero to four, and RA’ is selected from the group consisting of (a) C1-6 alkyl, (b) C6-10 aryl, (c) hydrogen, and (d) C1-6 alk- C6-10 aryl; (18) –(CH2)qCONRB’RC’, where q is an integer from zero to four and where RB’ and RC’ are independently selected from the group consisting of (a) hydrogen, (b) C1-6 alkyl, (c) C6-10 aryl, and (d) C1-6 alk-C6-10 aryl; (19) –(CH2)qSO2RD’, where q is an integer from zero to four and where RD’ is selected from the group consisting of (a) alkyl, (b) C6-10 aryl, and (c) alk-C6-10 aryl; (20) –(CH2)qSO2NRE’RF’, where q is an integer from zero to four and where each of RE’ and RF’ is, independently, selected from the group consisting of (a) hydrogen, (b) C1-6 alkyl, (c) C6-10 aryl, and (d) C1-6 alk-C6-10 aryl; (21) thiol; (22) C6-10 aryloxy; (23) C3-8 cycloalkoxy; (24) C6-10 aryl-C1-6 alkoxy; (25) C1-6 alk-C1-12 heterocyclyl (e.g., C1-6 alk-C1-12 heteroaryl); (26) C2-20 alkenyl; and (27) C2-20 alkynyl. In some embodiments, each of these groups can be further substituted as described herein. For example, the alkylene group of a C1-alkaryl or a C1- alkheterocyclylcan be further substituted with an oxo group to afford the respective aryloyl and (heterocyclyl)oyl substituent group. [62] The term “acyl,” as used herein, represents an a radical of general formula –C(O)R, where R is an alkyl or aryl group. Examples of an “acyl” group include, but are not limited to, – C(O)CH3, –C(O)C2H5, and –C(O)Ph. [63] The term “carbonyl,” as used herein, represents a C(O) group, which can also be represented as C=O. [64] The term “carboxy,” as used herein, means –CO2H. [65] The term “cycloalkyl,” as used herein represents a monovalent saturated or unsaturated non- aromatic cyclic hydrocarbon group from three to eight carbons, unless otherwise specified, and is exemplified by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicycle heptyl, and the like. When the cycloalkyl group includes one carbon-carbon double bond or one carbon- carbon triple bond, the cycloalkyl group can be referred to as a “cycloalkenyl” or “cycloalkynyl” group respectively. Exemplary cycloalkenyl and cycloalkynyl groups include cyclopentenyl, cyclohexenyl, cyclohexynyl, and the like. Cycloalkyl groups can be optionally substituted with: (1) C1-7 acyl (e.g., carboxyaldehyde); (2) C1-20 alkyl (e.g., C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C1-6 alkylsulfinyl-C1-6 alkyl, amino-C1-6 alkyl, azido-C1-6 alkyl, (carboxyaldehyde)-C1-6 alkyl, halo- C1-6 alkyl (e.g., perfluoroalkyl), hydroxy-C1-6 alkyl, nitro-C1-6 alkyl, or C1-6 thioalkoxy-C1-6
alkyl); (3) C1-20 alkoxy (e.g., C1-6 alkoxy, such as perfluoroalkoxy); (4) C1-6 alkylsulfinyl; (5) C6- 10 aryl; (6) amino; (7) C1-6 alk-C6-10 aryl; (8) azido; (9) C3-8 cycloalkyl; (10) C1-6 alk-C3-8 cycloalkyl; (11) halo; (12) C1-12 heterocyclyl (e.g., C1-12 heteroaryl); (13) (C1-12 heterocyclyl)oxy; (14) hydroxy; (15) nitro; (16) C1-20 thioalkoxy (e.g., C1-6 thioalkoxy); (17) –(CH2)qCO2RA’, where q is an integer from zero to four, and RA’ is selected from the group consisting of (a) C1-6 alkyl, (b) C6-10 aryl, (c) hydrogen, and (d) C1-6 alk-C6-10 aryl; (18) –(CH2)qCONRB’RC’, where q is an integer from zero to four and where RB’ and RC’ are independently selected from the group consisting of (a) hydrogen, (b) C6-10 alkyl, (c) C6-10 aryl, and (d) C1-6 alk-C6-10 aryl; (19) – (CH2)qSO2RD’, where q is an integer from zero to four and where RD’ is selected from the group consisting of (a) C6-10 alkyl, (b) C6-10 aryl, and (c) C1-6 alk-C6-10 aryl; (20) –(CH2)qSO2NRE’RF’, where q is an integer from zero to four and where each of RE’ and RF’ is, independently, selected from the group consisting of (a) hydrogen, (b) C6-10 alkyl, (c) C6-10 aryl, and (d) C1-6 alk-C6-10 aryl; (21) thiol; (22) C6-10 aryloxy; (23) C3-8 cycloalkoxy; (24) C6-10 aryl-C1-6 alkoxy; (25) C1-6 alk-C1-12 heterocyclyl (e.g., C1-6 alk-C1-12 heteroaryl); (26) oxo; (27) C2-20 alkenyl; and (28) C2-20 alkynyl. In some embodiments, each of these groups can be further substituted as described herein. For example, the alkylene group of a C1-alkaryl or a C1-alkheterocyclyl can be further substituted with an oxo group to afford the respective aryloyl and (heterocyclyl)oyl substituent group. [66] The term “halogen,” as used herein, represents a halogen selected from bromine, chlorine, iodine, or fluorine. [67] The terms “heteroalkyl” and “heteroalkylidene,” as used herein, each refer to an alkyl group, as defined herein, in which one or two of the constituent carbon atoms have each been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkyl groups. The terms “heteroalkenyl” and heteroalkynyl,” as used herein refer to alkenyl and alkynyl groups, as defined herein, respectively, in which one or two of the constituent carbon atoms have each been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkenyl and heteroalkynyl groups can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkyl groups. [68] The term “heteroaryl,” as used herein, represents that subset of heterocyclyls, as defined herein, which are aromatic: i.e., they contain 4n+2 pi electrons within the mono- or multicyclic
ring system. Exemplary unsubstituted heteroaryl groups are of 1 to 12 (e.g., 1 to 11, 1 to 10, 1 to 9, 2 to 12, 2 to 11, 2 to 10, or 2 to 9) carbons. In some embodiment, the heteroaryl is substituted with 1, 2, 3, or 4 substituents groups as defined for a heterocyclyl group. [69] The term “oxo” as used herein, represents =O. [70] The term “polyethylene glycol,” as used herein, represents an alkoxy chain comprised of one or more monomer units, each monomer unit consisting of –OCH2CH2-. Polyethyelene glycol (PEG) is also sometimes referred to as polyethylene oxide (PEO) or polyoxyethylene (POE), and these terms may be considered interchangeable for the purpose of this disclosure. For example, a polyethylene glycol may have the structure, -(CH2)s2(OCH2CH2)s1(CH2)s3O-, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), and each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10). Polyethylene glycol may also be considered to include an amino-polyethylene glycol of - NRN1(CH2)s2(CH2CH2O)s1(CH2)s3NRN1-, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each RN1 is, independently, hydrogen or optionally substituted C1-6 alkyl. [71] The term “isomer,” as used herein, means any tautomer, stereoisomer, enantiomer, or diastereomer of any compound. It is recognized that the compounds can have one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as double-bond isomers (i.e., geometric E/Z isomers) or diastereomers, enantiomers (i.e., (+) or (-)) or cis/trans isomers). Unless otherwise noted, chemical structures depicted herein encompass all of the corresponding stereoisomers, that is, both the stereomerically pure form (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) and enantiomeric and stereoisomeric mixtures, e.g., racemates. Enantiomeric and stereoisomeric mixtures of compounds can typically be resolved into their component enantiomers or stereoisomers by well-known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent. Enantiomers and stereoisomers can also be obtained from stereomerically or enantiomerically pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods.
[72] The term “stereoisomer,” as used herein, refers to all possible different isomeric as well as conformational forms which a compound may possess (e.g., a compound of any formula described herein), in particular all possible stereochemically and conformationally isomeric forms, all diastereomers, enantiomers and/or conformers of the basic molecular structure. Some compounds may exist in different tautomeric forms, all of the latter being included within the scope of the present disclosure. [73] The term “diastereomer,” as used herein means stereoisomers that are not mirror images of one another and are non-superimposable on one another. [74] The term “enantiomer,” as used herein, means each individual optically active form of a compound, having an optical purity or enantiomeric excess (as determined by methods standard in the art) of at least 80% (i.e., at least 90% of one enantiomer and at most 10% of the other enantiomer), preferably at least 90% and more preferably at least 98%. Other terms [75] As used herein, the term “about” or “approximately” refers to a ±10% variation from the recited quantitative value (and includes the recited quantitative value itself) unless otherwise indicated or inferred from the context. For example, unless otherwise stated or inferred from the context, a dose of about 100 kBq/kg indicates a dose range of 100±10% kBq/kg, i.e., from 90 kBq/kg to 110 kBq/kg, inclusive. [76] As used herein, the term “administered in combination,” “combined administration,” or “co- administered” means that two or more agents are administered to a subject at the same time or within an interval such that there may be an overlap of an effect of each agent on the patient. Thus, two or more agents that are administered in combination need not be administered together. In some embodiments, they are administered within 90 days (e.g., within 80, 70, 60, 50, 40, 30, 20, 10, 5, 4, 3, 2, or 1 day(s)), within 28 days (e.g., with 14, 7, 6, 5, 4, 3, 2, or 1 day(s), within 24 hours (e.g., 12, 6, 5, 4, 3, 2, or 1 hour(s), or within about 60, 30, 15, 10, 5, or 1 minute of one another. In some embodiments, the administrations of the agents are spaced sufficiently closely together such that a combinatorial effect is achieved. [77] As used herein, “administering” an agent to a subject includes contacting cells of said subject with the agent.
[78] The term “cancer” refers to any cancer caused by the proliferation of malignant neoplastic cells, such as tumors, neoplasms, carcinomas, sarcomas, leukemias, and lymphomas. A “solid tumor cancer” is a cancer comprising an abnormal mass of tissue, e.g., sarcomas, carcinomas, and lymphomas. A “hematological cancer” or “liquid cancer,” as used interchangeably herein, is a cancer present in a body fluid, e.g., lymphomas and leukemias. [79] The term “chelate” as used herein, refers to an organic compound or portion thereof that can be bonded to a central metal or radiometal atom at two or more points. [80] The term “conjugate,” as used herein, refers to a molecule that contains a chelating group or metal complex thereof, a linker group, and which optionally contains a therapeutic moiety or a targeting moiety. [81] The term “therapeutic moiety” as used herein refers to any molecule or any part of a molecule that confers a therapeutic benefit. In some embodiments, the therapeutic moiety is a protein or polypeptide, e.g., an antibody, an antigen-binding fragment thereof. In some embodiments, the therapeutic moiety is a small molecule. [82] The term “targeting moiety” as used herein refers to any molecule or any part of a molecule that binds to a given target. In some embodiments, the targeting moiety is a protein or polypeptide such as an antibody or antigen binding fragment thereof, a nanobody, an affibody, or a consensus sequence from a Fibronectin type III domain. In some embodiments, the targeting moiety is a peptide or a small molecule. [83] As used herein, the term “compound,” is meant to include all stereoisomers, geometric isomers, and tautomers of the structures depicted. [84] The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present disclosure that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically active starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present disclosure. Cis and trans geometric isomers of the compounds of the present disclosure are described and may be isolated as a mixture of isomers or as separated isomeric forms.
[85] Compounds of the present disclosure also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond and the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Examples prototropic tautomers include ketone – enol pairs, amide – imidic acid pairs, lactam – lactim pairs, amide – imidic acid pairs, enamine – imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, such as, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4- triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution. [86] At various places in the present specification, substituents of compounds of the present disclosure are disclosed in groups or in ranges. It is specifically intended that the present disclosure include each and every individual sub-combination of the members of such groups and ranges. For example, the term “C1-6 alkyl” is specifically intended to individually disclose methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl. Herein a phrase of the form “optionally substituted X” (e.g., optionally substituted alkyl) is intended to be equivalent to “X, wherein X is optionally substituted” (e.g., “alkyl, wherein said alkyl is optionally substituted”). It is not intended to mean that the feature “X” (e.g., alkyl) per se is optional. [87] As used herein, the terms “decrease,” “decreased,” “increase,” “increased,” or “reduction,” “reduced,” (e.g., in reference to therapeutic outcomes or effects) have meanings relative to a reference level. In some embodiments, the reference level is a level as determined by the use of said method with a control in an experimental animal model or clinical trial. In some embodiments, the reference level is a level in the same subject before or at the beginning of treatment. In some embodiments, the reference level is the average level in a population not being treated by said method of treatment. [88] The term an “effective amount” of an agent (e.g., any of the foregoing compounds or conjugates), as used herein, is that amount sufficient to effect beneficial or desired results, such as clinical results, and, as such, an “effective amount” depends upon the context in which it is being applied. [89] The term “pharmaceutical composition,” as used herein, represents a composition containing a compound described herein formulated with a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition is manufactured or sold with the approval of a
governmental regulatory agency as part of a therapeutic regimen for the treatment of disease in a mammal. Pharmaceutical compositions can be formulated, for example, for oral administration in unit dosage form (e.g., a tablet, capsule, caplet, gelcap, or syrup); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); or in any other formulation described herein. [90] A “pharmaceutically acceptable excipient,” as used herein, refers any ingredient other than the compounds described herein (for example, a vehicle capable of suspending or dissolving the active compound) and having the properties of being nontoxic and non-inflammatory in a patient. Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, radioprotectants, sorbents, suspending or dispersing agents, sweeteners, or waters of hydration. Exemplary excipients include, but are not limited to: ascorbic acid, histidine, phosphate buffer, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol. [91] The term “pharmaceutically acceptable salt,” as use herein, represents those salts of the compounds described here that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, or allergic response. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J. Pharmaceutical Sciences 66:1-19, 1977 and in Pharmaceutical Salts: Properties, Selection, and Use, (Eds. P.H. Stahl and C.G. Wermuth), Wiley-VCH, 2008. The salts can be prepared in situ during the final isolation
and purification of the compounds described herein or separately by reacting the free base group with a suitable organic acid. [92] Compounds may have ionizable groups so as to be capable of preparation as pharmaceutically acceptable salts. These salts may be acid addition salts involving inorganic or organic acids or the salts may, in the case of acidic forms of compounds, be prepared from inorganic or organic bases. Frequently, the compounds are prepared or used as pharmaceutically acceptable salts prepared as addition products of pharmaceutically acceptable acids or bases. Suitable pharmaceutically acceptable acids and bases are well-known in the art, such as hydrochloric, sulphuric, hydrobromic, acetic, lactic, citric, or tartaric acids for forming acid addition salts, and potassium hydroxide, sodium hydroxide, ammonium hydroxide, caffeine, various amines for forming basic salts. Methods for preparation of the appropriate salts are well- established in the art. [93] Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts, among others. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine. [94] The term “radiopharmaceutical” or “radioconjugate,” as used herein, refers to any compound or conjugate that includes a radioisotope or radionuclide, such as any of the radioisotopes or radionuclides described herein. [95] As used herein, the term “radionuclide,” refers to an atom capable of undergoing radioactive decay (e.g., 3H, 14C, 15N, 18F, 35S, 47Sc, 55Co, 60Cu, 61Cu, 62Cu, 64Cu, 67Cu, 75Br, 76Br , 77Br , 89Zr, 86Y, 87Y, 90Y, 97Ru, 99Tc, 99mTc, 105Rh, 109Pd, 111In, 123I, 124I, 125I, 131I, 149Pm, 149Tb, 153Sm, 166Ho,
177Lu, 186Re, 188Re, 198Au, 199Au, 203Pb, 211At, 212Pb , 212Bi, 213Bi, 223Ra, 225Ac, 227Th, 229Th, 66Ga, 67Ga, 68Ga, 82Rb, 117mSn, or 201Tl). The terms radioactive nuclide, radioisotope, or radioactive isotope may also be used to describe a radionuclide. Radionuclides may be used as detection agents. Exemplary radionuclides used in this disclosure include, but are not limited to, 43Sc, 44Sc, 47Sc, 55Co, 60Cu, 61Cu, 62Cu, 64Cu, 67Cu, 66Ga, 67Ga, 68Ga, 82Rb, 86Y, 87Y, 89Zr, 90Y, 97Ru, 99Tc, 99mTc, 105Rh, 109Pd, 111In, 117mSn, 133La, 134Ce, 149Pm, 149Tb, 153Sm, 152Tb, 155Tb, 161Tb, 166Ho, 177Lu, 186Re, 188Re, 198Au, 199Au, 201Tl, 203Pb, 211At, 212Pb, 212Bi, 213Bi, 223Ra, 225Ac, 227Th, and 229Th. [96] As used herein, and as well understood in the art, “to treat” a condition or “treatment” of the condition (e.g., the conditions described herein such as cancer) is an approach for obtaining beneficial or desired results, such as clinical results. Beneficial or desired results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions; diminishment of extent of disease, disorder, or condition; stabilized (i.e., not worsening) state of disease, disorder, or condition; preventing spread of disease, disorder, or condition; delay or slowing the progress of the disease, disorder, or condition; amelioration or palliation of the disease, disorder, or condition; and remission (whether partial or total), whether detectable or undetectable. In the context of cancer treatment, “ameliorating” may include, for example, reducing incidence of metastases, reducing tumor volume, reducing tumor vascularization and/or reducing the rate of tumor growth. “Palliating” a disease, disorder, or condition means that the extent and/or undesirable clinical manifestations of the disease, disorder, or condition are lessened and/or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment. Compounds [97] The disclosure is directed to, in part, compounds that are radiopharmaceuticals. In some embodiments, a disclosed compound is selected from the group consisting of the compounds identified in Table 1.
Table 1. Compound Structure Compound A HO2C HO 2C N N O O O O N N N O O N CO2H H CO2H HO HN N O N N OH Compound B CO 2 H N N CO 2 H O O O O N N N O O N 3 H HO 2 C HO HN N O N N OH Compound C CO 2 H N N CO2 H O O O O N N N O O N 9 H HO 2 C HO HN N O OH N N Compound D O CO H 2H O O N COH N N O O N N 2 H O N N HO2C HO2C HO HN N O OH N N
Compound E HO O O HO N N O H H O O N N N N OH N O O N H O O O OH HO O N N N H OH N Compound F HO O O OH HO N N O O O H O N N N OH N O O N H O O O OH HO O N N OH N N H Compound G O O OH H O N N N N OH O HO N N O HO O HO O N N N N H OH Compound H O N O OH H N O N N O OH HO O HO N N HO O O N HO N O N N H OH
Compound I O HO O OH O HO N N O H O N N OH N N N H O O O OH HO O N N N N H OH Compound J HO O O HO O O H H N N N N N N H OH O O N N O H2N O HN OH HO O H2N NH O N N N H OH N Compound K O OH O H O N N N N H N OH O HO N N O HO O HO O N N N N H OH Compound L O OH N O N O N N OH N HO O HO O N N N N H OH
Compound M HO O O HO N N O N N OH N O O OH HO O N N H OH N N Compound N HO O O HO N N O N N OH N O O OH BnO O N N N N H OBn Chelators [98] The compounds of Formula I comprise chelating moieties or chelators. [99] As disclosed herein, the chelator can be selected from the group consisting of DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), DOTMA (1R,4R,7R,10R)-Į^^Į¶^^Į´^^ Į¶´-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, DOTAM (1,4,7,10- tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane), DOTPA (1,4,7,10- tetraazacyclododecane-1,4,7,10-tetra propionic acid), DO3AM-acetic acid (2-(4,7,10-tris(2- amino-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid), DOTA-GA anhydride (2,2’,2”-(10-(2,6-dioxotetrahydro-2H-pyran-3-yl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)triacetic acid, DOTP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methylene phosphonic acid)), DOTMP (1,4,6,10-tetraazacyclodecane-1,4,7,10-tetramethylene phosphonic acid, DOTA- 4AMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(acetamido-methylenephosphonic acid), CB-TE2A (1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-diacetic acid), NOTA (1,4,7-
triazacyclononane-1,4,7-triacetic acid), NODA-GA (1,4,7-triazacyclononane-4,7-diacetic acid-1- [2-glutaric acid]), NOTP (1,4,7-triazacyclononane-1,4,7-tri(methylene phosphonic acid), TETPA (1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetrapropionic acid), TETA (1,4,8,11- tetraazacyclotetradecane-1,4,8,11-tetra acetic acid), HEHA (1,4,7,10,13,16- hexaazacyclohexadecane-1,4,7,10,13,16-hexaacetic acid), PEPA (1,4,7,10,13- pentaazacyclopentadecane-N,N’,N”,N’’’, N’’’’-pentaacetic acid), H4octapa (N,N’-bis(6-carboxy- 2-pyridylmethyl)-ethylenediamine-N,N’-diacetic acid), H2dedpa (1,2-[[6-(carboxy)-pyridin-2- yl]-methylamino]ethane), H6phospa (N,N’-(methylenephosphonate)-N,N’-[6- (methoxycarbonyl)pyridin-2-yl]-methyl-1,2-diaminoethane), TTHA (triethylenetetramine- N,N,N’,N”,N’’’, N’’’-hexaacetic acid), DO2P (tetraazacyclododecane dimethanephosphonic acid), HP-DO3A (hydroxypropyltetraazacyclododecanetriacetic acid), EDTA (ethylenediaminetetraacetic acid), Deferoxamine, DTPA (diethylenetriaminepentaacetic acid), DTPA-BMA (diethylenetriaminepentaacetic acid-bismethylamide), and porphyrin. [100] In certain embodiments, the chelator is selected from DOTA, DOTA-GA, NOTA, NODA-GA, NODA-SA, DTPA, TETA, EDTA, TRITA, CDTA, and DFO, which are defined as below: DOTA stands for 1,4,7,10-tetrazacyclododecane-1,4,7,10-tetraacetic acid, DOTA-GA, or DOTAGA as used herein, stands for 1,4,7,10-tetraazacyclododececane,1- (glutaric acid)-4,7,10-triacetic acid, NOTA stands for 1,4,7-triazacyclononanetriacetic acid, NODA-GA, or NODAGA as used herein, stands for 1,4,7-triazacyclononane-N-glutaric acid-N',N"-diacetic acid, NODA-SA stands for 1,4,7- triazacyclononane -1-succinic acid-4,7-diacetic acid, DTPA stands for diethylenetriaminepentaacetic acid, TETA stands for 1,4,8,11-tetraazacyclododecane-1,4,8,11-tetraacetic acid, EDTA stands for ethylenediamine-N,N'-tetraacetic acid, TRITA stands for 1,4,7,10 tetraazacyclotridecane-l,4,7,10-tetraacetic acid, CDTA stands for trans-1,2-diaminocyclohexane-1^1^1ƍ^1ƍ-tetraacetic acid, DFO stands for the Desferal or Desferrioxamine type group of chelators, the chemical name of the non-limiting example is N-[5-({3-[5-(Acetyl-hydroxy-amino)-pentylcarbamoyl]- propionyl}-hydroxy-amino)-pentyl]-N'-(5-amino-pentyl)-N'-hydroxy-succinamide,
and with the chemical structures thereof being as follows: O HO O N N HO O OH N N HO O O OH DOTA-GA CO2H CO2 H N COH N N 2 HO2C N CO2H N N CO HO2C HO 2H 2C N N COH HO 2 2C EDTA NODA-GA NODA-SA COH CO2H 2 [101] In certain embodiments, the chelator is selected from DOTA, DOTAGA, NOTA, and NODAGA. [102] In certain embodiments, the chelator is DOTAGA and the compounds have the structure of Formula II:
O HO O N N HO O Z1 OH X N N N Y Z2 n O O OH HO HN N O N N OH (II), wherein each of variables X, Y, n, Z1, and Z2 is as defined in the SUMMARY section above. [103] In certain embodiments, the chelator is represented by the variable W. In some O HO O N N HO O OH N N embodiments, W is selected from the group consisting of O , O HO O OH OH N N O HO O O N OH N N N N N O N N O O OH , O O OH , and O OH O OH . Radionuclides [104] The present disclosure includes radiopharmaceuticals each comprising a radionuclide. Examples of suitable radionuclides include, but are not limited to, 43Sc, 44Sc, 47Sc, 55Co, 60Cu, 61Cu, 62Cu, 64Cu, 67Cu, 66Ga, 67Ga, 68Ga, 82Rb, 86Y, 87Y, 89Zr, 90Y, 97Ru, 99Tc, 99mTc, 105Rh, 109Pd, 111In, 117mSn, 133La, 134Ce, 149Pm, 149Tb, 153Sm, 152Tb, 155Tb, 161Tb, 166Ho, 177Lu, 186Re, 188Re, 198Au, 199Au, 201Tl, 203Pb, 211At, 212Pb, 212Bi, 213Bi, 223Ra, 225Ac, 227Th, and 229Th. [105] In some embodiments, the radionuclide is selected from the group consisting of 64Cu, 67Cu, 68Ga, 90Y, 111In, 149Tb, 153Sm, 177Lu, 211At, 212Bi, 212Pb, 213Bi, 223Ra, 225Ac, and 227Th.
[106] In some embodiments, the radionuclide is 68Ga, 89Zr, 90Y, 111In, 177Lu, or 225Ac. In certain embodiments, the radionuclide is 177Lu or 225Ac. [107] In some embodiments, the radionuclide used herein is a beta-emitting radionuclide such as 177Lu. In some embodiments, the radionuclide used herein is an alpha-emitting radionuclide such as 225Ac. Linkers [108] The compounds of the present disclosure comprise the unique linker as shown within the Z1 X Y 2 n Z structure of Formula I that comprises , wherein X is absent or C=O; Y is each independently O or NR, R being H, alkyl, aryl, or acyl; n is an integer of 0-5 (inclusive); Z1 and Z2 each are, independently, absent or an amino acid unit. [109] The term “amino acid unit” described herein refers to one or more organic moieties each formed from an amino acid (e.g., a natural amino acid or an unnatural amino acid). Typically, an amino acid unit is formed as shown below: O O H N NH HO 2 2 2 R R amino acid amino acid unit where R2 represents an alkyl, cycloalkyl, aryl, or heteroaryl, each of which can be optionally substituted with a suitable substituent described herein (e.g., -C(O)OH, -NH2, -NH3+, - NH(CNH2+)NH2); alternatively, R2 together with the -NH2 group within the amino acid form a heterocycle. [110] In some embodiments, an amino acid unit refers to an organic moiety formed from aspartic acid (Asp), glutamic acid (Glu), 2,4-diaminobutyric acid (Dab), 2,3-diaminopropionic acid (Dap), lysine (Lys), or arginine (Arg), with their structures shown below:
NH2 H2N COOH H2N COOH 2,4-diaminobutyric acid (Dab) Glycine (Gly, G) NH2 H2N COOH 2,3-diaminopropionic acid (Dap) [111] In some embodiments, the compounds of Formula I or Formula II feature that the amino acid unit comprises an organic moiety formed from aspartic acid (Asp), for example, with the OH O N H structure shown as (including its stereoisomers) O . [112] In some embodiments, the compounds of Formula I or Formula II feature that the amino O H N acid unit is formed from glycine (Gly), for example, with the structure .
[113] In some embodiments, the compounds of Formula I or Formula II feature that the amino acid unit is formed from glutamic acid (Glu), for example, with the structure shown below O H N (including its stereoisomers) HO O . [114] In some embodiments, an amino acid unit refers to a fragment comprising multiple organic moieties formed from glutamine, glutamic acid, and arginine, with their structures shown below, including all their stereoisomers: HO O HO O HO O O O O O H H H H N N N N N N N H H H O O O H H2N O HN H N O N 2 H2N NH H2N NH . [115] In some embodiments, the compounds of Formula I or Formula II feature that X is C=O. [116] In some embodiments, the compounds of Formula I or Formula II feature that n is 1, 2, 3, 4, or 5. In certain embodiments, n is 4 or 5. [117] In some embodiments, the compounds of Formula I or Formula II feature that each of Z1 and Z2 is absent. [118] In some embodiments, the compounds of Formula I or Formula II feature that each of Z1 and Z2 is absent, X is C=O, Y is each independently O or NH, and n is 0, 1, 2, 3, 4, or 5. Exemplary linkers include, but are not limited to, the following: O O O H O N O N , , O O N H , H , O O H O N O O O O O O N , and H , each of which can be optionally substituted with a suitable substituent described herein.
[119] In some embodiments, the compounds of Formula I or Formula II feature that X is C=O, n is 4 or 5, Z1 is an amino acid unit, and Z2 is absent. A representative exemplary compound is one of the following: O HO O N N HO O H O OH (S) N O O N N N O N H O O CO2 H O OH HO HN N O N N OH , and O HO O N N HO O H O OH (S) N O O N N N O N H O O CO 2 H HO HN N O OH N N . [120] In some embodiments, the compounds of Formula I or Formula II feature that X is C=O, n is 4 or 5, Z1 is absent, and Z2 is an amino acid unit. A representative exemplary compound is one of the following: O HO O N N HO HO O 2C O H OH O N N N N O O (S) N H O O O OH HO HN N O N N OH , and
O HO O N N HO HO O 2 C O H OH O N N N N O O (S) N H O O HO HN N O N N OH . [121] In some embodiments, the compounds of Formula I or Formula II feature that X is (C=O)NH, n is 4 or 5, each of Z1 and Z2 is absent. A representative exemplary compound is one of the following: O OH O H O N O N N O O O N N H O OH HO N N O HO O HO HN N O OH N N , and O H O N O N N O O O H O N N OH HO N N O HO O HO HN N O OH N N . [122] In some embodiments, the compounds of Formula I or Formula II feature that X is C=O, n is 4 or 5, Z1 is absent, and Z2 is (C=O)NH(CH2CH2)NH. A representative exemplary compound is one of the following:
HO O O N N HO O H H O OH O N N N N N O O N O H O O OH HO HN N O OH N N , and HO O O N N HO O H H O OH O N N O N N N O N O H O HO HN N O N N OH . [123] In some embodiments, the compounds of Formula I or Formula II feature that X is absent, n is 0, Z1 is absent, and Z2 is an amino acid unit. Thus, the linker of such compounds O H N would be: R2 , wherein R2 represents an alkyl, cycloalkyl, aryl, or heteroaryl, each of which can be optionally substituted with a suitable substituent described herein; alternatively, R2 together with the -NH2 group within the amino acid form a heterocycle. [124] A representative exemplary compound is one of the following:
O O OH H O (S) N N N N O OH CO2 H HO N N O HO O HO HN N O N N OH , and O O H N OH (S) N N N O N CO H HO N 2 HO O O HO HN N O N N OH . [125] In some embodiments, the compounds of Formula I or Formula II feature that X is absent, n is 0, each of Z1 and Z2 is absent. A representative exemplary compound is one of the following: O O HO HO O O N N N N HO HO O OH O OH N N N N N O N O O OH HO HN HO HN N N O O N N N N OH , and OH . Subjects [126] In some disclosed methods, a therapy (e.g., comprising a therapeutic agent) is administered to a subject. In some embodiments, the subject is a mammal, e.g., a human.
[127] In some embodiments, the subject has cancer or is at risk of developing cancer. For example, the subject may have been diagnosed with cancer. The cancer may be a primary cancer or a metastatic cancer. Subjects may have any stage of cancer, e.g., stage I, stage II, stage III, or stage IV with or without lymph node involvement and with or without metastases. Provided compositions may prevent or reduce further growth of the cancer and/or otherwise ameliorate the cancer (e.g., prevent or reduce metastases). In some embodiments, the subject does not have cancer but has been determined to be at risk of developing cancer, e.g., because of the presence of one or more risk factors such as environmental exposure, presence of one or more genetic mutations or variants, family history, etc. In some embodiments, the subject has not been diagnosed with cancer. [128] In some embodiments, the cancer is small-cell lung cancer, non-small-cell lung cancer, sarcoma, pancreatic cancer, breast cancer, or colon cancer. Administration and dosage Effective doses [129] The present disclosure provides methods of using a compound of Formula I for treating clinical indications expressing HSP90, with the compound administered to a subject (e.g., a human) in an amount therapeutically effective for such treatment. [130] This disclosure also covers combination therapies in which the amounts of each therapeutic may or may not be, on their own, therapeutically effective. In some embodiments, therapeutic combinations as disclosed herein are administered to a subject in a manner (e.g., dosing amount and timing) sufficient to cure or at least partially arrest the symptoms of the disorder and its complications. In the context of a single therapy (a “monotherapy”), an amount adequate to accomplish this purpose is defined as a “therapeutically effective amount,” an amount of a compound sufficient to substantially improve at least one symptom associated with the disease or a medical condition. The “therapeutically effective amount” typically varies depending on the therapeutic. For known therapeutic agents, the relevant therapeutically effective amounts may be known to or readily determined by those of skill in the art. [131] For example, in the treatment of cancer, an agent or compound that decreases, prevents, delays, suppresses, or arrests any symptom of the disease or condition would be therapeutically effective. A therapeutically effective amount of an agent or compound is not required to cure a
disease or condition but will provide a treatment for a disease or condition such that the onset of the disease or condition is delayed, hindered, or prevented, or the disease or condition symptoms are ameliorated, or the term of the disease or condition is changed or, for example, is less severe or recovery is accelerated in an individual. For example, a treatment may be therapeutically effective if it causes a cancer to regress or to slow the cancer’s growth. [132] The dosage regimen (e.g., amounts of each therapeutic, relative timing of therapies, etc.) that is effective for these uses may depend on the severity of the disease or condition and the weight and general state of the subject. For example, the therapeutically effective amount of a particular composition comprising a therapeutic agent applied to mammals (e.g., humans) can be determined by the person of ordinary skill in the art with consideration of individual differences in age, weight, and the condition of the mammal. Because certain conjugates of the present disclosure exhibit an enhanced ability to target cancer cells and residualize, the dosage of these compounds can be lower than (e.g., less than or equal to about 90%, 75%, 50%, 40%, 30%, 20%, 15%, 12%, 10%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1% of) the equivalent dose of required for a therapeutic effect of the unconjugated agent. Therapeutically effective and/or optimal amounts can also be determined empirically by those of skill in the art. Thus, lower effective doses can also be determined by those of skill in the art. [133] Single or multiple administrations of a radiopharmaceutical or a composition (e.g., a pharmaceutical composition comprising a therapeutic agent or a radiopharmaceutical) can be carried out with dose levels and pattern being selected by the treating physician. The dose and administration schedule can be determined and adjusted based on the severity of the disease or condition in the subject, which may be monitored throughout the course of treatment according to the methods commonly practiced by clinicians or those described herein. [134] As provided above, a radiopharmaceutical compound of this disclosure may be administered in combination with another therapeutic agent. In the disclosed combination therapy methods, the first and second therapies may be administered sequentially or concurrently to a subject. For example, a first composition comprising a first therapeutic agent and a second composition comprising a second therapeutic agent may be administered sequentially or concurrently to a subject. Alternatively, a composition comprising a combination of a first therapeutic agent and a second therapeutic agent may be administered to the subject.
[135] In some embodiments, the radiopharmaceutical is administered in a single dose. In some embodiments, the radiopharmaceutical is administered more than once, i.e., multiple doses. When the radiopharmaceutical is administered more than once, the dose of each administration may be the same or different. [136] In some embodiments, compositions (such as compositions comprising radiopharmaceuticals) are administered for radiation treatment planning or diagnostic purposes. When administered for radiation treatment planning or diagnostic purposes, compositions may be administered to a subject in a diagnostically effective dose and/or an amount effective to determine the therapeutically effective dose. In some embodiments, a first dose of disclosed conjugate or a composition (e.g., pharmaceutical composition) thereof is administered in an amount effective for radiation treatment planning, followed administration of a combination therapy including a conjugate as disclosed herein and another therapeutic. [137] Pharmaceutical compositions comprising one or more agents (e.g., radiopharmaceuticals) can be formulated for use in accordance with disclosed methods and systems in a variety of drug delivery systems. One or more physiologically acceptable excipients or carriers can also be included in the composition for proper formulation. Examples of suitable formulations are found in Remington’s Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 17th ed., 1985. For a brief review of methods for drug delivery, see, e.g., Langer (Science 249:1527- 1533, 1990). Formulations [138] Pharmaceutical compositions may be formulated for parenteral, intranasal, topical, oral, or local administration, such as by a transdermal means, for prophylactic and/or therapeutic treatment. Pharmaceutical compositions can be administered parenterally (e.g., by intravenous, intramuscular, or subcutaneous injection), or by oral ingestion, or by topical application or intraarticular injection at areas affected by the vascular or cancer condition. Examples of additional routes of administration include intravascular, intra-arterial, intratumor, intraperitoneal, intraventricular, intraepidural, as well as nasal, ophthalmic, intrascleral, intraorbital, rectal, topical, or aerosol inhalation administration. Also specifically contemplated are sustained release administration, by such means as depot injections or erodible implants or components. Suitable compositions include compositions comprising include agents (e.g.,
compounds as disclosed herein) dissolved or suspended in an acceptable carrier, preferably an aqueous carrier, e.g., water, buffered water, saline, or PBS, among others, e.g., for parenteral administration. Compositions may contain pharmaceutically acceptable auxiliary substances to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents, or detergents, among others. In some embodiments, compositions are formulated for oral delivery; for example, compositions may contain inert ingredients such as binders or fillers for the formulation of a unit dosage form, such as a tablet or a capsule. In some embodiments, compositions are formulated for local administration; for example, compositions may contain inert ingredients such as solvents or emulsifiers for the formulation of a cream, an ointment, a gel, a paste, or an eye drop. [139] Compositions may be sterilized, e.g., by conventional sterilization techniques, or sterile filtered. Aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the preparations typically will be between 3 and 11, more preferably between 5 and 9 or between 6 and 8, and most preferably between 6 and 7, such as 6 to 6.5. In some embodiments, compositions in solid form are packaged in multiple single dose units, each containing a fixed amount of the above-mentioned agent or agents, such as in a sealed package of tablets or capsules. In some embodiments, compositions in solid form are packaged in a container for a flexible quantity, such as in a squeezable tube designed for a topically applicable cream or ointment. Synthesis of Radiopharmaceuticals Comprising Compounds of Formula I [140] Compounds of Formula I comprise conjugates targeting HSP90, which can be radiolabeled with a radionuclide such as Indium-111 (111In), Lutetium-177 (177Lu), or Actinium- 225 (225Ac) to form radionuclide-chelated radiopharmaceuticals. The synthesis of compounds of Formula I, or their radionuclide-chelated radiopharmaceuticals, can be referred to WO 2020/205948. Below are the synthetic schemes or protocols that can be followed to synthesize the corresponding compounds. A person of ordinary skill in the art would have been able, based on the disclosures provided herein and the knowledge in the field, to prepare the depicted compounds and their structurally similar analogs (e.g., compounds with different chelators such as DOTA, NOTA, and NODA-GA).
[141] Synthetic scheme 1. O t O BuO O O O O O O NH2 t N N BuO O OtBu N N Coupling agents (PyBOP or HATU or HBTU or CDI) HO O Base (TEA or DIPEA) O O tBu Solvent (THF or DMF) t O BuO O t N N BuO O H O , Pd OtBu 2 /C O O N N O O O N MeOH H O O OtBu NH tBuO O O HO HN N t N N BuO O O O OtBu OH N N O O N N HO O O N H O O O tBu Coupling agents (PyBOP or HATU or HBTU or CDI) Base (TEA or DIPEA) Solvent (THF or DMF)
t O BuO O t N N BuO O O OtBu O O N N N O O N H O O OtBu 95% TFA, 2.5% TIPS, 2.5% water HO HN N O N N OH O HO O N N HO O O OH O O N N N O O N H O O OH Chemical Formula: C 56 H 84 N 10 O 17 HO HN Exact Mass: 1168.60 N Molecular Weight: 1169.34 O N N OH [142] Synthetic scheme 2.
t O BuO O NH t N N BuO O OtBu N N HO O O OtBu HO HN N Coupling agents (PyBOP or HATU or HBTU or CDI) O Base (TEA or DIPEA) N N OH Solvent (THF or DMF) tBuO O O HO O N N O tBuO O Ot N N Bu HO N N O OH N O N N O OtBu N O O OH 95% TFA, 2.5% TIPS, 2.5% water Chemical Formula: C HO HN 45H63N9O12 Exact Mass: 921.46 N HO HN N Molecular Weight: 922.05 O OH N N O OH N N [143] Synthetic scheme 3. tBuO O O t N N BuO O OtBu t N N O O O Bu O HO H O O (S) N NH 2 t MeO N N MeO (S) O O Bu OtBu t O BuO2C tBuO N N CO2 tBu Coupling agents (PyBOP or HATU or HBTU or CDI) O Base (TEA or DIPEA) tBuO O Solvent (THF or DMF)
NH O O O t Bu HO HN H O N (S)N HO O LiOH.H2O N N N N OtBu OH t O BuOC tBuO THF, MeOH, water 2 N N Coupling agents (PyBOP or HATU or HBTU or CDI) O t Base (TEA or DIPEA) BuO O Solvent (THF or DMF) O O O t Bu H N O (S) N N N O OtBu tBuO 2C tBuO N N O 95% TFA, 2.5% TIPS, 2.5% water tBuO O HO HN N O N N OH O O OH H N O (S) N N N O OH CO2H HO N N O HO O HO HN N Chemical Formula: C49H68N10O15 Exact Mass: 1036.49 O N N Molecular Weight: 1037.14 OH
[144] Synthetic scheme 4. tBuO O t N N BuO O N N O tBu O O O tBu O HO H O O (S)N MeO MeO (S) NH 2 O O tBu N N O O tBu tBuO2C tBuO 2t N N CO Bu Coupling agents (PyBOP or HATU or HBTU or CDI) O Base (TEA or DIPEA) tBuO O Solvent (THF or DMF) O O O O t Bu RO O NH2 H O O O (S)N LiOH.H2O HO N N R = Benzyl O OtBu tBuOC t THF, MeOH, water 2 BuO N N Coupling agents (PyBOP or HATU or HBTU or CDI) O t Base (TEA or DIPEA) BuO O Solvent (THF or DMF) NH t O BuO O HO HN N N N tBuO tBuO O O 2C O t N N H N O Bu OH O N N RO O O (S) N H O O O O t Coupling agents (PyBOP or HATU or HBTU or CDI) Bu Base (TEA or DIPEA) R = Benzyl H2, Pd-C Solvent (THF or DMF) MeOH R = H
t O BuO O tBuO t N N 2C BuO O O H OtBu O N N N N O O (S) N H O O O OtBu 95% TFA, 2.5% TIPS, 2.5% water HO HN N O N N OH O HO O N N HO2C HO O O H OH O N N N N O O (S) N H O O O OH Chemical Formula: C58H85N11O19 HO HN Exact Mass: 1239.60 N Molecular Weight: 1240.38 O N N OH [145] Synthetic scheme 5. O t O BuO O NH O RO O O 2 t N N BuO R = Benzyl O OtBu N N HO Coupling agents (PyBOP or HATU or HBTU or CDI) O t Base (TEA or DIPEA) O OBu Solvent (THF or DMF)
tBuO O O O (S) NH 2 N N MeO tBuO O OtBu N N CO2 tBu RO O O O N H O O Coupling agents (PyBOP or HATU or HBTU or C O Ot DI) Bu R = Benzyl Base (TEA or DIPEA) H2, Pd-C Solvent (THF or DMF) MeOH R = H t O BuO O t N N BuO LiOH.H2O O H O OtBu (S)N O O N N THF, MeOH, water MeO O N H O O t CO2tBu O OBu NH tBuO O O HO HN N t N N BuO O O O N N H O tBu OH ( N O O N N HO S) O N H O Coupling agents (PyBOP or HATU or HBTU or CDI) O CO2 tBu O O tBu Base (TEA or DIPEA) Solvent (THF or DMF) t O BuO O t N N BuO O H O O tBu (S)N O O N N N O N H O O CO2 tBu O OtBu 95% TFA, 2.5% TIPS, 2.5% water HO HN N O N N OH
O HO O N N HO O H O OH (S) N O O N N N O N H O O CO2H O OH Chemical Formula: C58H85N11O19 Exact Mass: 1239.60 HO HN Molecular Weight: 1240.38 N O N N OH [146] Synthetic scheme 6. NO O 2 NH N O Cl O O NO2 , Base (TEA or DIPEA) RO HN RO HN N N (Z) (Z) O N N O OR OR N N R = Benzyl O HO O N N HO O OH 1) H2N O O N N O O N H O O OH R = Benzyl 2) H2, Pd-C R = H
O O OH H O O N O N N O O N N H O OH HO N N O HO O HO HN N O OH N N Chemical Formula: C56 H 85 N 11O17 Exact Mass: 1183.61 Molecular Weight: 1184.36 [147] Synthetic scheme 7. O O NH O 2 N O O NH 1) HO2C O O NHBn Coupling agents (PyBOP or HATU or HBTU or CDI) Base (TEA or DIPEA) Solvent (THF or DMF) HO HN N HO HN N , P O 2) H2 d-C N N OH O N N OH O O HO HO O O O Cl N N N N HO O HO O OH O2N O H OH N N N N H2N O N N Ba N O H O se H TEA or DIPEA) O O OH ( O2N O OH O HO O N N HO O O H H OH O N N N N N O O N O H O O OH Chemical Formula: C58H88N12O17 HO HN Exact Mass: 1224.64 N Molecular Weight: 1225.41 O N N OH
Materials and Analytical Assays Provided below are analytical assays for characterizing the compounds of Formula I. [148] Actinium-225 (225Ac) was supplied by the U.S. Department of Energy Isotope Program in the Office of Science for Nuclear Physics. Lutetium-177 (177Lu) was received from ITG Isotope Technologies Garching GmbH. Indium-111 (111In) was supplied from BWXT. [149] RadioTLC was performed with Bioscan AR-2000 Imaging Scanner, carried out on iTLC- SG glass microfiber chromatography paper (Agilent Technologies, SGI0001) plates or iTLC-SA glass microfiber chromatography paper (Agilent Technologies, A120B12) plates. [150] Radioactive HPLC was performed using a Waters system comprised of a Waters 1525 Binary HPLC pump, a Waters 2489 UV/Visible Detector (monitoring at 254 and 214 nm), and a Bioscan Flow Count radiodetector (FC-3300) and a reverse phase (C18) column. Alternatively, analysis was performed using a Waters Acquity UPLC system comprised of a Waters Acquity Binary Solvent Manager, a Waters Acquity Sample Manager, a Waters Acquity Column Manager (column temperature 30 °C), a Water Acquity Photodiode Array Detector (monitoring 254 nm and 214 nm), a Bioscan Flow Count radiodetector (FC-3300), and a reverse phase (C18) column. [151] Analytical HPLC-MS was performed using a Waters Acquity HPLC-MS system comprised of a Waters Acquity Binary Solvent Manager, a Waters Acquity Sample Manager, a Waters Acquity Column Manager (column temperature 30 °C), a Waters Acquity Photodiode Array Detector (monitoring at 254 nm and 214 nm), a Waters Acquity TQD with electrospray ionization and a Waters Acquity BEH C18, 2.1 x 50 mm (1.7 μm) column. Preparative HPLC was performed using a Waters HPLC system comprised of a Waters 1525 Binary HPLC pump, a Waters 2489 UV/Visible Detector (monitoring at 254 nm and 214 nm) and a Waters XBridge Prep C1819 x 100 mm (5 μm) column. [152] HPLC elution method 1: Waters Acquity BEH C182.1 x 50 mm (1.7 μm) column; mobile phase A: H2O (0.1% v/v TFA); mobile phase B: acetonitrile (0.1% v/v TFA); flow rate = 0.3 mL/min; wavelength = 214, 254 nm; initial = 90% A, 8 min = 0% A, 10 min = 0% A, 11 min = 90% A, 12 min = 90% A. [153] HPLC elution method 2: Waters Acquity BEH C182.1 x 50 mm (1.7 μm) column; mobile phase A: H2O (0.1% v/v TFA); mobile phase B: acetonitrile (0.1% v/v TFA); flow rate =
0.3 mL/min; wavelength = 214, 254 nm; initial = 90% A, 3 min = 0% A, 3.5 min = 0% A, 4 min = 90% A, 5 min = 90% A. [154] HPLC elution method 3: Waters Acquity BEH C182.1 x 50 mm (1.7 μm) column; mobile phase A: H2O (0.1% v/v Formic Acid); mobile phase B: acetonitrile (0.1% v/v Formic Acid); flow rate = 0.3 mL/min; wavelength = 214, 254 nm; initial = 90% A, 3 min = 0% A, 3.5 min = 0% A, 4 min = 90% A, 5 min = 90% A. [155] HPLC elution method 4: Waters Acquity BEH C182.1 x 50 mm (1.7 μm) column; mobile phase A: H2O (0.1% v/v Formic Acid); mobile phase B: acetonitrile (0.1% v/v Formic Acid); flow rate = 0.3 mL/min; wavelength = 214, 254 nm; initial = 90% A, 8 min = 0% A, 10 min = 0% A, 11 min = 90% A, 12 min = 90% A. [156] HPLC elution method 5 (radioHPLC): Phenomenex Gemini 5 μm C18110 Å, LC Column 150 x 4.6 mm; mobile phase A: H2O (0.1% v/v TFA); mobile phase B: acetonitrile (0.1% v/v TFA); flow rate = 1.0 mL/min; wavelength = 214, 254 nm; initial = 100% A, 2 min = 100% A, 10 min = 0% A, 12 min = 0% A, 14 min = 100% A, 15 min = 100% A. [157] HRMS was performed using an Agilent G1969 ESI TOF system. EXAMPLES Example 1: Synthesis of (R)-2,2',2''-(10-(20-Carboxy-1-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-1,17-dioxo- 4,7,10,13-tetraoxa-16-azaicosan-20-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound A) tBuO2C t t BuO BuO 2C 2C N N tBuO2C O O N N i) CDI O O N N Bn CO2 tBu O ii) O BnO O O N O O NH N N O O 2 H CO tB C tBu 2 u HO O2 CO2 t O Bu Intermediate 1 - A iii) re-subjected with HBTU, DIPEA Step 1
tBuO2C tBuO2C N N O O Pd/C; H (atm), MeOH 2 O O N N t HO O O N CO2Bu H CO2 tBu Step 2 Intermediate 1 - B NH •HCl tBuO2C tBuO2C N N HO HN N O O O O O N N N N CO2 tBu OH N O O N H t Intermediate 1 - C CO2 Bu HBTU, DIPEA, DMF Step 3 HO HN Intermediate 1 - D N O N N OH HO 2 C HO 2 C N N O O O O N N N O O N CO 2 H H CO H TFA/TIPS/H 2 2 O Step 4 Compound A HO HN N O N N OH Step 1: Synthesis of 1-Benzyl 21-(tert-butyl) (R)-17-oxo-20-(4,7,10-tris(2-(tert-butoxy)-2- oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)-4,7,10,13-tetraoxa-16-azahenicosanedioate (Intermediate 1 – A) To a 20 mL scintillation vial was added (R)-DOTAGA(tBu)4 (500 mg, 0.71 mmol, 1 equiv.) and a stir bar followed by anhydrous dichloromethane (3.6 mL) to make a 0.2 M solution. Next CDI (126 mg, 0.74 mmol, 1.1 equiv.) was added and the solution stirred at RT and monitored by HPLC-MS. After 3 h only ~35% conversion was observed, so the reaction was re-dosed with CDI (70 mg, 0.43 mmol, 0.6 equiv.) and stirred at RT for 18.5 h. At this point, an aliquot of the reaction was checked and found to have the same approximate conversion.
The reaction solution was transferred into a second vial containing Amino-PEG4-benzyl ester (279 mg, 0.78 mmol, 1.1 equiv.) in anhydrous dichloromethane (1 mL) and stirred at RT. The reaction was monitored by HPLC-MS and after 3h ~29% conversion to product was found with the remainder being DOTAGA(tBu)4 by HPLC-MS. The reaction was worked up by concentration under vacuum and then resubjected to the reaction conditions by adding the following reagents: anhydrous THF (4.6 mL) and HBTU (803 mg, 2.12 mmol, 3 equiv.), at which point the reaction was stirred for 5 minutes before adding DIPEA (0.62 mL) and stirring over the weekend at RT (22.5 °C). After 88 h,the reaction had gone to completion and was worked up by concentration under vacuum. The crude product was purified by reverse phase-C18 column chromatography to afford Intermediate 1 - A (436 mg, 47%, purity: >96%) as a pale-yellow sticky solid, TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 4.90 min; MS (positive ESI): found m/z 1038.6 [M+H]+; C53H92N5O15 (calc. 1038.6). 1H NMR (700 MHz, DMSO-d6^^į^^^^^^^EU^V^^^+^^^^^^^-7.31 (m, 5H), 5.11 (s, 2H), 4.62-2.65 (multiplets overlapping with H2O, 43H), 2.60 (t, J = 7.0 Hz, 2H), 2.49-2.43 (m, 1H), 2.43-2.35 (m, 1H), 1.47 (br s, 9H), 1.46 (br s, 9H), 1.42 (br s, 9H), 1.40 (br s, 9H); 13C NMR (176 MHz, DMSO-d6^^į^^^^^^^^^^^^^^^ 158.3 (TFA, q, J = 35.2 Hz), 136.5, 128.4, 128.0, 127.8, 115.8 (TFA, q, J = 299.2 Hz), 83.8 (br), 81.6 (br), 69.8 (2C), 69.7 (2C), 69.6, 69.1, 66.0, 65.4, 54.5 (br), 53.4 (br), 38.5, 34.7, 31.8 (br), 27.8, 27.7, 27.6 (2C). Step 2: Synthesis of (R)-2,2-Dimethyl-4,8-dioxo-5-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)- 1,4,7,10-tetraazacyclododecan-1-yl)-3,12,15,18,21-pentaoxa-9-azatetracosan-24-oic acid (Intermediate 1 - B) To a solution of Intermediate 1 - A (396 mg, 0.30 mmol, 1 equiv.) in anhydrous MeOH (4 mL) in a 20 mL vial was added a stir bar and Pd/C, 10% Pd basis (32 mg, 0.03 mmol, 0.1 equiv.). The reaction mixture was degassed and subjected to H2 atmosphere via a balloon (3X). The reaction was then left to stir at RT (22 deg °C) and monitored by HPLC-MS. After 18 h the reaction was filtered through an Acrodisc One (0.2 μm PTFE) syringe filter into a 20 mL scintillation vial. The reaction vial was then rinsed with MeOH (4 mL), and this was also filtered into the scintillation vial. The crude reaction was then concentrated under vacuum to afford 387 mg of a clear film.
The crude product was purified by reverse phase-C18 column chromatography to afford Intermediate 1 - B (237 mg, 66%, purity: 99%) as a clear film, TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 4.06 min; MS (positive ESI): found m/z 948.7 [M+H]+; C46H86N5O15 (calc.948.6).1H NMR (700 MHz, DMSO-d6^^į^ 7.98 (s, 1H), 4.62-2.60 (multiplets overlapping with H2O, 43H), 2.48-2.45 (m, 1H), 2.44 (t, J = 7.0 Hz, 2H), 2.41-2.35 (m, 1H), 1.45 (br s, 18H), 1.41 (br s, 18H); 13C NMR (176 MHz, DMSO- d6^^į^^^^^^^^^^^^^^^^^^^2 (TFA, q, J = 33.4 Hz), 116.4 (TFA, q, J = 303.8 Hz), 69.8, 69.7 (2C), 69.6 (2C), 69.1, 66.2, 54.6 (br), 53.7 (br), 38.6, 31.8 (br), 27.8, 27.7 (2C), 27.6. Step 3: Synthesis of tri-tert-Butyl 2,2',2''-(10-(24-(4-(4-(3-(2,4-Dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,2-dimethyl-4,8,24-trioxo- 3,12,15,18,21-pentaoxa-9-azatetracosan-5-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)(R)- triacetate (Intermediate 1 - D) To a 20 mL vial was added Intermediate 1 - B (14 mg, 15 μmol, 1 equiv.) followed by 1 anhydrous DMF (1 mL) and stir bar. The vessel was then loaded with HBTU (5.6 mg, 15 μmol, 1 equiv.) and lastly DIPEA (12.4 μL, 71 μmol, 5 equiv.) and stirred at RT (22 °C) for 5 min. A solution of Intermediate 1 - C (8 mg, 1 equiv.) in anhydrous DMF (1 mL) was then added, and an additional 1 mL of anhydrous DMF was used to rinse the vial containing the Intermediate and added to the reaction vessel. The resulting solution was stirred at RT (22 °C) and monitored by HPLC-MS. After 1 h the reaction was worked up by concentration under vacuum. The crude product was purified by reverse phase-C18 column chromatography to afford Intermediate 1 - D (12.4 mg, 96%, purity: 96%) as a clear film, TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 4.72 min; MS (positive ESI): found m/z 1393.9 [M+H]+; C72H117N10O17 (calc.1393.8).1H NMR (700 MHz, DMSO-d6 + ~10% D22^^į^^^^^^^G^^J = 7.0 Hz, 2H), 7.20 (d, J = 7.0 Hz, 2H), 6.55 (s, 1H), 6.33 (s, 1H), 4.35- 0.92 (multiplets overlapping with H2O and DMSO and triplet at 0.99 ppm, 97H), 0.99 (t, J = 7.0 Hz, 3H), 0.76 (d, J = 7.0 Hz, 6H). Step 4: Synthesis of (R)-2,2',2''-(10-(21-Carboxy-1-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)- 5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-1,18-dioxo-5,8,11,14-tetraoxa-
2,17-diazahenicosan-21-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound A) To a 20 mL vial was added Intermediate 1 - D (10.4 mg, 6.4 μmol, 1 equiv.) and a stir bar, followed by 2 mL of TFA/TIPS/H2O (95:2.5:2.5 v/v/v). The resulting clear solution was placed in a 3^^°C oil bath and the reaction was monitored by HPLC-MS. After 3 h the reaction was complete and was concentrated under a stream of air. The crude product was purified by reverse phase-C18 column chromatography to afford Compound A (6.5 mg, 75%, purity: >99%) as a white solid, TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 3.00 min; HRMS (positive ESI): found m/z 1169.6074 [M+H]+; C56H85N10O17 (calc.1169.6089).1H NMR (700 MHz, DMSO-d6 + ~10% D22^^į^^^^^^^G^^J = 7.0 Hz, 2H), 7.20 (d, J = 7.0 Hz, 2H), 6.56 (s, 1H), 6.32 (s, 1H), 4.30 (br d, 2H), 4.05-2.35 (multiplets overlapping with H2O and DMSO, 47H), 1.90-1.80 (br m, 3H), 1.77-1.71 (m, 2H), 1.61-1.55 (m, 3H), 1.11-1.08 (m, 2H), 1.00 (t, J = 7.0 Hz, 3H), 0.98-0.95 (m, 2H), 0.76 (d, J = 7.0 Hz, 6H); 13C NMR (175 MHz, DMSO-d6^^į^^^^^^^^^^^^5, 157.9 (TFA, app q, J = 31.5 Hz), 157.3, 156.2 (2C), 154.4, 147.8, 141.4, 133.2, 129.6, 127.3, 125.8, 125.5, 117.3 (TFA, app q, J =297.5 Hz), 102.6, 102.5, 69.8 (2C), 69.7 (2C), 69.6, 69.1, 66.9, 53.7, 45.1, 41.7, 41.1, 40.0, 38.6, 37.3, 33.6, 32.9, 32.2, 31.3, 25.3, 22.4, 14.5. Example 2: Synthesis of 2,2',2''-(10-(24-(4-(4-(3-(2,4-Dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,24-dioxo-6,9,12,15,18,21- hexaoxa-3-azatetracosyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound B) i) DSC, pyridine, MeCN CO tBu ii) HBTU, DMF 2 CO2 tBu CO2 tBu O O N HO N CO tB 2C N N 2 u O O NH2 O 3 HO2C O O N N O O N HO2C N N H 3 tBuO2C t Step 1 Intermediate 2 - A BuO2C
NH •HCl CO2 tBu BnO HN N N CO2 tBu N O O O N N O O N N OBn N O O N H 3 BuO2 t C Intermediate 2 - B HBTU, DIPEA Step 2 BnO HN Intermediate 2 - C N O N N OBn CO2 t Bu N C t N O2 Bu O O O O N N Pd/C; H (atm), MeOH N O O N 2 H 3 BuO2 tC Step 3 Intermediate 2 - D HO HN N O N N OH CO 2 H N N CO 2 H O O O O N N N O O N H 3 HO C TFA/TIPS/H 2 O 2 Step 4 Compound B HO HN N O N N OH Step 1: Synthesis of 2-Oxo-1-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10- tetraazacyclododecan-1-yl)-6,9,12,15,18,21-hexaoxa-3-azatetracosan-24-oic acid (Intermediate 2 - A) To a solution of DOTAtris(tert-butyl ester) (50 mg, 0.09 mmol, 1 equiv.) in MeCN (2.0 mL) was added N,N’-disuccinimidyl carbonate (DSC) (32 mg, 0.11 mmol, 1.3 equiv.) and pyridine (0.20 mL, 2.5 mmol, 28 equiv.). The reaction mixture was stirred RT (22.5 °C) and monitored by
HPLC-MS. After 70 min ~80% starting material was remaining, so the reaction was dosed with HBTU (34 mg, 0.09 mmol, 1 equiv.) and stirred for 10 min at RT. The reaction mixture was then transferred to a second vial containing Amino-PEG6-acid (64 mg, 0.17 mmol, 2 equiv.) in anhydrous DMF (1 mL, limited solubility) and stirred at RT. The reaction was monitored by HPLC-MS and worked up after 64 hours by concentration under vacuum to afford a clear oil. The crude product was purified by reverse phase-C18 column chromatography to afford Intermediate 2 - A (35 mg, 36%, purity >99%) as a clear film, TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 3.70 min; MS (positive ESI): found m/z 908.9 [M+H]+; C43H82N5O15 (calc.908.6).1H NMR (700 MHz, DMSO-d6 + ~10% D22^^į 4.20-2.46 (multiplets overlapping with H2O, triplet at 3.57 ppm J = 7.0 Hz, 2H and DMSO; total 50H), 2.42 (t, J = 7.0 Hz, 2H), 1.44 (br s, 9H), 1.36 (br s, 18H). Step 2: Synthesis of tri-tert-Butyl 2,2',2''-(10-(24-(4-(4-(3-(2,4-bis(benzyloxy)-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,24-dioxo- 6,9,12,15,18,21-hexaoxa-3-azatetracosyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (Intermediate 2 - C) To a solution of Intermediate 2 - A (30 mg, 26 μmol, 1 equiv.) in MeCN (2 mL) was added HBTU (12 mg, 32 μmol, 1.2 equiv.), and DIPEA (18 μL, 0.11 mmol, 4 equiv.). This was stirred at RT (22.5^°^C) for 10 min before Intermediate 2 - B (22 mg, 32 μmol, 1.2 equiv) was added and the solution was stirred and monitored by HPLC-MS. After 1 h the reaction was worked up by concentrating to dryness under vacuum. The crude product was purified by reverse phase-C18 column chromatography to afford Intermediate 2 - C (35 mg, 77%, purity >99%) as a clear film, TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 5.52 min; MS (positive ESI): found m/z 1533.7 [M+H]+; C83H125N10O17 (calc.1533.9).1H NMR (700 MHz, DMSO-d6 + ~10% D22^^į^^^^^-7.26 (m, 8H), 7.19 (d, J = 6.8 Hz, 2H), 7.05 (d, J = 7.6 Hz, 2H), 6.96 (s, 1H), 6.92 (d, J = 8.0 Hz, 2H), 6.67 (s, 1H), 5.01 (s, 2H), 4.88 (s, 2H), 4.27 (d, J = 14.0 Hz, 1H), 3.78 (d, J = 14.0 Hz, 1H), 3.55 (t, J = 7.0 Hz, 2H), 3.49-2.36 (multiplets overlapping with H2O and DMSO, 57H), 1.70-1.63 (m, 1H), 1.52-1.17 (multiplets overlapping with broad 2 singlets at 1.42 ppm and 1.33 ppm, 29H), 1.05-0.98 (m overlapping with triplet at 1.00 ppm J = 7.0 Hz, total 4H), 0.95 (d, J = 7.0 Hz, 6H), 0.92-0.85 (m, 1H).
Step 3: Synthesis of tri-tert-Butyl 2,2',2''-(10-(24-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,24-dioxo-6,9,12,15,18,21- hexaoxa-3-azatetracosyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (Intermediate 2 - D) To a solution of Intermediate 2 - C (28.3 mg, 16.1 μmol, 1 equiv.) in MeOH (2.5 mL) in a microwave vial was added a stir bar and Pd/C, 10% Pd basis (7 mg, 6 μmol 0.4 equiv.). The reaction mixture was degassed and subjected to H2 atmosphere via a balloon (3X). The reaction was then left to stir at RT (23 °C) and monitored by HPLC-MS. After 16 h the reaction was filtered through an Acrodisc PSF syringe filter into a 20 mL scintillation vial. The reaction vial was rinsed with MeOH (2 x1.5 mL), and this was also filtered into the scintillation vial. The crude reaction was then concentrated crude under vacuum to afford a 23 mg of a yellow film. The crude product was dissolved in MeOH (2 mL) and stirred with SiliaMetS® Thiol (SH) Metal scavenger resin (200 mg, 40-63 μm, loading =1.46 mmol/g) to remove apparent Pd coordination in a 37 °C oil bath and was monitored by HPLC-MS. After 1 h the reaction was filtered through an Acrodisc PSF syringe filter into a 20 mL scintillation vial. The reaction vial was rinsed with MeOH (2 x 1.5 mL), and this was also filtered into the scintillation vial. The crude reaction was then concentrated crude under vacuum to afford Intermediate 2 - D (20.8 mg, 81%, purity >97%) as a clear film, TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 4.45 min; MS (positive ESI): found m/z 1354.3 [M+H]+; C69H113N10O17 (calc.1353.8).1H NMR (700 MHz, DMSO-d6 + ~10% D22^^į^^^^^^^G^^J = 7.0 Hz, 2H), 7.20 (d, J = 7.0 Hz, 2H), 6.55 (s, 1H), 6.32 (s, 1H), 4.30 (br d, J = 14.0 Hz, 1H), 4.20- 2.36 (multiplets overlapping with H2O, triplet at 3.57 ppm J = 7.0 Hz, q at 3.14 ppm, J = 7.0 Hz and DMSO, 60H), 1.76-1.70 (m, 1H), 1.62-1.55 (m, 2H), 1.49 (br s, 9H), 1.34 (br s, 18H), 1.12- 1.06 (m, 1H), 1.01-0.92 (m overlapping with triplet at 0.99 ppm J = 7.0 Hz, total 4H), 0.77 (d, J = 7.0 Hz, 6H). Step 4: Synthesis of 2,2',2''-(10-(24-(4-(4-(3-(2,4-Dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,24-dioxo-6,9,12,15,18,21-
hexaoxa-3-azatetracosyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound B) To a 20 mL vial was added Intermediate 2 - D (18.0 mg, 11.4 μmol, 1 equiv.), and a stir bar followed by 2 mL of TFA/TIPS/H2O (95:2.5:2.5 v/v/v). The resulting clear solution was placed in a 37 °C oil bath and the reaction was monitored by HPLC-MS. After 2.5 h the reaction was complete and was subsequently concentrated under vacuum. The crude product was purified by reverse phase-C18 column chromatography to afford Compound B (4.6 mg, 29%, purity: 99%) as a white solid, TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 3.15 min; HRMS (positive ESI): found m/z 1185.6386 [M+H]+; C57H89N10O17 (calc.1185.6402).1H NMR (700 MHz, DMSO-d6 + ~10% D22^^į^^^^^^^G^^J = 7.0 Hz, 2H), 7.20 (d, J = 7.0 Hz, 2H), 6.56 (s, 1H), 6.32 (s, 1H), 4.30 (br d, J = 14.0 Hz, 2H), 4.10-2.38 (multiplets overlapping with H2O and DMSO, 57H), 1.76-1.68 (m, 2H), 1.63-1.52 (m, 3H), 1.13-1.07 (m, 1H), 0.99-0.93 (m overlapping with triplet at 0.99 ppm J = 7.0 Hz, total 4H), 0.77 (d, J = 7.0 Hz, 6H). Example 3: Synthesis of 2,2',2''-(10-(42-(4-(4-(3-(2,4-Dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,42-dioxo- 6,9,12,15,18,21,24,27,30,33,36,39-dodecaoxa-3-azadotetracontyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound C) CO2 tBu i) DSC, pyridine, MeCN CO2 tBu ii) HBTU, DMF CO t CO t N N 2 Bu N N 2 Bu HO 2 C O O O O NH2 O HO2C N N 9 HO2C O O N N O O N H tBuO2C 9 Step 1 Intermediate 3 - A tBuO2C
NH •HCl BnO HN t N CO2Bu O t N N CO2Bu OBn N N O O O O N N Intermediate 2 - B N O O N HBTU, DIPEA H 9 tBuO2C Step 2 Intermediate 3 - B BnO HN N O OBn N N CO2 tBu t N N CO2Bu O O O O N N (atm), MeOH N O O N Pd/C; H2 H 9 tBuO2C Step 3 Intermediate 3 - C HO HN N O OH N N CO2 H N N CO2H O O O O N N N O O N H 9 HO2C TFA/TIPS/H2O Step 4 Compound C HO HN N O OH N N Step 1: Synthesis of 2-oxo-1-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10- tetraazacyclododecan-1-yl)-6,9,12,15,18,21,24,27,30,33,36,39-dodecaoxa-3-azadotetracontan- 42-oic acid (Intermediate 3 – A)
To a solution of DOTAtris(tert-butyl ester) (50 mg, 0.09 mmol, 1 equiv.) in MeCN (2.0 mL) was added N,N’-disuccinimidyl carbonate (DSC) (32 mg, 0.11 mmol, 1.3 equiv.) and pyridine (0.20 mL, 2.5 mmol, 28 equiv.). The reaction mixture was stirred at RT (22.5 °C) and monitored by HPLC-MS. After 70 min, ~80% starting material remained, so the reaction was dosed with HBTU (34 mg, 0.09 mmol, 1 equiv.) and stirred for 10 min at RT. The reaction mixture was then transferred to a second vial containing Amino-PEG12-acid (81 mg, 0.13 mmol, 1.5 equiv.) in anhydrous DMF (1 mL, limited solubility) and stirred at RT. The reaction was monitored by HPLC-MS and worked up after 64 hours by concentration under vacuum to afford a clear oil. The crude product was purified by reverse phase-C18 column chromatography to afford Intermediate 3 – A (49 mg, 32%, purity 80%) as a clear film, TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 3.70 min; MS (positive ESI): found m/z 1173.2 [M+H]+; C55H106N5O21 (calc. 1172.7). Step 2: Synthesis of tri-tert-Butyl 2,2',2''-(10-(42-(4-(4-(3-(2,4-bis(benzyloxy)-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,42-dioxo- 6,9,12,15,18,21,24,27,30,33,36,39-dodecaoxa-3-azadotetracontyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetate (Intermediate 3 - B) To a solution of Intermediate 3 - A (49 mg, 35 μmol, 1 equiv.) in MeCN (2 mL) was added HBTU (14 mg, 46 μmol, 1.3 equiv.), DIPEA (24 μL, 0.14 mmol, 5 equiv.), and a stir bar. The reaction was stirred at RT (22.5 °C) for 10 min and before Intermediate 2 – B (26 mg, 38 μmol, 1.3 equiv.) was added and the solution was stirred and monitored by HPLC-MS. After 1 h the reaction was worked up by concentrating to dryness under vacuum. The crude product was purified by reverse phase-C18 column chromatography to afford Intermediate 3 - B (40 mg, 70%, purity >99%) as a clear film, TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 5.40 min; MS (positive ESI): found m/z 1797.9 [M+H]+; C95H149N10O23 (calc.1798.1).1H NMR (700 MHz, DMSO-d6 + ~10% D2O) į^^^^^-7.26 (m, 8H), 7.19 (d, J = 7.0 Hz, 2H), 7.05 (d, J = 7.0 Hz, 2H), 6.96 (s, 1H), 6.92 (d, J = 7.0 Hz, 2H) 6.67 (s, 1H), 5.01 (s, 2H), 4.88 (s, 2H), 4.27 (br d, J = 14.0 Hz, 1H), 3.78 (br d, J = 14.4 Hz, 1H), 3.55 (t, J = 7.0 Hz, 2H), 3.52-2.37 (multiplets overlapping with H2O and DMSO, 81H), 1.69-1.63 (m, 1H), 1.52-1.38 (m overlapping with br s at 1.42 ppm, 12H),
1.34 (br s, 18H), 1.05-0.98 (m overlapping with triplet at 1.00 ppm J = 7.0 Hz, total 4H), 0.96 (d, J = 7.0 Hz, 6H). Step 3: Synthesis of tri-tert-Butyl 2,2',2''-(10-(42-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,42-dioxo- 6,9,12,15,18,21,24,27,30,33,36,39-dodecaoxa-3-azadotetracontyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetate (Intermediate 3 - C) To a solution of Intermediate 3 - B (33 mg, 0.02 mmol, 1 equiv.) in MeOH (2.5 mL) in a microwave vial was added a stir bar and Pd/C, 10% Pd basis (7 mg, 6 μmol 0.4 equiv.). The reaction mixture was degassed and subjected to H2 atmosphere via a balloon (3X). The reaction was then left to stir at RT (23 °C) and monitored by HPLC-MS. After 16 h the reaction was filtered through an Acrodisc PSF syringe filter into a 20 mL scintillation vial.The reaction vial was rinsed with MeOH (2 x1.5 mL), and this was also filtered into the scintillation vial. The crude reaction was then concentrated under vacuum to afford 30 mg of a pale-yellow film. The crude mixture was then dissolved in MeOH (3 mL) and half was stirred with with SiliaMetS® Thiol (SH) Metal scavenger resin (200 mg, 40-63 μm, loading =1.46 mmol/g) to remove apparent Pd coordination in a 50 °C oil bath, with monitoring by HPLC-MS. After 2 h the reaction was filtered through an Acrodisc PSF syringe filter into a 20 mL scintillation vial. The reaction vial was rinsed with MeOH (2 x 2 mL), and this was also filtered into the scintillation vial. The crude reaction was then concentrated crude under vacuum. This protocol was repeated with the 2nd half of the crude material and combined to afford Intermediate 3 – C (19.8 mg, 66%, purity >99%) as a clear film, TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 4.40 min; MS (positive ESI): found m/z 1618.2 [M+H]+; C 81H137N10O23 (calc.1618.0).1H NMR (700 MHz, DMSO-d6 + ~10% D22^^į^^^^^^^EU^ d, J = 7.0 Hz, 2H), 7.19 (br d, J = 7.0 Hz, 2H), 6.56 (s, 1H), 6.32 (s, 1H), 4.41-2.37 (multiplets overlapping with H2O, d at 3.83 ppm J = 14.7 Hz, t at 3.57 ppm, J = 7.0Hz, q at 3.14 ppm, J = 7.0 Hz and DMSO, 85H), 1.75-1.68 (m, 1H), 1.62-1.52 (m, 2H), 1.51-1.04 (multiplet overlapping with br singlets at 1.42, 1.34 and 1.18 ppm, 28H), 1.00-0.92 (triplet at 0.99 ppm overlapping with multiplet, 4H), 0.76 (br d, J = 7.0 Hz, 6H).
Step 4: Synthesis of 2,2',2''-(10-(42-(4-(4-(3-(2,4-Dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,42-dioxo- 6,9,12,15,18,21,24,27,30,33,36,39-dodecaoxa-3-azadotetracontyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound C) To a 20 mL vial was added Intermediate 3 - C (18.0 mg, 9.8 μmol, 1 equiv.) and a stir bar, followed by 2 mL of TFA/TIPS/H2O (95:2.5:2.5 v/v/v). The resulting clear solution was placed in a 37 °C oil bath and the reaction was monitored by HPLC-MS. After 2.5 h the reaction appeared complete and was worked up by transferring to a 50 mL Falcon tube. The reaction vial was washed with TFA (2x0.5 mL), and this was also added to the Falcon tube. The Falcon tube was cooled in an ice bath and thenEt2O (pre-chilled in the ice bath) was added up to the 45 mL mark. After 5 min in the ice bath the flask was centrifuged (5 min, 4^^ C, 3700 rpm) to afford an off-white pellet. The Et2O layer was decanted into a round bottomed flask, and the pellet was dissolved in ACN/H2O (2 mL, 1:1 v/v) and transferred to a tared 20 mL scintillation vial. The Falcon tube was rinsed with additional ACN/H2O (2x2 mL, 1:1 v/v), which was added to the scintillation vial and concentrated under vacuum to afford 9 mg of crude product as a clear film. The crude product was purified by reverse phase-C18 column chromatography to afford Compound C (6.6 mg, 40%, purity: 97%) as a white solid, TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 3.27 min; HRMS (positive ESI): found m/z 1487.7508 [M+K]+; C69H112KN10O23 (calc.1487.7533).1H NMR (700 MHz, DMSO- d6 + ~10% D22^^į^^^^^^^G^^J = 7.0 Hz, 2H), 7.20 (d, J = 7.0 Hz, 2H), 6.55 (s, 1H), 6.32 (s, 1H), 4.30 (br d, J = 14.0 Hz, 1H), 4.10-2.37 (multiplets overlapping with H2O and DMSO, 84H), 1.76-1.71 (m, 1H), 1.61-1.54 (m, 2H), 1.13-1.06 (m, 1H), 1.01-0.92 (m overlapping with triplet at 0.99 ppm J = 7.0 Hz, total 4H), 0.77 (d, J = 7.0 Hz, 6H). Example 4: Synthesis of (R)-2,2',2''-(10-(21-Carboxy-1-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-1,18-dioxo- 5,8,11,14-tetraoxa-2,17-diazahenicosan-21-yl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)triacetic acid (Compound D)
CO2 tBu CO H 2 tBu HO CO2 tBu H2N O O O O N CO2 tBu N N O O NH2 H2N O O N N O O HBTU, DIPEA N t N N BuO t N 2C BuO2C tBuO2C t St Intermediate 4 - A BuO 2C ep 1 O CO tBu H 2 O O N CO tBu ) 4-Nitrophenylchloroformate, DIPEA N N 2 i O O H N N O ii) NH •HCl Intermediate 4 - B t N N BuO2C tBuO2C HO HN N H O HO N OH N N N O OH N N Intermediate 1 - C Step 2 O CO H H 2 O O N CO2H N N O O H N N TFA/TIPS/H2O O Step 3 Compound D HO N N 2C HO2C HO HN N O OH N N Step 1: Synthesis of tri-tert-Butyl 2,2',2''-(10-(1-amino-22,22-dimethyl-16,20-dioxo-3,6,9,12,21- pentaoxa-15-azatricosan-19-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)(R)-triacetate (Intermediate 4 - A) A 20 mL scintillation vial was charged with (R)-DOTAGA(tBu)4 (1.00g, 1.41 mmol, 1 equiv), amino-PEG4-amine (511 mg, 2.12 mmol, 1.5 equiv), HBTU (607 mg, 1.56 mmol, 1.1 equiv), anhydrous acetonitrile and lastly DIPEA (1.24 mL, 7.06 mmol, 5 equiv). The reaction was stirred at RT (22^^C) and monitored by HPLC-MS. After 2 h the reaction was worked up by concentration under vacuum to afford a pale yellow oil. The crude product was purified by reverse phase-C18 column chromatography to afford Intermediate 4 - A (448 mg, 26%, purity: >93%) as a clear sticky film, TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 3.63 min; MS (positive ESI): found m/z 919.5 [M+H]+; C45H87N6O13 (calc.919.6).1H NMR (700 MHz,
DMSO-d6 + ~10% D22^^į^^^^^-2.30 (multiplets including overlap with H2O and DMSO, 45H), 1.92-1.80 (br m, 1H), 1.69-1.57 (br m, 1H), 1.44 (br s, 18H), 1.33 (br s, 9H), 1.31 (br s, 9H). Step 2: Synthesis of tri-tert-Butyl 2,2',2''-(10-(1-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-24,24-dimethyl-1,18,22-trioxo- 5,8,11,14,23-pentaoxa-2,17-diazapentacosan-21-yl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)(R)-triacetate (Intermediate 4 - B) To a solution of Intermediate 4 – A (50 mg, 41 μmol, 1 equiv) in anhydrous THF (1 mL) and stir bar was added DIPEA (28.7 μL, 164 μmol, 4 equiv) and cooled to 0 °C, followed by addition of 4-nitrophenylchloroformate (8.6 mg, 41 μmol, 1 equiv) at 0 °C in one portion. Following the addition the reaction was removed from the icebath to stir at RT (21.5^^C), purged with an argon balloon and monitored by HPLC-MS. After 45 min observed complete conversion to the nitrophenyl intermediate and proceeded to add Intermediate 1 - C (24 mg, 46 μmol, 1.1 equiv) directly to the reaction followed by DIPEA (7.2 μL, 46 μmol, 1.1 equiv) and lastly purged the reaction with an argon balloon. The reaction was stirred at RT and monitored by HPLC-MS. After 1 h anhydrous DMF (1 mL) was added which resulted in a homogeneous solution and the reaction was continued to stir at RT and monitored by HPLC-MS. After 1 h the reaction temperature was elevated to 50^^C and monitored by HPLC- MS. After 43 h the reaction was redosed with DIPEA (28.7 μL, 164 μmol, 4 equiv), purged with an argon balloon and stirred in the 50^^C bath for an additional 21 h which resulted in complete conversion. The reaction was then worked up by concentration under vacuum to afford a yellow film. The crude product was purified by reverse phase-C18 column chromatography to afford Intermediate 4 - B (26 mg, 38%, purity: >98%) as a clear film, TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 2.42 min; MS (positive ESI): found m/z 1408.8 [M+H]+; C72H118N11O17 (calc.1408.9).1H NMR (700 MHz, DMSO-d6 + ~10% D22^^į^^^^^^^G^^J = 8.0 Hz, 2H), 7.21 (d, J = 7.9 Hz, 2H), 6.56 (s, 1H), 6.35 (s, 1H), 4.38- 2.29 (multiplets including overlap with H2O and DMSO, 55H), 1.67-1.59 (m, 2H), 1.52 (br d, J = 12.9 Hz, 2H), 1.50-1.21 (4 broad singlets overlapping, 36H), 1.04-0.94 (m overlapping with t at 0.99 ppm with J = 7.2 Hz, 5H total), 0.75 (d, J = 7.0 Hz, 6H).
Step 3: Synthesis of (R)-2,2',2''-(10-(21-Carboxy-1-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)- 5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-1,18-dioxo-5,8,11,14-tetraoxa- 2,17-diazahenicosan-21-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound D) To a 20 mL vial was added Intermediate 4 - B (16.2 mg, 9.7 μmol, 1 equiv), stir bar followed by 2 mL of TFA/TIPS/H2O (95:2.5:2.5 v/v/v). The resulting clear solution was placed in a 37 ^^C oil bath and the reaction was monitored by HPLC-MS. After 3.5 h the reaction had went to completion and was concentrated under a stream of air. The crude product was purified by reverse phase-C18 column chromatography to afford Compound D (10 mg, 72%, purity: >99%) as a white solid, TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 2.97 min; HRMS (positive ESI): found m/z 1184.6175 [M+H]+; C56H86N11O17 (calc.1184.6198).1H NMR (700 MHz, DMSO-d6 + ~10% D22^^į^^^^^^^G^^J = 7.0 Hz, 2H), 7.20 (d, J = 7.0 Hz, 2H), 6.55 (s, 1H), 6.33 (s, 1H), 4.10-2.30 (multiplets including overlap with H2O and DMSO, 52H), 1.95-1.77 (m, 3H), 1.68- 1.59 (m, 2H), 1.52 (app br d, J = 14.0 Hz, 2H), 1.03-0.97 (m overlapping with triplet at 0.99 ppm with J = 7.1 Hz, 5H total), 0.76 (d, J = 7.1 Hz, 6H). Example 5: Synthesis of (R)-2,2',2''-(10-(22-Carboxy-1-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-1,14,19- trioxo-4,7,10-trioxa-13,15,18-triazadocosan-22-yl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)triacetic acid (Compound E) tB O O uO tB O O uO tBuO N N FmocHN t N N 1. HBTU, DIPEA, DMF O NH 2 + BuO O H N N N OtBu N N OtBu 2 2. Piperidine N H HO t O O S O O Bu Ot tep 1 O Bu Intermediate 5-A t O O BuO 1. p-NO2-Phenyl chloroformate tBuO N N DIPEA, THF O H H O t O N N N N OBu O O O N O H O t O 2. O O O Bu O O O NH 2 Step 2 Intermediate 5-B
Bu t O O O t N N LiOH BuO O H H O t N N N OBu THF:H2O O N HO O O N H O O t O OBu Step 3 Intermediate 5-C NH.HCl B t O O uO BuOt N N O H H O t O N N N N OBu HO O N O O N N H O O N O OtBu N N H OH Intermediate 1-C HO O HBTU, DIPEA, DMF N N Step 4 H OH N N Intermediate 5-D HO O O HO N N O H H O O N N N N OH N O O N H O O TFA:TIPS:H2O 95:2.5:2.5 O OH 37 °C Step 5 HO O N N H OH N N Compound E Step 1: Synthesis of tri-tert-Butyl 2,2',2''-(10-(5-((2-aminoethyl)amino)-1-(tert-butoxy)-1,5- dioxopentan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)(R)-triacetate (Intermediate 5- A): To a 20 mL scintillation vial with a stir bar was added, (R)-5-(tert-butoxy)-5-oxo-4-(4,7,10- tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanoic acid - (R)- DOTAGA(tBu)4 (1.50 g, 2.09 mmol, 1 equiv.), mono-Fmoc ethylene diamine hydrochloride (817 mg, 2.51 mmol, 1.2 equiv.), HBTU (900 mg, 2.09 mmol, 1.1 equiv.) and then charged with anhydrous acetonitrile (11 mL) and then DIPEA (1.84 mL, 1370 mg, 10.46 mmol, 5 equiv.) and stirred at RT. Reaction monitored by HPLC-MS and stopped after 18 h and solvent evaporated under vacuum to give the crude product, which was subjected to Fmoc deprotection. To the crude product dissolved in anhydrous DMF (8 mL) was added piperidine (2 mL) and the resulting clear orange solution was stirred at RT. Reaction stopped after 30 min and solvent evaporated. The obtained crude product was purified by RP chromatography to give
Intermediate 5-A (550 mg, 24%, purity: 90%) as white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 3.55 min; MS (positive ESI): found m/z 743.5 [M+H]+; C37H71N6O9 (calc.743.5). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C37H71N6O9743.5277; Found 743.5291.1H NMR (700 MHz, DMSO-d6 + 10% D2O) 4.40 – 4.17 (m, 2H), 3.82 – 3.43 (m, 8H), 3.40 – 2.88 (m, 9H), 2.87 – 2.79 (m, 2H), 2.62 (br s, 2H), 2.60 (br s, 3H), 2.47 – 2.38 (m, 2H), 1.98 – 1.79 (m, 1H), 1.65 (s, 1H), 1.54 – 1.26 (m, 36H). *Protons obscured by H2O and DMSO not reported. Step 2: Synthesis of 23-(tert-Butyl) 1-methyl (R)-14,19-dioxo-22-(4,7,10-tris(2-(tert-butoxy)-2- oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)-4,7,10-trioxa-13,15,18-triazatricosanedioate (Intermediate 5-B) To a solution of tri-tert-butyl 2,2',2''-(10-(5-((2-aminoethyl)amino)-1-(tert-butoxy)-1,5- dioxopentan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)(R)-triacetate (Intermediate 5-A) (50 mg, 0.07 mmol, 1 equiv.) in anhydrous THF (3 mL) and stir bar was added DIPEA (35.5 μL, 0.20 mmol, 3 equiv.) and cooled to 0 °C, followed by addition of 4-nitrophenylchloroformate (14.1 mg, 0.07 mmol, 1 equiv.) at 0 °C in one portion. Following the addition, the reaction was brought to RT and monitored by HPLC-MS. After 30 min complete conversion to the nitrophenyl intermediate was observed by HPLC-MS. Added methyl 3-(2-(2-(2- aminoethoxy)ethoxy)ethoxy)propanoate (30.4 mg, 0.13 mmol, 2 equiv.) dissolved in anhydrous DMF (1 mL) to the reaction followed by DIPEA (23.6 μL, 0.13 mmol, 2 equiv.) under argon. Continued stirring at room temperature, after 16 hours, the reaction was stopped and concentrated under vacuum, followed by RP chromatography to afford Intermediate 5-B (25 mg, 36 %, purity: 98%) as white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 2.24 min; MS (positive ESI): found m/z 1004.6 [M+H]+; C48H90N7O15 (calc. 1004.6).1H NMR (700 MHz, DMSO-d6) į 7.94 (s, 1H), 6.07 (s, 1H), 5.98 (s, 1H), 4.32-3.68 (br s, 15H), 3.62 (t, J = 6.2 Hz, 2H), 3.59 (s, 3H), 3.52 – 3.47 (m, 2H), 3.49 (s, 6H), 3.36 (t, J = 5.8 Hz, 2H), 3.13 (t, J = 5.8 Hz, 2H), 3.09 – 2.92 (m, 6H), 2.54 (t, J = 6.2 Hz, 2H), 2.07 (s, 4H), 1.61 – 1.27 (m, 42H). Step 3: Synthesis of (R)-2,2-Dimethyl-4,8,13-trioxo-5-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)- 1,4,7,10-tetraazacyclododecan-1-yl)-3,17,20,23-tetraoxa-9,12,14-triazahexacosan-26-oic acid (Intermediate 5-C)
To a flask containing Intermediate 5-B (32 mg, 0.03 mmol, 1 equiv.) was added THF (2 mL) and water (1 mL) and placed in an ice bath and stirred for 10 min. Lithium hydroxide, anhydrous, (2.96 mg, 0.12 mmol) was added as solid in one portion, and the reaction was continued in the ice-water bath. The reaction was monitored by HPLC-MS, and after 1h brought to RT and continued to stir overnight. The reaction solution was acidified (pH ~4) with Amberlite IR120 [H], ~200 mg by stirring for 10 min at RT, then filtered to remove resin. The resin was further washed with ACN, MeOH and then the solvent was evaporated under vacuum. The crude product was dissolved in 1:1 ACN/water/0.1TFA mixture and subjected to lyophilization, to give crude Intermediate 5-C (29 mg, 87%, purity 90%). An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 2.15 min; MS (positive ESI): found m/z 991.3 [M+H]+; C47H88N7O15 (calc.990.6). Step 4: Synthesis of tri-tert-Butyl 2,2',2''-(10-(26-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2,2-dimethyl-4,8,13,26-tetraoxo- 3,17,20,23-tetraoxa-9,12,14-triazahexacosan-5-yl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)(R)-triacetate (Intermediate 5-D) To a 20 mL scintillation vial with a stir bar was added Intermediate 5-C, (19.9 mg, 0.02 mmol, 1 equiv.) and DMF (2 mL). The reaction mixture was cooled to 0 °C and DIPEA (13.8 μL, 10.2 mg, 0.08 mmol, 4 equiv.), followed by HBTU (7.7 mg, 0.04 mmol, 1 equiv.) was added and stirred for 10 min at 0 °C. The solution was brought to RT and stirred for 30 min and then Intermediate 1-C (10 mg, 0.02 mmol, 1 equiv.) was added as solid. Stirred at RT and reaction monitored by HPLC-MS. The reaction was stopped after 2 h and solvent evaporated under vacuum to give the crude product, which was purified by preparative HPLC to afford Intermediate 5-D (21.4 mg, 64%, purity: 99%) as white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 2.39 min; MS (positive ESI): found m/z 1435.4 [M+H]+; C73H119N12O17 (calc.1435.9). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C73H119N12O171435.8811; Found 1435.8833. 1H NMR (700 MHz, DMSO-d6) į 9.82 (br s, 1H), 8.95 (t, J = 5.9 Hz, 1H), 7.97 (br s, 1H), 7.29 – 7.24 (m, 4H), 7.10 (br s, 2H), 6.57 (s, 1H), 6.36 (s, 1H), 6.06 (br s, 1H), 5.97 (br s, 1H), 4.36 (d, J = 13.1 Hz, 1H), 3.98 – 3.74 (m, 12H), 3.61 (t, J = 6.7 Hz, 2H), 3.53 – 3.47 (m, 9H), 3.37 (t, J = 5.7 Hz, 2H), 3.19 – 3.12 (m, 5H), 3.07 (s, 3H), 3.01 (s, 3H), 2.94 – 2.87 (m, 2H), 2.60 – 2.51 (m, 4H), 2.49 – 2.42 (m, 2H), 2.07 (s,
4H), 1.81 – 1.73 (m, 1H), 1.66 – 1.57 (m, 2H), 1.52 – 1.31 (m, 42H), 1.17 – 1.10 (m, 1H), 1.03 (t, J = 7.2 Hz, 3H), 1.01 – 0.98 (m, 1H), 0.81 (d, J = 6.9 Hz, 6H). Step 5: (R)-2,2',2''-(10-(22-Carboxy-1-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-1,14,19-trioxo-4,7,10-trioxa- 13,15,18-triazadocosan-22-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound E) To a 20 mL scintillation vial with a stir bar was added Intermediate 5-D (37 mg, 0.03 mmol) and 4.5 mL of deprotection cocktail TFA:TIPS:H2O - 95:2.5:2.5 at RT. The reaction was brought to 37 °C by placing on a pre-heated oil bath at 37 °C and monitored by HPLC-MS. The reaction was stopped after 3h and reaction mixture placed under stream of air to remove TFA. The crude product was purified by preparative HPLC to afford Compound E (20 mg, 54%, purity: 99%) as a white solid TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 3.02 min; MS (positive ESI): found m/z 1211.5 [M+H]+; C57H87N12O17 (calc.1211.6). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C57H87N12O17 1211.6307; Found 1211.6330.1H NMR (700 MHz, DMSO-d6) į 12.98 (s, 3H), 10.65 (s, 1H), 9.83 (s, 1H), 8.94 (t, J = 5.9 Hz, 1H), 7.87 (s, 1H), 7.26 (s, 4H), 6.57 (s, 1H), 6.37 – 6.34 (m, 1H), 6.18 (s, 1H), 6.05 (s, 1H), 4.36 (d, J = 12.8 Hz, 1H), 4.05 – 3.73 (m, 11H), 3.61 (t, J = 6.8 Hz, 2H), 3.53 – 3.47 (m, 10H), 3.37 (t, J = 5.8 Hz, 2H), 3.22 – 3.10 (m, 5H), 3.07 – 2.99 (m, 4H), 2.96 – 2.87 (m, 3H), 2.60 – 2.51 (m, 4H), 2.46 (td, J = 12.9, 2.9 Hz, 1H), 2.35 (s, 3H), 1.88 (s, 2H), 1.80 – 1.73 (m, 1H), 1.63 (d, J = 12.7 Hz, 1H), 1.59 (d, J = 13.0 Hz, 1H), 1.18 – 1.10 (m, 1H), 1.03 (t, J = 7.2 Hz, 3H), 1.02 – 0.96 (m, 1H), 0.81 (d, J = 6.9 Hz, 6H). *Protons obscured by H2O and DMSO not reported. Example 6: Synthesis of 2,2',2''-(10-((15S,20R)-20-Carboxy-15-(carboxymethyl)-1-(4-(4-(3- (2,4-dihydroxy-5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1- yl)-1,14,17-trioxo-4,7,10-trioxa-13,16-diazaicosan-20-yl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)triacetic acid (Compound F)
t BuO O t BuO O O O OtBu HBTU, DIPEA, DMF OtBu LiOH tBuO N N tBuO N N O O t O O THF:H Bu tB 2O N O N N O u MeO N MeO NH2 HO N O O Step 1 H S O O tBu O O tep 2 O OtBu Intermediate 6-A tBuO O O t BuO O O O OtBu O NH t HO 2 OtBu BuO N N O O tBuO N N O O O O O N N OtBu H t N N N OBu HO HBTU, DIPEA O N , DMF HO O O N H O O H O O OtBu O Step 3 O OtBu Intermediate 6-B Intermediate 6-C NH.HCl t BuO O O OtBu tBuO N N O O O H N N OtBu O N N O O N HO O H N O O O OtBu N N N H OH Intermediate 1-C HO O N HBTU, DIPEA, DMF N Step 4 N N H OH Intermediate 6-D HO O O OH HO N N O O O H O N N N OH N O O N H O O O OH TFA:TIPS:H 2O 95:2.5:2.5 37 °C HO O Step 5 N N OH N N H Compound F Step 1: Synthesis of 4-(tert-Butyl) 1-methyl ((R)-5-(tert-butoxy)-5-oxo-4-(4,7,10-tris(2-(tert- butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanoyl)-L-aspartate (Intermediate 6-A) To a 20 mL scintillation vial with a stir bar was added (R)-DOTAGA(tBu)4, (869 mg , 0.04 mmol, 1 equiv.), THF (25 mL) and DMF (5 mL). The reaction mixture was cooled to 0 °C and DIPEA (650 μL, 18.7 mg, 0.14 mmol, 3 equiv.), followed by HBTU, (719 mg, 0.04 mmol, 1.5
equiv.) was added and stirred for 5 min at 0 °C. The solution was brought to RT and stirred for 15 min and then 4-(tert-butyl) 1-methyl L-aspartate hydrochloride (300 mg, 0.04 mmol, 1 equiv.) was added as solid. The reaction was stirred at RT and was monitored by HPLC-MS. The reaction was stopped after 3h 30 min and solvent was evaporated under vacuum to give the crude product, which was purified by RP chromatography to afford Intermediate 6-A (722 mg, 64%, purity: 98%) as white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 2.60 min; MS (positive ESI): found m/z 886.7 [M+H]+; C44H80N5O13 (calc. 886.6). 1H NMR (700 MHz, DMSO-d6) į 8.41 (s, 1H), 7.11 (s, 2H), 4.58 (q, J = 7.1 Hz, 1H), 4.06 (br s, 8H), 3.63 (s, 3H), 3.35 – 2.93 (m, 8H), 2.65 (dd, J = 16.1, 6.8 Hz, 2H), 2.56 – 2.49 (m, 2H), 1.87 (s, 2H), 1.52 – 1.40 (m, 36H), 1.39 (s, 9H). *Protons obscured by H2O and DMSO not reported. Step 2: Synthesis of (S)-4-(tert-Butoxy)-2-((R)-5-(tert-butoxy)-5-oxo-4-(4,7,10-tris(2-(tert- butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanamido)-4-oxobutanoic acid (Intermediate 6-B): A flask containing Intermediate 6-A, (400.00 mg, 0.45 mmol, 1 equiv.) was dissolved in THF (6 mL) and water (3 mL) and placed in an ice bath and stirred for 15 min. Lithium hydroxide anhydrous (LiOH), (64.87 mg, 2.71 mmol, 6 equiv.) was added as a solid in one portion, and the reaction was continued in an ice-water bath. The reaction was monitored by HPLC-MS, after 30 min the major product was observed. After 1h, the reaction solution was acidified with Amberlite IR120 [H], ~600 mg by stirring for 15 min at rt, then filtered to remove the resin. The resin was further washed with acetonitrile, MeOH and the solvent was evaporated under vacuum. The crude product was lyophilized to give Intermediate 6-B as a white solid (394 mg, 95%, purity: 95%) and used for the next step without further purification. An aliquot was analyzed by HPLC- MS elution using elution method 2; retention time: 2.55 min; MS (positive ESI): found m/z 872.5 [M+H]+; C43H78N5O13 (calc.872.6).1H NMR (700 MHz, DMSO-d6) į 12.77 (br s, 1H), 8.24 (d, J = 8.2 Hz, 1H), 4.57 (td, J = 7.9, 5.9 Hz, 1H), 3.75 (s, 3H), 3.53 (s, 2H), 3.42 – 3.30 (m, 5H), 3.12 – 3.06 (m, 5H), 2.91 – 2.81 (m, 5H), 2.80 – 2.73 (m, 2H), 2.66 (dd, J = 15.9, 5.9 Hz, 1H), 2.54 – 2.48 (m, 2H), 2.23 – 2.13 (m, 2H), 1.93 – 1.85 (m, 1H), 1.82 – 1.75 (m, 1H), 1.48 – 1.41 (m, 36H), 1.39 (s, 9H).
Step 3: Synthesis of (5R,10S)-10-(2-(tert-Butoxy)-2-oxoethyl)-2,2-dimethyl-4,8,11-trioxo-5- (4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)-3,15,18,21- tetraoxa-9,12-diazatetracosan-24-oic acid (Intermediate 6-C) To a 20 mL scintillation vial with a stir bar was added Intermediate 6-B, (70 mg, 0.08 mmol, 1 equiv.) and DMF (3 mL). The reaction mixture was cooled to 0 °C and DIPEA, (42 μL, 31.1 mg, 0.24 mmol, 3 equiv.), followed by HBTU, (31.1 mg, 0.08 mmol, 1.0 equiv.) was added and stirred for 10 min at 0 °C. The solution was brought to RT and stirred for 15 min and then 4- (tert-butyl) 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoic acid (19.7 mg, 0.08 mmol, 1 equiv.) was added as solid. The reaction was stirred at RT and was monitored by HPLC-MS. The reaction was stopped after 1h 45m and solvent was evaporated under vacuum to give the crude product, which was purified by RP chromatography to afford Intermediate 6-C (70 mg, 66%, purity: 99%) as white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 2.40 min; MS (positive ESI): found m/z 1075.5 [M+H]+; C52H95N6O17 (calc. 1075.7). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C52H95N6O171075.6748; Found 1075.6750.1H NMR (700 MHz, DMSO-d6) 8.12 (d, J = 8.4 Hz, 1H), 7.91 (br s, 1H), 7.08 (br s, 1H), 4.59 – 4.49 (m, 1H), 3.75 (s, 1H), 3.61 – 3.57 (m, 2H), 3.52 – 3.45 (m, 10H), 3.39 (dt, J = 6.1, 3.1 Hz, 3H), 3.27 – 3.20 (m, 2H), 3.20 – 3.12 (m, 3H), 3.12 – 3.02 (m, 3H), 2.91 – 2.72 (m, 2H), 2.61 (dd, J = 15.6, 5.4 Hz, 1H), 2.44 (t, J = 6.4 Hz, 2H), 2.41 – 2.29 (m, 1H), 1.93 – 1.70 (m, 2H), 1.50 – 1.39 (m, 36H), 1.38 – 1.36 (m, 9H). *Protons obscured by H2O and DMSO not reported. Step 4: Synthesis of (5R,10S)-10-(2-(tert-Butoxy)-2-oxoethyl)-2,2-dimethyl-4,8,11-trioxo-5- (4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)-3,15,18,21- tetraoxa-9,12-diazatetracosan-24-oic acid (Intermediate 6-D) To a 20 mL scintillation vial with a stir bar was added Intermediate 6-C (40 mg , 0.04 mmol, 1 equiv.) and 2.5 mL DMF. The reaction mixture cooled to 0 °C and DIPEA, (30.8 μL, 22.8 mg, 0.14 mmol, 4 equiv.), followed by HBTU, (13.7 mg, 0.04 mmol, 1 equiv.) was added and stirred for 5 min at 0 °C. The solution was brought to RT and stirred for 20 min and then Intermediate 1-C (17.9 mg, 0.04 mmol, 1 equiv.) was added as a solid. The reaction was stirred at RT and was monitored by HPLC-MS. The reaction was stopped after 75 min and solvent evaporated under vacuum to give the crude product, which was purified by RP chromatography to afford
Intermediate 6-D (36 mg, 57%, purity: 98%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 2.62 min; MS (positive ESI): found m/z 1520.9 [M+H]+; C78H126N11O19 (calc.1520.9).HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C78H126N11O191520.9226; Found 1520.9172. 1H NMR (700 MHz, DMSO-d6) į 9.82 (br s, 2H), 8.95 (t, J = 5.9 Hz, 1H), 8.15 (br s, 1H), 7.93 (br s, 1H), 7.29 – 7.23 (m, 4H), 6.57 (s, 1H), 6.36 (s, 1H), 4.61 – 4.47 (m, 1H), 4.41 – 4.27 (m, 1H), 3.87 (d, J = 13.2 Hz, 1H), 3.79 – 3.65 (m, 10H), 3.63 – 3.59 (m, 8H), 3.54 – 3.47 (m, 11H), 3.39 (t, J = 6.1 Hz, 3H), 3.28 – 3.19 (m, 2H), 3.16 (qd, J = 7.1, 4.2 Hz, 3H), 3.08 (s, 1H), 2.97 – 2.80 (m, 4H), 2.61 – 2.51 (m, 6H), 2.49 – 2.43 (m, 3H), 1.81 – 1.73 (m, 2H), 1.68 – 1.56 (m, 2H), 1.50 – 1.39 (m, 36H), 1.37 (s, 9H), 1.21 – 1.08 (m, 1H), 1.03 (t, J = 7.2 Hz, 3H), 1.00 (dd, J = 12.2, 4.2 Hz, 1H), 0.80 (d, J = 6.9 Hz, 6H). Step 5: Synthesis of 2,2',2''-(10-((15S,20R)-20-Carboxy-15-(carboxymethyl)-1-(4-(4-(3-(2,4- dihydroxy-5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)- 1,14,17-trioxo-4,7,10-trioxa-13,16-diazaicosan-20-yl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)triacetic acid (Compound F) To a 20 mL scintillation vial with a stir bar was added Intermediate 6-D (46 mg, 0.03 mmol, 1 equiv.) and 2.5 mL of deprotection cocktail TFA:TIPS:H2O - 95:2.5:2.5 (v/v/v) at RT. The reaction was brought to 37 °C by placing on a pre-heated oil bath at 37 °C and monitored by HPLC-MS. The reaction was stopped after 4h and reaction mixture placed under stream of air to remove TFA. The crude product was purified by preparative RP HPLC to afford Compound F (10.3 mg, 26 %, purity: 99%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 3.07 min; MS (positive ESI): found m/z 1240.3 [M+H]+; C58H86N11O19 (calc.1240.6). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C58H86N11O191240.6096; Found 1240.6109.1H NMR (700 MHz, DMSO-d6) į 10.65 (br s, 1H), 9.80 (br s, 1H), 8.94 (t, J = 5.9 Hz, 1H), 8.12 (d, J = 8.4 Hz, 1H), 7.89 (q, J = 6.0 Hz, 1H), 7.29 – 7.23 (m, 4H), 6.57 (s, 1H), 6.35 (s, 1H), 4.51 (dtd, J = 15.8, 7.9, 5.7 Hz, 2H), 4.36 (d, J = 13.0 Hz, 1H), 3.87 (d, J = 13.3 Hz, 1H), 3.61 (td, J = 6.7, 1.6 Hz, 2H), 3.52 – 3.47 (m, 20H), 3.42 – 3.35 (m, 2H), 3.28 – 3.19 (m, 1H), 3.19 – 3.11 (m, 6H), 3.09 (s, 1H), 2.96 – 2.86 (m, 5H), 2.65 – 2.57 (m, 2H), 2.55 (tt, J = 7.2, 3.6 Hz, 4H), 2.50 – 2.43 (m, 4H), 2.40 – 2.38 (m, 1H), 1.91 (s, 1H), 1.80 – 1.72 (m, 2H), 1.64 (d, J = 13.0 Hz, 1H), 1.59 (d, J = 12.7 Hz, 1H), 1.14 (qd, J = 12.6,
4.0 Hz, 2H), 1.03 (t, J = 7.2 Hz, 3H), 1.02 – 0.96 (m, 2H), 0.81 (d, J = 6.9 Hz, 6H). *4 exchangeable protons not observed. Example 7: Synthesis of (R)-2,2',2''-(10-(1-Carboxy-4-((2-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2- oxoethyl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound G) HO O OtBu NH2 O t O OBu O O H O HO N N N O t HO Bu N N O t Bu O HBTU, DIPEA, DMF O BuOt t N N BuO N N O BuOt Step 1 O O BuOt O Intermediate 7-A NH.HCl O t O O Bu H O N N HO O N N O t Bu N O N BuOt H N N N N OH O termediate 1-C B t In uO O HO O N HBTU, DIPEA, DMF N N N H OH Step 2 Intermediate 7-B O O OH H O N N N N OH O HO N N TFA:TIPS:H O 95 O 2 :2.5:2.5 HO O HO O 37 °C N N Step 3 N N H OH Compound G
Step 1: Synthesis of (R)-(5-(tert-Butoxy)-5-oxo-4-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)- 1,4,7,10-tetraazacyclododecan-1-yl)pentanoyl)glycine (Intermediate 7-A) To a 20 mL scintillation vial with a stir bar was added (R)-DOTAGA(tBu)4 (462.2 mg , 0.66 mmol, 1 equiv.) and DMF (3 mL). The reaction mixture was cooled to 0 °C and DIPEA, (345μL, 256 mg, 1.98 mmol, 3 equiv.), followed by HBTU, (255mg, 0.66 mmol, 1 equiv.) was added and stirred for 10 min at 0 °C. The solution was brought to RT and stirred for 30 min and then glycine (50 mg, 0.66 mmol, 1 equiv.) was added as a solid. Glycine solubility was poor in reaction mixture, therefore TFA (0.3 mL) and pyridine (0.6 mL) were added to the reaction mixture and continued stirring at RT, pH ~5. The reaction was monitored by HPLC-MS. The reaction was stopped after 3h30m and solvent was evaporated under vacuum to give the crude product, which was purified by RP chromatography to afford Intermediate 7-A (409 mg, 59%, purity: 95%) as white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 4.12 min; MS (positive ESI): found m/z 758.4 [M+H]+; C37H68N5O11 (calc. 758.5). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C37H68N5O11758.4910; Found 758.4928. 1H NMR (700 MHz, DMSO-d6) į 8.28 (s, 1H), 7.10 (s, 1H), 4.51–3. 96 (m, 1H), 3.90 – 3.57 (m, 4H), 3.28 (s, 1H), 3.07 (s, 2H), 2.87 (s, 1H), 2.45 (s, 1H), 2.07 – 1.63 (m, 1H), 1.57 – 1.31 (m, 36H). *Protons obscured by H2O and DMSO not reported. Step 2: Synthesis of tri-tert-Butyl 2,2’,2’’-(10-(1-(tert-butoxy)-5-((2-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2- oxoethyl)amino)-1,5-dioxopentan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)®-triacetate (Intermediate 7-B) To a 20 mL scintillation vial with a stir bar was added Intermediate 7-A (66.2 mg, 0.08 mmol, 1.4 equiv.) and DMF (3 mL). The reaction mixture was cooled to 0 °C and DIPEA, (51.7 μL, 38.4 mg, 0.3 mmol, 5 equiv.), followed by HBTU, (23 mg, 0.06 mmol, 1 equiv.) was added and stirred for 10 min at 0 °C. The solution was brought to RT and stirred for 15 min and then Intermediate 1-C (30 mg, 0.06 mmol, 1 equiv.) was added as a solid. The reaction was stirred at RT and monitored by HPLC-MS. Reaction was stopped after 2h and the solvent was evaporated under vacuum to give the crude product, which was purified by preparative RP HPLC to afford Intermediate 7-B (67 mg, 77%, purity: 98%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 5.21 min; MS (positive
ESI): found m/z 1203.4 [M+H]+; C63H99N10O13 (calc.1203.7). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C63H99N10O131203.7388; Found 1203.7361.1H NMR (700 MHz, DMSO-d6) į 9.84 (s, 1H), 8.96 (t, J = 5.9 Hz, 1H), 7.98 (s, 1H), 7.30 – 7.25 (m, 4H), 7.14 (s, 1H), 6.57 (s, 1H), 6.36 (s, 1H), 4.39 – 4.28 (m, 1H), 3.89 (s, 2H), 3.82 – 3.70 (m, 2H), 3.18 – 3.13 (m, 2H), 3.07 (s, 2H), 2.96 – 2.87 (m, 1H), 2.59 – 2.52 (m, 3H), 2.47 – 2.45 (m, 1H), 1.80 (t, J = 8.1 Hz, 1H), 1.64 (t, J = 15.6 Hz, 2H), 1.49 – 1.37 (m, 36H), 1.21 – 1.07 (m, 1H), 1.03 (t, J = 7.2 Hz, 3H), 1.02 – 0.97 (m, 1H), 0.81 (d, J = 6.9 Hz, 6H). *Protons obscured by H2O and DMSO not reported. Step 3: Synthesis of (R)-2,2',2''-(10-(1-Carboxy-4-((2-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2- oxoethyl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound G) To a 20 mL scintillation vial with a stir bar was added Intermediate 7-B (35 mg, 0.03 mmol) and 4 mL of deprotection cocktail TFA:TIPS:H2O - 95:2.5:2.5 (v/v/v) at RT. The reaction was brought to 37 °C by placing on a pre-heated oil bath at 37 °C and monitored by HPLC-MS. The reaction was stopped after 3h and reaction mixture was placed under stream of air to remove TFA. The crude product was purified by preparative RP HPLC to afford Compound G (20 mg, 57 %, purity: 99%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 1.70 min; MS (positive ESI): found m/z 979.3 [M+H]+; C44H62N10O11 (calc.979.4). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C44H62N10O11 979.4884; Found 979.4885. 1H NMR (700 MHz, DMSO-d6) į 10.62 (br s, 1H), 9.84 (br s, 1H), 8.95 (t, J = 6.0 Hz, 1H), 7.96 (br s, 1H), 7.28 – 7.25 (m, 4H), 6.57 (s, 1H), 6.36 (s, 1H), 4.34 – 4.30 (m, 1H), 4.07 (s, 1H), 3.91 (d, J = 5.6 Hz, 2H), 3.79 (d, J = 13.5 Hz, 2H), 3.50 (m, 13H), 3.16 (app. p, J = 7.0 Hz, 2H), 3.08 (s, 4H), 2.97 – 2.86 (m, 3H), 2.60 – 2.51 (m, 3H), 1.92 (br s, 2H), 1.83 – 1.75 (m, 1H), 1.64 (dd, J = 22.7, 12.9 Hz, 2H), 1.19 – 1.13 (m, 1H), 1.03 (t, J = 7.1 Hz, 3H), 1.02 – 0.97 (m, 1H), 0.81 (d, J = 6.9 Hz, 6H). *4 exchangeable protons not observed. Example 8: Synthesis of 2,2',2''-(10-((R)-1-Carboxy-4-(((S)-1-carboxy-4-(4-(4-(3-(2,4- dihydroxy-5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)- 4-oxobutyl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound H)
O NH•HCl N O NHFmoc HO NHFmoc HBTU, DIPEA, DMF BuOt O HO O BuOt Step 1 HO O N O N N N N N H N H OH OH N Intermediate 1-C Intermediate 8-A O N O OtBu NH2 HO O N N Piperidine, DMF OtBu BuOt O O BuOt N N Step 2 HO O N O BuOt N O N N H OH Intermediate 8-B O N O O t Bu H N O N N O OtBu HBTU, DIPEA, DMF BuOt O BuOt N N HO O Step 3 O N BuOt N O N N H OH Intermediate 8-C O N O OH H N O N N O OH TFA:TIPS:H2O 95:2.5:2.5 HO O HO N N HO O 37 °C O N HO N O Step 4 N N H OH Compound H
Step 1: Synthesis of tert-Butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(4-(4-(3- (2,4-dihydroxy-5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1- yl)-5-oxopentanoate (Intermediate 8-A) To a 20 mL scintillation vial with a stir bar was added (S)-4-((((9H-fluoren-9- yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-5-oxopentanoic acid, (43 mg, 0.10 mmol, 1 equiv.) and DMF (3 mL). The reaction mixture was cooled to 0 °C and DIPEA, (70 μL, 51.7 mg, 0. 40 mmol, 4 equiv.), followed by HBTU, (38.7 mg, 0.10 mmol, 1 equiv.) was added and stirred for 15 min at 0 °C. The solution was brought to RT and stirred for 20 min and then Intermediate 1- C (50 mg, 0.10 mmol, 1 equiv.) was added as solid. The reaction was stirred at RT and monitored by HPLC-MS. The reaction was stopped after 2 h and solvent was evaporated under vacuum to give the crude product. The crude product was purified by RP chromatography to afford Intermediate 8-A (66 mg, 75%, purity: 98%) as a colorless film/solid. An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 3.15 min; MS (positive ESI): found m/z 870.9 [M+H]+; C50H59N6O8 (calc.871.4). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C50H59N6O8871.4389; Found 871.4396.1H NMR (700 MHz, DMSO-d6) į 9.80 (br s, 1H), 8.96 (t, J = 5.9 Hz, 1H), 7.89 (t, J = 6.6 Hz, 2H), 7.73 (t, J = 7.0 Hz, 2H), 7.69 (dd, J = 8.0, 2.9 Hz, 1H), 7.42 (td, J = 7.5, 3.1 Hz, 2H), 7.35 – 7.31 (m, 2H), 7.30 – 7.19 (m, 4H), 6.58 (d, J = 4.1 Hz, 1H), 6.37 (d, J = 1.2 Hz, 1H), 4.39 – 4.21 (m, 4H), 4.00 – 3.92 (m, 1H), 3.79 (d, J = 13.0 Hz, 1H), 3.20 – 3.14 (m, 2H), 2.95 – 2.88 (m, 2H), 2.57 – 2.54 (m, 1H), 2.49 – 2.44 (m, 1H), 2.43 – 2.31 (m, 2H), 1.97 – 1.90 (m, 1H), 1.83 – 1.74 (m, 2H), 1.67 – 1.55 (m, 2H), 1.40 (s, 9H), 1.12 – 1.07 (m, 1H), 1.04 (t, J = 7.2 Hz, 3H), 0.99 (td, J = 12.4, 4.3 Hz, 1H), 0.82– 0.78 (m, 6H). *2 exchangeable protons not observed Step 2: Synthesis of tert-Butyl (S)-2-amino-5-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-5-oxopentanoate (Intermediate 8- B) To a 20 mL scintillation vial with a stir bar was added Intermediate 8-A, (60 mg, 0.07 mmol, 1 equiv.), followed by 6 mL of 15% piperidine solution in DMF at RT. The reaction was monitored by HPLC-MS. Reaction stopped after 1h and solvent was evaporated under vacuum to give the crude product. The product was obtained by precipitation with acetonitrile to afford Intermediate 8-B (37 mg, 67%, purity: 96%) as a colorless film/ solid. An aliquot was analyzed
by HPLC-MS elution using elution method 2; retention time: 2.07 min; MS (positive ESI): found m/z 649.0 [M+H]+; C35H49N6O6 (calc.649.4). Step 3: Synthesis of tri-tert-Butyl 2,2',2''-(10-((R)-1-(tert-butoxy)-5-(((S)-1-(tert-butoxy)-5-(4-(4- (3-(2,4-dihydroxy-5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4- yl)benzyl)piperidin-1-yl)-1,5-dioxopentan-2-yl)amino)-1,5-dioxopentan-2-yl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetate (Intermediate 8-C): To a 20 mL scintillation vial with a stir bar was added (R)-5-(tert-butoxy)-5-oxo-4-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)- 1,4,7,10-tetraazacyclododecan-1-yl)pentanoic acid, (16.5 mg, 0.02 mmol, 1 equiv.) and DMF (1.5 mL). Reaction mixture was cooled to 0 °C and DIPEA, (16.2 μL, 12 mg, 0.09 mmol, 4 equiv.), followed by HBTU, (9.2 mg, 0.02 mmol, 1 equiv.) was added and stirred for 15 min at 0 °C. The solution was brought to RT and stirred for 20 min and then Intermediate 8-B (18.5 mg, 0.02 mmol, 1 equiv.) was added as solution in DMF (0.5 mL). The reaction was stirred at RT and monitored by HPLC-MS. The reaction was stopped after 3h 30 min and the solvent was evaporated under vacuum to give the crude product, which was purified by RP chromatography to afford Intermediate 8-C (24 mg, 64%, purity: 97%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 5.31 min; MS (positive ESI): found m/z 1331.8 [M+H]+; C70H111N10O15 (calc.1331.8). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C70H111N10O151331.8225; Found 1331.8283.1H NMR (700 MHz, DMSO- d6) į 9.84 (br s, 1H), 8.96 (t, J = 5.9 Hz, 1H), 8.24 (br s, 1H), 7.31 – 7.25 (m, 4H), 7.10 (br s, 1H), 6.57 (s, 1H), 6.37 (d, J = 1.8 Hz, 1H), 4.37 (d, J = 12.9 Hz, 1H), 4.11 – 4.07 (m, 2H), 3.83 – 3.68 (m, 3H), 3.19 – 3.14 (m, 2H), 3.08 (s, 2H), 2.98 – 2.81 (m, 3H), 2.57 (d, J = 7.0 Hz, 2H), 2.50 – 2.45 (m, 1H), 2.43 (s, 1H), 2.37 – 2.31 (m, 2H), 1.91 – 1.86 (m, 2H), 1.82 – 1.76 (m, 3H), 1.68 – 1.60 (m, 2H), 1.49 – 1.42 (m, 36H), 1.40 (s, 9H), 1.11 (s, 1H), 1.04 (t, J = 7.2 Hz, 3H), 1.02 – 0.97 (m, 1H), 0.81 (d, J = 6.9 Hz, 6H). *Protons obscured by H2O and DMSO not reported. Step 3: Synthesis of 2,2',2''-(10-((R)-1-Carboxy-4-(((S)-1-carboxy-4-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-4- oxobutyl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound H)
To a 20 mL scintillation vial with a stir bar was added Intermediate 8-C (17 mg, 9.3 μmol, 1 equiv.) and 2.5 mL of deprotection cocktail TFA:TIPS:H2O - 95:2.5:2.5 (v/v/v) at RT. The reaction was brought to 37 °C by placing on a pre-heated oil bath at 37 °C and monitored by HPLC-MS. The reaction was stopped after 2h30 min and the reaction mixture was placed under stream of air to remove TFA. The crude product was purified by preparative RP HPLC to afford Compound H (10.5 mg, 87 %, purity: 99%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 1.71 min; MS (positive ESI): found m/z 1051.6 [M+H]+; C50H71N10O15 (calc.1051.5). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C50H71N10O151051.5095; Found 1051.5125.1H NMR (700 MHz, DMSO-d6) į 9.82 (s, 1H), 8.95 (t, J = 5.9 Hz, 1H), 8.19 (d, J = 7.5 Hz, 1H), 7.27 (d, J = 1.6 Hz, 4H), 6.57 (s, 1H), 6.36 (s, 1H), 4.38 – 4.34 (m, 1H), 4.20 – 4.16 (m, 1H), 3.80 (d, J = 13.5 Hz, 1H), 3.18 – 3.13 (m, 2H), 2.97 – 2.86 (m, 3H), 2.62 – 2.52 (m, 2H), 2.49 – 2.41 (m, 5H), 2.40 – 2.32 (m, 2H), 1.96 – 1.89 (m, 3H), 1.84 – 1.76 (m, 1H), 1.66 (d, J = 12.5 Hz, 1H), 1.59 (d, J = 12.8 Hz, 1H), 1.18 – 1.09 (m, 1H), 1.03 (t, J = 7.2 Hz, 3H), 1.02 – 0.98 (m, 1H), 0.81 (d, J = 6.9 Hz, 6H). *Protons obscured by H2O and DMSO not reported. Example 9: Synthesis of 2,2',2''-(10-((R)-1-Carboxy-4-(((S)-4-carboxy-1-((2-(4-(4-(3-(2,4- dihydroxy-5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)- 2-oxoethyl)amino)-1-oxobutan-2-yl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)triacetic acid (Compound I) O OtBu tB O O t O uO t B Bu O O t BuO O O u O O NH2 O OtBu O tBuO N N O N N LiOH tBuO N N HBTU, DIPEA, DMF tBuO O O OtBu O O HO N N N OtBu THF:H 2 N N N OtBu O N N H O O HO H Step O OtBu O O 2 O Ot O Bu Step 1 O OtBu Intermediate 9-A Intermediate 9-B
NH•HCl O O NHFmoc BnO O N NH N 2 N N N N H OBn Intermediate 2-B BnO O O O N Piperidine, DMF BnO HBTU, DIPEA, DMF N NHFmoc N HO N N H Step N OBn 4 N N H Step 3 OBn Intermediate 9-C Intermediate 9-D t O t BuO O OBu O tBuO N N O Intermediate 9-B H O N N OtBu N N N H HBTU, DIPEA, DMF O O O OtBu Step 5 Intermediate 9-D BnO O N N N N H OBn Intermediate 9-E t O O BuO O t Bu O tBuO N N O H O N N N Ot Bu N N H Pd/C, H2 O O O O t Bu Step 6 HO O N N N N H OH Intermediate 9-F OH HO O O O HO N N O H O N N OH N N N H O O TFA:TIPS:H2O 95:2.5:2.5 O OH 37 °C Step 7 HO O N N N N H OH Compound I
Step 1: Synthesis of 5-(tert-Butyl) 1-methyl ((R)-5-(tert-butoxy)-5-oxo-4-(4,7,10-tris(2-(tert- butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanoyl)-L-glutamate (Intermediate 9-A) To a 20 mL scintillation vial with a stir bar was added (R)-DOTAGA(tBu)4 (350 mg, 0.5 mmol, 1 equiv.) and 7 mL DMF. The reaction mixture was cooled to 0 °C and DIPEA, (348 μL, 258 mg, 2 mmol, 4 equiv.), followed by HBTU, (208mg, 0.55 mmol, 1.1 equiv.) was added and stirred for 10 min at 0 °C. The solution was brought to RT and was stirred for 15 min and then 5- (tert-butyl) 1-methyl L-glutamate HCl (127 mg, 0.5 mmol, 1 equiv.) was added as a solid. The reaction was stirred at RT and was monitored by HPLC-MS. The reaction was stopped after 2 h and the solvent was evaporated under vacuum to give the crude product, which was purified by RP chromatography to afford Intermediate 9-A (412 mg, 71%, purity: 97%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 2.67 min; MS (positive ESI): found m/z 900.4 [M+H]+; C45H82N5O13 (calc. 900.6). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C45H82N5O13900.5904; Found 900.5936. 1H NMR (700 MHz, DMSO-d6) į 8.32 (s, 1H), 7.05 (s, 1H), 4.35 (s, 1H), 4.24 – 4.19 (m, 1H), 3.62 (s, 3H), 3.28 (s, 3H), 3.07 (s, 2H), 2.58 – 2.51 (m, 1H), 2.45 (s, 1H), 2.25 (t, J = 7.6 Hz, 2H), 1.94 – 1.86 (m, 1H), 1.82 – 1.74 (m, 1H), 1.52 – 1.40 (m, 36H), 1.39 (s, 9H). *Protons obscured by H2O and DMSO not reported. Step 2: Synthesis of (S)-5-(tert-Butoxy)-2-((R)-5-(tert-butoxy)-5-oxo-4-(4,7,10-tris(2-(tert- butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanamido)-5-oxopentanoic acid (Intermediate 9-B) To a flask containing 5-(tert-Butyl) 1-methyl ((R)-5-(tert-butoxy)-5-oxo-4-(4,7,10-tris(2-(tert- butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanoyl)-L-glutamate (Intermediate 9-A) (164mg, 0.18 mmol, 1 equiv.) was dissolved in THF (5 mL) and water (2.5 mL) and placed in an ice bath and stirred for 10 min. Lithium hydroxide anhydrous (LiOH), (21.8 mg, 0.91 mmol, 5 equiv.) was added as a solid in one portion and thereaction was stirredin an ice-water bath. The reaction was monitored by HPLC-MS, after 1h was worked up by acidification with Amberlite IR120 [H], at rt to pH ~5, then filtered via a 0.2 μM filter disk to remove resin. The resin was further washed with ACN, MeOH and the solvent was evaporated under vacuum. The crude product was dissolved in acetonitrile/water and lyophilised to give Intermediate 9-B (159
mg, 94%, purity: 95%) as a white solid. An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 2.57 min; MS (positive ESI): found m/z 886.3 [M+H]+; C44H80N5O13 (calc. 886.6). Step 3: Synthesis of (9H-Fluoren-9-yl)methyl (2-(4-(4-(3-(2,4-bis(benzyloxy)-5-isopropylphenyl)- 5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2-oxoethyl)carbamate (Intermediate 9-C) To a 20 mL scintillation vial with a stir bar was added (((9H-fluoren-9- yl)methoxy)carbonyl)glycine, (24.4 mg, 0.08 mmol, 1 equiv.) and DMF (1.5 mL). The reaction mixture was cooled to 0 °C and DIPEA, (28 μL, 0.16 mmol, 2 equiv.), followed by HBTU, (31.4 mg, 0.08 mmol, 1 equiv.) was added and stirred for 5 min at 0 °C. The solution was brought to RT and stirred for 20 min and then solution of Intermediate 2-B (55 mg, 0.08 mmol, 1 equiv.) in DMF (1.5 mL) containing DIPEA, (53 μL, 0.24 mmol, 3 equiv.) was added. The reaction was stirred at RT and was monitored by HPLC-MS. The reaction was stopped after 1h 30 min and solvent was evaporated under vacuum to give the crude product, which was purified by normal phase chromatography to afford Intermediate 9-C (58 mg, 76%, purity: 98%) as a white solid. An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 3.48 min; MS (positive ESI): found m/z 923.1 [M+H]+; C57H59N6O6 (calc.923.5). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C57H59N6O6923.4491; Found 923.4525.1H NMR (700 MHz, DMSO-d6) į 8.97 (t, J = 5.9 Hz, 1H), 7.90 (d, J = 7.5 Hz, 2H), 7.72 (d, J = 7.5 Hz, 2H), 7.44 – 7.30 (m, 13H), 7.25 (d, J = 7.4 Hz, 2H), 7.08 (d, J = 8.1 Hz, 2H), 7.05 (s, 1H), 6.98 (d, J = 8.0 Hz, 2H), 6.77 (s, 1H), 5.08 (s, 2H), 4.94 (s, 2H), 4.33 – 4.21 (m, 4H), 3.83 (qd, J = 16.7, 5.9 Hz, 2H), 3.78 – 3.72 (m, 1H), 3.66 – 3.59 (m, 1H), 3.18 (q, J = 6.9 Hz, 2H), 3.13 – 3.08 (m, 1H), 2.92 – 2.86 (m, 1H), 2.69 (s, 1H), 2.49 – 2.47 (m, 1H), 1.77 – 1.69 (m, 1H), 1.52 (dd, J = 22.9, 13.0 Hz, 2H), 1.27 – 1.25 (m, 2H), 1.05 (t, J = 7.2 Hz, 3H), 1.03 (d, J = 6.9 Hz, 6H). Step 4: Synthesis of 5-(2,4-bis(Benzyloxy)-5-isopropylphenyl)-N-ethyl-4-(4-((1-glycylpiperidin-4- yl)methyl)phenyl)-4H-1,2,4-triazole-3-carboxamide (Intermediate 9-D) Piperidine (0.45 mL) was added to a solution of (9H-fluoren-9-yl)methyl (2-(4-(4-(3-(2,4- bis(benzyloxy)-5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1- yl)-2-oxoethyl)carbamate (Intermediate 9-C), ( 50 mg, 0.05 mmol, 1 equiv) in DMF (2.55 mL)
and the mixture stirred at RT. The reaction was monitored by HPLC-MS and after 1h at RT the reaction stopped. The solvent was evaporated under vacuum and the crude product was purified by RP chromatography to give Intermediate 9-D (24.6 mg, 64%, purity 98%) as a white solid. An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 2.48 min; MS (positive ESI): found m/z 701.1 [M+H]+; C42H49N6O4 (calc.701.4). Step 5: Synthesis of tri-tert-Butyl 2,2',2''-(10-((R)-5-(((S)-1-((2-(4-(4-(3-(2,4-bis(benzyloxy)-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2- oxoethyl)amino)-5-(tert-butoxy)-1,5-dioxopentan-2-yl)amino)-1-(tert-butoxy)-1,5-dioxopentan-2- yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (Intermediate 9-E) To a 20 mL scintillation vial with a stir bar was added Intermediate 9-B (22.8 mg, 0.02 mmol, 1 equiv.) and DMF (2 mL). The reaction mixture was cooled to 0 °C and DIPEA, (19 μL, 14.2 mg, 0.11 mmol, 4.5 equiv.), followed by HBTU(9.4 mg, 0.02 mmol, 1 equiv.) was added and stirred for 15 min at 0 °C. The solution was brought to RT and stirred for 20 min and then Intermediate 9-D (18 mg, 0.02 mmol, 1 equiv.) was added dissolved in DMF (1 mL). The reaction was stirred at RT and was monitored by HPLC-MS. The reaction was stopped after 1 h 45 min and the solvent was evaporated under vacuum to give the crude product, which was purified by RP chromatography to afford Intermediate 9-E (30 mg, 65%, purity: 95%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 3.12 min; MS (positive ESI): found m/z 1569.5 [M+H]+; C86H126N11O16 (calc.1568.9). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C86H126N11O161568.9379; Found 1568.9403.1H NMR (700 MHz, DMSO-d6) į 8.98 (td, J = 6.0, 2.2 Hz, 1H), 7.92 (s, 1H), 7.41 – 7.36 (m, 4H), 7.36 (t, J = 7.4 Hz, 2H), 7.35 – 7.29 (m, 2H), 7.27 – 7.23 (m, 2H), 7.10 – 7.06 (m, 2H), 7.03 (d, J = 2.4 Hz, 1H), 7.01 – 6.97 (m, 2H), 6.77 (s, 1H), 5.08 (s, 2H), 4.95 (d, J = 3.3 Hz, 2H), 4.31 – 4.29 (m, 2H), 4.00 – 3.81 (m, 2H), 3.74 (d, J = 13.6 Hz, 2H), 3.22 – 3.14 (m, 2H), 3.13 – 3.06 (m, 2H), 2.96 – 2.85 (m, 1H), 2.49 – 2.48 (m, 4H), 2.28 – 2.20 (m, 2H), 1.92 – 1.84 (m, 1H), 1.77 – 1.69 (m, 3H), 1.47 – 1.40 (m, 36H), 1.38 (s, 9H), 1.05 (t, J = 7.2 Hz, 3H), 1.01 (dd, J = 6.9, 2.0 Hz, 6H). *Protons obscured by H2O and DMSO not reported. Step 6: Synthesis of tri-tert-Butyl 2,2',2''-(10-((R)-1-(tert-butoxy)-5-(((S)-5-(tert-butoxy)-1-((2-(4- (4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-
yl)benzyl)piperidin-1-yl)-2-oxoethyl)amino)-1,5-dioxopentan-2-yl)amino)-1,5-dioxopentan-2-yl)- 1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (Intermediate 9-F) To a flask containing Intermediate 9-E (26 mg, 16.6 μmol, 1 equiv.) and methanol (5 mL) was added 10% Pd/C (3.4 mg, 3.32 μmol, 0.2 equiv.) at room temperature. The reaction mixture was degassed under vacuum and subjected to hydrogen gas via a balloon. The reaction was stirred overnight and was monitored by HPLC-MS. The reaction was stopped after 15 hours, filtered through 0.2 μM filter disk and solvent evaporated under vacuum to give the crude Intermediate 9-F (22 mg, 86 %, purity: 90%) as colorless film, which was used for next step without further purification. An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 2.73 min; MS (positive ESI): found m/z 1389.4 [M+H] +; C72H114N11O18 (calc. 1388.8). Step 7: Synthesis of 2,2',2''-(10-((R)-1-Carboxy-4-(((S)-4-carboxy-1-((2-(4-(4-(3-(2,4-dihydroxy- 5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2- oxoethyl)amino)-1-oxobutan-2-yl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)triacetic acid (Compound I) To a 20 mL scintillation vial with a stir bar was added Intermediate 9-F (22 mg, 15.68 μmol) and 2.5 mL of deprotection cocktail TFA:TIPS:H2O - 95:2.5:2.5 (v/v/v) at RT. The reaction was brought to 37 °C by placing on a pre-heated oil bath at 37 °C and was monitored by HPLC-MS. The reaction was stopped after 4h and the reaction mixture was placed under stream of air to remove TFA. The crude product was purified by preparative RP HPLC to afford Compound I (5 mg, 23 %, purity: 97%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 2.84 min; MS (positive ESI): found m/z 1108.5 [M+H]+; C52H74N11O16 (calc.1108.5). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C52H74N11O161108.5310; Found 1108.5332.1H NMR (700 MHz, DMSO-d6) į 10.65 (s, 1H), 9.79 (s, 1H), 8.95 (td, J = 5.9, 2.4 Hz, 1H), 8.09 (d, J = 9.2 Hz, 1H), 7.95 – 7.91 (m, 1H), 7.28 – 7.26 (m, 3H), 6.57 (d, J = 1.9 Hz, 1H), 6.35 (s, 1H), 4.34 – 4.28 (m, 2H), 4.04 – 3.84 (m, 1H), 3.77 (d, J = 13.5 Hz, 1H), 3.19 – 3.13 (m, 2H), 3.09 (s, 2H), 2.97 – 2.86 (m, 3H), 2.58 – 2.52 (m, 3H), 2.44 (s, 2H), 2.32 – 2.26 (m, 2H), 1.94 – 1.87 (m, 3H), 1.81 – 1.71 (m, 1H), 1.65 – 1.60 (m, 2H), 1.18 – 1.14 (m, 1H), 1.03 (t, J = 7.2 Hz, 3H), 0.81 (d, J = 6.9 Hz, 6H). *Protons obscured by H2O and DMSO not reported.
Example 10: Synthesis of 2,2',2''-(10-(2-(((S)-1-(((S)-1-(((S)-5-Amino-1-(4-(4-(3-(2,4- dihydroxy-5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)- 1,5-dioxopentan-2-yl)amino)-4-carboxy-1-oxobutan-2-yl)amino)-5-guanidino-1-oxopentan-2- yl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound J) NH •HCl BnO O N tBuO O N O tBuO O N N H tBuO O OBn O O tBuO H H O O Intermediate 2-B N N N N N N t SPPS H H HBTU, DIPEA H OBu N N N O O Cl HO N N N H O tBu N O Cl O O N DMF, RT HN HN Step 1 N O O Step 2 Trt OtBu HN O HN t BnO O HN NH O Trt OBu N Pbf HN NH O N Pbf H OBn N N Intermediate 10-A Intermediate 10-B HO O O HO O O H H N N N N N N H OH 1) Pd/C, H2 , MeOH, RT O O N N O 2) TFA/TIPS/H2 O 95:2.5:2.5 37 °C H 2 N O HN OH HO O H 2 N NH O N Step 3 N N H Compound J OH N Step 1: Synthesis of N2-((S)-5-(tert-Butoxy)-5-oxo-2-((S)-5-(3-((2,2,4,6,7-pentamethyl-2,3- dihydrobenzofuran-5-yl)sulfonyl)guanidino)-2-(2-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)- 1,4,7,10-tetraazacyclododecan-1-yl)acetamido)pentanamido)pentanoyl)-N5-trityl-L-glutamine (Intermediate 10-A) The protected peptide was synthesized by solid phase peptide synthesis (SPPS) on 2- chlorotritylchloride resin (Chem-Impex, 0.72 mmol/g, 139 mg, 0.1 mmol). Fmoc-Gln(Trt)-OH (305 mg, 0.5 mmol) was dissolved in DMF (4 mL) with potassium iodide (16 mg, 0.1 mmol) and DIPEA (174 μL, 1.0 mmol). The resulting solution was combined with the resin and stirred at room temperature overnight. Fmoc deprotection was performed for 5 and 15 minutes with 20% piperidine in DMF. Subsequent couplings were performed using 0.3 mmol of protected amino acids (Fmoc-Glu(OtBu)-OH, Fmoc-Arg(Pbf)-OH and DOTA(OtBu)3) 0.3 mmol of HBTU and
0.6 mmol of DIPEA in DMF for 1 hour. Couplings were monitored by Kaiser test. After the final coupling, the resin was washed thoroughly with DCM. Cleavage from resin was performed with 20% HFIP in DCM (5 mL) for 30 minutes. The resin was drained and washed with DCM (2 mL), and the combined washings were concentrated under a stream of air. The resulting crude protected peptide was dissolved in DMSO and purified by preparative RP HPLC. Purified protected peptide Intermediate 10-A was obtained as a colourless solid after lyophilization (38.5 mg, 25%, purity: 98%). An aliquot was analyzed by HPLC-MS using elution method 4; retention time: 4.98 min; MS (ESI+) m/z calculated for C80H118N11O17S [M+H]+ 1536.8; found 1536.9. 1H NMR (700 MHz, DMSO-d6^^į^^^^^^^V^^^+^^^^^^^^^V^^^+^^^^^^^^^V^^^+^^^^^^^^^V^^^+^^^ 7.31 (s, 1H), 7.28 – 7.24 (m, 7H), 7.21 – 7.18 (m, 3H), 7.17 – 7.15 (m, 7H), 6.68 (s, 1H), 6.37 (s, 1H), 4.35 – 4.29 (m, 1H), 4.26 (s, 1H), 4.22 – 4.12 (m, 2H), 4.12 – 4.01 (m, 1H), 3.92 (s, 1H), 3.60 – 3.43 (m, 5H), 3.36 (s, 3H), 3.32 – 3.19 (m, 3H), 3.19 – 3.09 (m, 2H), 3.08 – 2.97 (m, 4H), 2.95 (s, 3H), 2.89 (s, 2H), 2.81 (d, J = 26.0 Hz, 1H), 2.47 (s, 3H), 2.41 (s, 3H), 2.39 – 2.34 (m, 2H), 2.24 (t, J = 8.5 Hz, 2H), 2.07 (s, 1H), 2.00 (s, 3H), 1.93 – 1.85 (m, 2H), 1.79 – 1.73 (m, 2H), 1.73 – 1.66 (m, 1H), 1.47 (s, 9H), 1.40 (s, 9H), 1.38 (m, 27H). Step 2: Synthesis of tri-tert-Butyl 2,2',2''-(10-((6S,9S,12S)-6-(4-(4-(3-(2,4-bis(benzyloxy)-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidine-1-carbonyl)-9-(3- (tert-butoxy)-3-oxopropyl)-3,8,11,14-tetraoxo-12-(3-(3-((2,2,4,6,7-pentamethyl-2,3- dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-1,1,1-triphenyl-2,7,10,13- tetraazapentadecan-15-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (Intermediate 10-B) Intermediate 10-A (21 mg, 0.02 mmol), Intermediate 2-B (15 mg, 0.022 mmol), HBTU (7.6 mg, 0.02 mmol) and DIPEA (18 μL, 0.1 mmol) were dissolved in DMF (2 mL) and stirred for 1 hour at room temperature. The solvent was evaporated under reduced pressure and the residue redissolved in DMSO (<1 mL). The crude product was purified by preparative RP HPLC to give Intermediate 10-B as a colourless solid after lyophilization (23 mg, 54%, purity: 98%). An aliquot was analyzed by HPLC-MS using elution method 4; retention time: 6.15 min; MS (ESI+) m/z calculated for C120H162N16O19S [M+2H]2+ 1082.1; found 1082.3.
Step 3: Synthesis of 2,2',2''-(10-(2-(((S)-1-(((S)-1-(((S)-5-Amino-1-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-1,5- dioxopentan-2-yl)amino)-4-carboxy-1-oxobutan-2-yl)amino)-5-guanidino-1-oxopentan-2- yl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound J) 10% w/w Palladium on carbon (30% w/w, 3.5 mg) was added to a 5 mL microwave vial with a stir bar and sealed with a septum and crimp cap. The vial was purged with nitrogen, followed by the addition of Intermediate 10-B (23 mg, 10.8 μmol) dissolved in methanol (2 mL). The vial was then purged with hydrogen and a hydrogen balloon attached to the vial. After stirring for 2 hours at room temperature, the vial was purged with nitrogen and the vial unsealed. The reaction mixture was filtered through a 0.2 μm syringe filter and the solvent evaporated under reduced pressure. The resulting product was dissolved in 2 mL of 95:2.5:2.5 TFA/ /TIPS/H2O (v/v/v) and stirred at 37 °C in a heating block for 90 minutes. The solvent was then evaporated under a stream of air and the resulting crude product redissolved in DMSO, filtered through a 0.2 μm syringe filter and purified by preparative RP HPLC. Compound J was obtained as a colourless solid after lyophilization (5.9 mg, 34%, purity: 99%) as the TFA salt. An aliquot was analyzed by HPLC-MS using elution method 4; retention time: 4.53 min; HRMS (ESI+) m/z calculated for C58H88N16O16 [M+2H]2+ 632.3277; found 632.3268.1H NMR (700 MHz, DMSO-d6^^į^^^^^^^V^^ 1H), 8.96 (t, J = 5.4 Hz, 1H), 8.71 (s, 1H), 8.27 – 8.03 (m, 2H), 7.81 (s, 1H), 7.29 – 7.25 (m, 4H), 7.25 (m, 1H), 6.82 (m, 1H), 6.57 (s, 1H), 6.36 (s, 1H), 4.79 – 4.67 (m, 2H), 4.43 – 4.32 (m, 4H), 4.32 – 4.28 (m, 1H), 4.27 – 4.22 (m, 1H), 4.12 – 3.88 (m, 9H), 3.71 – 3.52 (m, 4H), 3.47 – 3.24 (m, 7H), 3.19 – 3.15 (m, 2H), 3.13 – 3.02 (m, 8H), 3.02 – 2.93 (m, 1H), 2.90 (h, J = 6.7 Hz, 1H), 2.32 – 2.20 (m, 2H), 2.20 – 2.00 (m, 2H), 1.97 – 1.82 (m, 2H), 1.81 – 1.68 (m, 3H), 1.68 – 1.59 (m, 3H), 1.59 – 1.45 (m, 3H), 1.03 (t, J = 7.2 Hz, 3H), 0.81 (d, J = 6.7 Hz, 6H). * 9 exchangeable protons not observed. Example 11: Synthesis of (S)-2,2',2''-(10-(1-Carboxy-4-((2-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidine-1- carboxamido)ethyl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound K)
O OtBu O H O tBuO O N O N N N N OtBu -NO-Phenyl chl H O tBuO N N 1. p 2 oroformate tBuO N N O t DIPEA, THF Bu H2N N N O O N tBuO H O NH•HCl O Bn O O t O OBu 2. N N N N H Intermediate 5-A OBn Intermediate 11-A BnO O N N N N H OBn Intermediate 2-B Step 1 O OtBu O H O N N N N N H OtBu O Pd/C, H2 BuOt N N Step 2 O BuOt O HO O N N N N H OH Intermediate-11-B O OH O H O N N N N N H OH O HO N N TFA:TIPS:H2O 95:2.5:2.5 O HO 37 °C O HO O N Step 3 N N N H OH Compound K Step 1: Synthesis of tri-tert-Butyl 2,2',2''-(10-(5-((2-(4-(4-(3-(2,4-bis(benzyloxy)-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidine-1- carboxamido)ethyl)amino)-1-(tert-butoxy)-1,5-dioxopentan-2-yl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)(S)-triacetate (Intermediate 11-A)
To a solution of tri-tert-butyl 2,2',2''-(10-(5-((2-aminoethyl)amino)-1-(tert-butoxy)-1,5- dioxopentan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)(R)-triacetate (Intermediate 5-A) (50 mg, 0.06 mmol, 1 equiv.) in anhydrous THF (4 mL) and stir bar was added DIPEA (32 μL, 0.18 mmol, 3 equiv.) and cooled to 0 °C, followed by addition of 4-nitrophenylchloroformate (12.7 mg, 0.06 mmol, 1 equiv.) at 0 °C in one portion. The reaction was initially stirred at 0 °C for 20 min., after which was brought to RT and was monitored by HPLC-MS. After 30 min at RT complete conversion to the nitrophenyl intermediate was observed by HPLC-MS. Added Intermediate 2-B (59 mg, 0.08 mmol, 1.4 equiv.) as a solid to the reaction and continued stirring at RT. After 1h additional Intermediate 2-B (26 mg, 0.04 mmol, 0.6 equiv.), followed by DIPEA (32 μL, 0.18 mmol, 3 equiv.) was added^^7KH^UHDFWLRQ^PL[WXUH^ZDV^EURXJKW^WR^^^^^^ and stirring was continued overnight. $IWHU^^^^K^DW^^^^^^^WKH^UHDFWLRQ^ZDV^VWRSSHG^E\^DGGLQJ^ methanol and stirring for 10 min at RT. The reaction mixture was concentrated under vacuum, followed by RP chromatography to afford Intermediate 11-A (34 mg, 40%, purity: 95%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 2.92 min; MS (positive ESI): found m/z 1412.5 [M+H]+; C78H114N11O13 (calc. 1412.9). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C78H114N11O131412.8592; Found 1412.8552. 1H NMR (700 MHz, DMSO-d6) į 8.99 (t, J = 5.9 Hz, 1H), 7.96 (br s, 1H), 7.42 – 7.34 (m, 6H), 7.36 – 7.30 (m, 2H), 7.28 – 7.24 (m, 2H), 7.11 – 7.06 (m, 4H), 7.03 (s, 1H), 6.99 (d, J = 8.0 Hz, 2H), 6.78 (s, 1H), 6.51 (t, J = 5.5 Hz, 1H), 5.09 (s, 2H), 4.96 (s, 2H), 4.43 – 3.94 (m, 1H), 3.89 (d, J = 12.8 Hz, 2H), 3.20 – 3.15 (m, 2H), 3.14 – 2.98 (m, 7H), 2.56 (t, J = 12.5 Hz, 2H), 2.48 (d, J = 7.1 Hz, 2H), 1.51 – 1.39 (m, 40H), 1.05 (t, J = 7.2 Hz, 3H), 1.01 (d, J = 6.9 Hz, 6H). *Protons obscured by H2O and DMSO not reported. Step 2: Synthesis of tri-tert-Butyl 2,2',2''-(10-(1-(tert-butoxy)-5-((2-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidine-1- carboxamido)ethyl)amino)-1,5-dioxopentan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)(S)-triacetate (Intermediate 11-B) To a flask containing Intermediate 11-A (30 mg, 19.11 μmol) and methanol (4.5 mL) was added 10% Pd/C (8 mg, 7.64 μmol, 0.4 equiv.) at room temperature. The reaction mixture was degassed under vacuum and subjected to hydrogen gas via a balloon. The reaction was stirred overnight and was monitored by HPLC-MS. The reaction was stopped after 15 hours, filtered
through a 0.2 μM filter disk and solvent evaporated under vacuum to give the crude product, which was purified by RP chromatography to afford Intermediate 11-B (18.4 mg, 66 %, purity: 98%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 4.78 min; MS (positive ESI): found m/z 1232.5 [M+H] +; C64H102N11O13 (calc.1232.8). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C64H102N11O13 1232.7680; Found 1232.7680.1H NMR (700 MHz, DMSO-d6) į 9.82 (br s, 1H), 8.96 (t, J = 5.9 Hz, 1H), 7.31 – 7.25 (m, 4H), 7.11 (s, 2H), 6.57 (s, 1H), 6.54 (br s, 1H), 6.37 (s, 1H), 3.92 (d, J = 13.4 Hz, 2H), 3.20 – 3.13 (m, 2H), 3.10 – 3.01 (m, 8H), 2.94 – 2.87 (m, 1H), 2.61 – 2.54 (m, 4H), 2.47 – 2.39 (m, 2H), 1.72 – 1.65 (m, 1H), 1.57 (d, J = 12.6 Hz, 2H), 1.51 – 1.37 (m, 38H), 1.09 – 1.05 (m, 1H), 1.04 (t, J = 7.2 Hz, 3H), 0.80 (d, J = 6.0 Hz, 6H). *Protons obscured by H2O and DMSO not reported. Step 3: Synthesis of (S)-2,2',2''-(10-(1-Carboxy-4-((2-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidine-1- carboxamido)ethyl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound K) To a 20 mL scintillation vial with a stir bar was added Intermediate 11-B (18 mg, 10.73 μmol, 1 equiv.) and 2.5 mL of deprotection cocktail TFA:TIPS:H2O - 95:2.5:2.5 (v/v/v) at RT. The reaction was brought to 37 °C by placing on a pre-heated oil bath at 37 °C and monitored by HPLC-MS. The reaction was stopped after 4h and reaction mixture placed under stream of air to remove TFA. The crude product was purified by preparative RP HPLC to afford Compound K (13 mg, 97 %, purity: 99%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC- MS elution using elution method 1; retention time: 2.89 min; MS (positive ESI): found m/z 1009.0 [M+H]+; C48H70N11O13 (calc. 1008.5). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C48H70N11O131008.5149; Found 1008.5157.1H NMR (700 MHz, DMSO-d6) į 13.14 (br s, 2H), 10.71 (br s, 1H), 9.84 (s, 1H), 8.95 (t, J = 5.9 Hz, 1H), 7.93 (br s, 1H), 7.29 – 7.24 (m, 4H), 6.58 (s, 1H), 6.57 (s, 1H), 6.36 (s, 1H), 3.92 (d, J = 12.9 Hz, 2H), 3.29 – 3.20 (m, 1H), 3.19 – 3.13 (m, 2H), 3.07 (d, J = 5.6 Hz, 6H), 2.93 – 2.87 (m, 1H), 2.61 – 2.53 (m, 4H), 2.42 – 2.33 (m, 3H), 2.00 – 1.83 (m, 2H), 1.71 – 1.64 (m, 1H), 1.56 (app. dd, J = 13.3, 3.6 Hz, 2H), 1.09 – 1.05 (m, 1H), 1.03 (t, J = 7.2 Hz, 3H), 0.80 (d, J = 6.8 Hz, 6H). *Protons obscured by H2O and DMSO not reported.
Example 12: Synthesis of 2,2',2''-(10-((R)-1-Carboxy-4-(((S)-4-carboxy-1-((2-(4-(4-(3-(2,4- dihydroxy-5-isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)- 2-oxoethyl)amino)-1-oxobutan-2-yl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyl)triacetic acid (Compound L) O OtBu N O N O NH•HCl O N N OtBu Ot N Bu BuOt N O N O O N HBTU, DIPEA, DMF HO O HO N OtBu HO O N N N BuOt Step 1 OH N N H N O N N H OH Intermediate 1-C Intermediate 12-A O OH N O N O N N N OH TFA:TIPS:H2O 95:2.5:2.5 HO 37 °C O Step 2 HO O N N N N H OH Compound L Step 1: Synthesis of tri-tert-Butyl 2,2',2''-(10-(2-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2-oxoethyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetate (Intermediate 12-A) To a 20 mL scintillation vial with a stir bar was added 2-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)- 1,4,7,10-tetraazacyclododecan-1-yl)acetic acid, DOTA-tris(tBu)ester, (20.2 mg, 0.04 mmol, 1 equiv.) and DMF (2 mL). The reaction mixture was cooled to 0 °C and DIPEA, (25 μL, 18.2 mg, 0.14 mmol, 4 equiv.), followed by HBTU, (13.6 mg, 0.04 mmol, 1 equiv.) was added and stirred for 10 min at 0 °C. The solution was brought to RT and stirred for 15 min and then Intermediate 1-C (18 mg, 0.04 mmol, 1 equiv.) was added as a solid. Stirred at RT and reaction monitored by HPLC-MS. The reaction was stopped after 4 h and solvent evaporated under vacuum to give the
crude product, which was purified by RP chromatography to afford Intermediate 12-A (38 mg, 73%, purity: 85%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 2; retention time: 2.44 min; MS (positive ESI): found m/z 1018.0 [M+H]+; C54H84N9O10 (calc.1018.6). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C54H84N9O10 1018.6336; Found 1018.6345.1H NMR (700 MHz, DMSO-d6) į 9.88 (br s, 1H), 8.96 (t, J = 5.9 Hz, 1H), 7.34 (br s, 1H), 7.30 (d, J = 8.0 Hz, 2H), 7.26 (d, J = 8.0 Hz, 2H), 6.55 (s, 1H), 6.37 (s, 1H), 4.32 (d, J = 12.8 Hz, 1H), 4.13 (br s, 5H), 3.67 – 3.62 (m, 2H), 3.16 (p, J = 6.9 Hz, 2H), 3.08 – 3.00 (m, 1H), 2.98 – 2.86 (m, 3H), 2.65 – 2.53 (m, 3H), 1.86 – 1.78 (m, 1H), 1.70 (d, J = 12.6 Hz, 1H), 1.62 (d, J = 12.6 Hz, 1H), 1.52 – 1.35 (m, 32H), 1.23 (t, J = 10.4 Hz, 1H), 1.06 (d, J = 10.4 Hz, 1H), 1.03 (t, J = 7.2 Hz, 3H), 0.78 (dd, J = 7.0, 3.2 Hz, 6H). Protons obscured by H2O and DMSO not reported. Step 2: Synthesis of 2,2',2''-(10-(2-(4-(4-(3-(2,4-Dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-2-oxoethyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound L) To a 20 mL scintillation vial with a stir bar was added Intermediate 12-A (25 mg, 21μmol) and 2.5 mL of deprotection cocktail TFA:TIPS:H2O - 95:2.5:2.5 (v/v/v) at RT. The reaction was brought to 37 °C by placing on a pre-heated oil bath at 37 °C and monitored by HPLC-MS. The reaction was stopped after 2h 30min and the reaction mixture was placed under stream of air to remove TFA. The crude product was purified by preparative RP HPLC to afford Compound L (11 mg, 48 %, purity: 99%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC- MS elution using elution method 1; retention time: 2.78 min; MS (positive ESI): found m/z 850.0 [M+H]+; C42H60N9O10 (calc.850.4). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C42H60N9O10 850.4458; Found 850.4456. 1H NMR (700 MHz, DMSO-d6) į 12.95 (br s, 2H), 9.85 (br s, 1H), 8.96 (t, J = 5.9 Hz, 1H), 7.77 (br s, 1H), 7.31 – 7.25 (m, 4H), 6.57 (s, 1H), 6.36 (s, 1H), 4.39 – 4.01 (m, 6H), 3.59 (d, J = 13.3 Hz, 1H), 3.39 (br s, 8H), 3.19 – 3.13 (m, 2H), 3.09 (d, J = 17.5 Hz, 2H), 2.99 – 2.87 (m, 2H), 2.68 – 2.55 (m, 3H), 1.85 – 1.79 (m, 1H), 1.68 – 1.63 (m, 2H), 1.28 – 1.21 (m, 1H), 1.16 – 1.09 (m, 1H), 1.04 (t, J = 7.2 Hz, 3H), 0.81 (d, J = 6.9 Hz, 6H). *Protons obscured by H2O and DMSO not reported.
Example 13: Synthesis of (R)-2,2',2''-(10-(1-Carboxy-4-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-4-oxobutyl)- 1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound M) BuO t O O BuOt N N O N N OtBu NH.HCl N BuO t O O O O OtBu BuOt N N HBTU, DIPEA, DMF OHO HN N N OtBu Step HO O N HO 1 N O O tBu N N N O O OH H OH N N Intermediate 1-C Intermediate 13-A HO O O HO N N O N N OH N O TFA:TIPS:H2O 95:2.5:2.5 O OH 37 °C Step 2 HO O N N N N H OH Compound M Step 1: Synthesis of tri-tert-Butyl 2,2',2''-(10-(1-(tert-butoxy)-5-(4-(4-(3-(2,4-dihydroxy-5- isopropylphenyl)-5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-1,5- dioxopentan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)(R)-triacetate (Intermediate 13- A) To a 20 mL scintillation vial with a stir bar was added (R)-DOTAGA(tBu)4 (15 mg, 0.02 mmol, 1 equiv.), followed by THF (0.9 mL) and DMF (0.1 mL). The reaction mixture was cooled to 0 °C and DIPEA, (11.3 μL, 8.4 mg, 0.06 mmol, 3 equiv.) and HBTU, (11 mg, 0.03 mmol, 1.3 equiv.) were added and stirred for 10 min at 0 °C. The solution was brought to RT and stirred for 15 min and then Intermediate 1-C (12 mg, 0.02 mmol, 1 equiv.) was added as solution in THF (0.4 mL) and DMF (0.3 mL) along with 5 μL DIPEA. The reaction was stirred at RT and was monitored by HPLC-MS. The reaction was stopped after 2h and solvent was evaporated under vacuum to give the crude product, which was purified by RP chromatography to afford Intermediate 13-A
(8.6 mg, 33%, purity: 96%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC- MS elution using elution method 2; retention time: 2.64 min; MS (positive ESI): found m/z 1146.5 [M+H]+; C61H96N9O12 (calc. 1146.7). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C61H96N9O121146.7173; Found 1146.7145. 1H NMR (700 MHz, DMSO-d6) į 10.67 (br s, 2H), 9.80 (br s, 1H), 8.96 (t, J = 6.5 Hz, 1H), 7.31 – 7.23 (m, 5H), 6.56 (d, J = 4.0 Hz, 1H), 6.36 (d, J = 2.3 Hz, 1H), 4.36 (s, 3H), 3.90 – 3.78 (m, 4H), 3.72 (br s, 2H), 3.18 – 3.13 (m, 3H), 3.06 (br s, 5H), 2.94 – 2.86 (m, 4H), 2.77 (br s, 3H), 2.58 – 2.54 (m, 2H), 1.96 – 1.87 (m, 2H), 1.84 – 1.73 (m, 3H), 1.68 – 1.59 (m, 3H), 1.51 – 1.37 (m, 38H), 1.03 (t, J = 7.2 Hz, 3H), 0.80 (app. dd, J = 6.9, 2.7 Hz, 6H). *Protons obscured by H2O and DMSO not reported Step 2: Synthesis of (R)-2,2',2''-(10-(1-Carboxy-4-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-4-oxobutyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound M) To a 20 mL scintillation vial with a stir bar was added Intermediate 13-A (7 mg, 0.01 μmol) and 0.6 mL of deprotection cocktail TFA:TIPS:H2O - 95:2.5:2.5 (v/v/v) DW^^^^^^After 5 min the reaction was brought to RT and was monitored by HPLC-MS. The reaction was stopped after 18h and reaction mixture was placed under stream of air to remove TFA. The crude product was purified by preparative RP HPLC to afford Compound M (4.3 mg, 79%, purity: 99%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 2.83 min; MS (positive ESI): found m/z 922.2 [M+H]+; C45H64N9O12 (calc. 922.5). HRMS (ESI-TOF) m/z: [M - H]- Calcd for C45H62N9O12920.4523; Found 920.4518.1H NMR (700 MHz, DMSO-d6) į 9.80 (br s, 1H), 8.96 (t, J = 5.9 Hz, 1H), 7.27 (d, J = 4.1 Hz, 4H), 6.57 (s, 1H), 6.35 (s, 1H), 4.36 (t, J = 14.6 Hz, 2H), 3.89 – 3.77 (m, 5H), 3.19 – 3.13 (m, 5H), 3.07 (s, 1H), 2.98 – 2.87 (m, 6H), 2.63 – 2.52 (m, 5H), 1.92 (s, 1H), 1.81 – 1.75 (m, 2H), 1.66 (d, J = 12.6 Hz, 1H), 1.61 (d, J = 12.6 Hz, 1H), 1.15 – 1.12 (m, 1H), 1.03 (t, J = 7.2 Hz, 3H), 1.02 – 0.97 (m, 2H), 0.81 (d, J = 6.8 Hz, 6H). *Protons obscured by H2O and DMSO not reported. Example 14: Synthesis of (R)-2,2',2''-(10-(4-(4-(4-(3-(2,4-bis(Benzyloxy)-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-1-carboxy-4-oxobutyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound N)
BuO t O O BuOt N N NH•HCl O BuO t O N OtBu O N N O BuOt N N HBTU, DIPEA, DMF O OtBu O N BnO N N OtBu H HO Step 1 N O O O OtBu BnO O N N N OBn N N N H OBn Intermediate 2-B Intermediate 14-A HO O O HO N N O N N OH N O TFA:TIPS:H2O 95:2.5:2.5 O OH 37 °C Step 2 BnO O N N N N H OBn Compound N Step 1: Synthesis of tri-tert-Butyl 2,2',2''-(10-(5-(4-(4-(3-(2,4-bis(benzyloxy)-5-isopropylphenyl)- 5-(ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-1-(tert-butoxy)-1,5-dioxopentan- 2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)(R)-triacetate (Intermediate 14-A) To a 20 mL scintillation vial with a stir bar was added (R)-DOTAGA(tBu)4 (24.5 mg, 0.03 mmol, 1 equiv.) and 2 mL DMF. The reaction mixture cooled to 0 °C and DIPEA, (30.3 μL, 22.5 mg, 0.17 mmol, 5 equiv.), followed by HBTU, (13.5 mg, 0.03 mmol, 1 equiv.) were added and stirred for 15 min at 0 °C. The solution was brought to RT and stirred for 15 min and then Intermediate 2-B (23 mg, 0.03 mmol, 1 equiv.) was added as a solid. The reaction was stirred at rt and was monitored by HPLC-MS. The reaction was stopped after 16 h and solvent was evaporated under vacuum to give the crude product, which was purified by RP chromatography to afford Intermediate 14-A (47 mg, 83%, purity: 95%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 6.31 min; MS (positive ESI): found m/z 1327.0 [M+H]+; C75H108N9O12 (calc.1326.8). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C75H108N9O121326.8112; Found 1326.8142.1H NMR (700 MHz, DMSO- d6) į 8.98 (td, J = 6.1, 2.6 Hz, 1H), 7.41 – 7.38 (m, 4H), 7.38 – 7.30 (m, 5H), 7.28 – 7.24 (m, 2H), 7.08 (dd, J = 15.5, 8.0 Hz, 2H), 7.04 – 6.98 (m, 3H), 6.78 (s, 1H), 5.08 (s, 2H), 4.97 (s, 2H),
4.34 – 4.30 (m, 1H), 3.91 – 3.65 (m, 3H), 3.28 (br s, 1H), 3.20 – 3.15 (m, 2H), 3.14 – 3.00 (m, 2H), 2.94 – 2.85 (m, 1H), 2.79 – 2.63 (m, 2H), 2.49 – 2.41 (m, 2H), 1.77 – 1.70 (m, 1H), 1.60 – 1.51 (m, 2H), 1.47 (br s, 11H), 1.43 – 1.34 (m, 25H), 1.05 (t, J = 7.2 Hz, 3H), 1.02 – 0.99 (m, 6H), 0.97 – 0.90 (m, 1H). *Protons obscured by H2O and DMSO not reported. Step 2: Synthesis of (R)-2,2',2''-(10-(4-(4-(4-(3-(2,4-bis(Benzyloxy)-5-isopropylphenyl)-5- (ethylcarbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)-1-carboxy-4-oxobutyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound N) To a 20 mL scintillation vial with a stir bar was added Intermediate 14-A (25 mg, 18.65 μmol, 1 equiv.) and 2.5 mL of deprotection cocktail TFA:TIPS:H2O - 95:2.5:2.5 (v/v/v) at RT. The reaction was brought to 37 °C by placing on a pre-heated oil bath at 37 °C and monitored by HPLC-MS. The reaction was stopped after 2h30min and the reaction mixture was placed under stream of air to remove TFA. The crude product was purified by preparative RP HPLC to afford Compound N (15 mg, 60%, purity: 99%) as a white solid as the TFA salt. An aliquot was analyzed by HPLC-MS elution using elution method 1; retention time: 4.37 min; MS (positive ESI): found m/z 1102.2 [M+H]+; C59H76N9O12 (calc. 1102.6). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C59H76N9O121102.5608; Found 1102.5624.1H NMR (700 MHz, DMSO-d6) į 13.16 (br s, 2H), 8.98 (t, J = 5.9 Hz, 1H), 7.40 – 7.38 (m, 4H), 7.37 – 7.30 (m, 4H), 7.25 (dd, J = 7.0, 1.7 Hz, 2H), 7.09 (dd, J = 8.5, 2.5 Hz, 2H), 7.03 (d, J = 1.6 Hz, 1H), 6.99 (dd, J = 8.4, 2.3 Hz, 2H), 6.77 (s, 1H), 5.08 (s, 2H), 4.95 (app. d, J = 2.9 Hz, 2H), 4.41 – 4.26 (m, 1H), 3.90 – 3.85 (m, 15H), 3.79 (t, J = 15.0 Hz, 1H), 3.56 – 3.24 (m, 5H), 3.21 – 3.14 (m, 2H), 3.14 – 3.06 (m, 1H), 2.96 – 2.86 (m, 2H), 2.62 – 2.54 (m, 1H), 2.50 – 2.41 (m, 2H), 1.99 – 1.84 (m, 1H), 1.77 – 1.69 (m, 1H), 1.58 (d, J = 12.3 Hz, 1H), 1.52 – 1.49 (m, 1H), 1.11 – 1.07 (m, 1H), 1.05 (t, J = 7.2 Hz, 3H), 1.01 (d, J = 6.9 Hz, 6H), 0.98 – 0.90 (m, 1H). *Protons obscured by H2O and DMSO not reported. Example 15: Method for Radiolabeling Disclosed Compounds Prior to radiolabeling, a stock solution of each Compound was made by dissolving the appropriate quantity of Compound in sodium acetate buffer. Ethanol may be added up to 10% by volume to improve solubility of the compounds. A 1.5 mL Eppendorf tube was charged with the
desired Compound followed by sodium acetate buffer to raise the total volume as desired (0.05- 0.5 mL). Next, a solution of [177Lu]LuCl3 or [111In]InCl3 or [225Ac]AcNO3 (or [225Ac]AcCl3) in hydrochloric acid solution was added and the mixture was heated. After heating the reaction for a desired amount of time, iTLC analysis of the reaction mixture (solid phase: Silica gel (SG) or silicic acid (SA) plate; mobile phase: 0.02 M citrate buffer with 5 % MeOH) indicated an acceptable radiochemical conversion (RCC), typically >95%. To the reaction mixture, sodium acetate buffer solutions of sodium L-ascorbate and diethylenetriamine-pentaacetic acid calcium trisodium salt hydrate (DTPA) were added. iTLC and reverse phase HPLC (elution method 5) at end-of-synthesis (EOS) indicated the formation of the desired radiolabeled products in typically >95% radiochemical purity (RCP). Table 1: Radiolabeling of Compounds with [177Lu]LuCl3. Compound RCP of 177Lu-Compound at EOS Compound A >99% Compound B 99% Compound C 95% Compound D >99% Compound E >99% Compound F >99% Compound G >99% Compound H >99% Compound I >99% Compound J 98% Compound K >99% Compound L >99% Compound M >99% Compound N >99%
Table 2: Radiolabeling of Compounds with [111In]InCl3. Compound RCP of 111In-Compound at EOS Compound A >99% Compound B 97% Compound C 90% Compound D >99% Compound G >99% Compound M >99% Table 3: Radiolabeling of Compounds with [225Ac]. Compound RCP of 225Ac-Compound at EOS Compound A 98% Compound D >99% Compound G >99% Below shows the sample radiolabeling of a Compound featuring a DOTAGA chelator with [177Lu]LuCl3, [111In]InCl3, or [225Ac] . O O OH H O O N O N N O O H N N O OH HO N N M3+ O HO Compound D O Sodium acetate buffer HO HN N O OH N N
O O O H O O N O N N O O H N N O O M O N N Na O O O HO HN N O N N M = 225Ac : 225Ac-Compound D OH M = 111In : 111In-Compound D M = 177Lu : 177Lu-Compound D Below shows the sample radiolabeling of a Compound featuring a DOTA chelator with [177Lu]LuCl3, [111In]InCl3, or [225Ac] . O O OH O N N O N O O M N O N N N N HO M3+ N N O HO O Sodium acetate buffer O O HO HN HO HN N N O O OH N N OH N N M = 225Ac : 225Ac-Compound L Compound L M = 111In : 111In-Compound L M = 177Lu : 177Lu-Compound L Example 16: In Vitro HSP90 Binding Studies of Radiopharmaceuticals Comprising Compounds of Formula I HSP90 binding was determined using a cell-free binding affinity assay, where recombinant HSP90 protein was coated onto a Reacti-Bind® microtiter plate. Plates were incubated at 4 °C overnight and then washed 3 times with cold PBS containing 0.05% Tween-20 (PBS-T). Plates were equilibrated to room temperature, blocked for 1 hour on ice with PBS-T containing 0.2% gelatin, followed by 3 washes with PBS-T. Radiolabeled (Lu-177) conjugates with increasing concentrations were incubated in the absence or presence of unlabeled conjugate,
and incubated at 37 °C for 1 hour with gentle shaking. Wells were then rinsed three times with PBS-T and stripped with a solution of 20 mM sodium acetate, pH 3.0 for up to 20 minutes at room temperature, followed by neutralization with an equal amount of 0.1N NaOH solution. Samples were transferred into gamma counting tubes and analyzed for Lu-177 content by gamma counter. Results were plotted relative to molar concentration of labeled conjugate, where specific binding affinity (Kd) is calculated using Graph Pad Prism. Binding affinity (Kd) results are summarized in Table 4^^ZKHUH^^^Q0^^^$^^^5 nM, ^^Q0^^^%^^^^^^^Q0^^DQG^C > 100 nM. Table 4: Binding affinities (Kd^^RI^VHOHFWHG^FRPSRXQGV^WR^UHFRPELQDQW^+VS^^Į^RU^ȕ^ isoforms. Compound Kd (nM) +VS^^Į +VS^^ȕ Compound A A A Compound B A A Compound C A A Compound D A A Compound E A A Compound F A A Compound G A A Compound H A A Compound I A B Compound J A A Compound K A A Compound L A A Compound M A A Compound N C C Example 17: Biodistribution Studies of Radiopharmaceuticals Comprising Compounds of Formula I In an animal model, Lutetium-177 (Lu-177) or Indium (In-111) accumulation was measured in tumor, blood and healthy tissues of subcutaneous xenograft tumor-bearing mice. Tumor bearing mice were GRVHG^ZLWK^^^^^&L^RI^HLWKHU^/X-177 or In-111 conjugates. At the time points indicated (1h, 4h, 24h), mice were sacrificed, and tumor, liver, kidneys and blood were
isolated. All tissues were analyzed for Lu-177 or In-111 content by gamma counter, and radioligand uptake was determined as percentage injected dose per gram of tissue (%ID/g). Average radioligand uptake (%ID/g, n = 3) is summarized in Table 5. Table 5. Biodistribution of selected compounds in tumor-bearing mice. Compound BioD (%ID/g) Lu-177 or In- 1h 4h 24h 111 tumor blood liver kidney tumor blood liver kidney tumor blood liver kidney Compound A 14.60 13.93 5.01 6.47 20.85 6.70 6.44 8.47 14.98 0.52 2.81 5.55 Compound B 12.97 15.33 7.38 7.28 10.41 7.80 7.25 6.34 5.59 0.37 1.38 0.87 Compound C 7.37 17.08 4.50 7.50 11.51 11.95 5.48 7.83 5.74 0.84 2.19 2.31 Compound D 9.22 16.35 7.43 9.41 13.01 9.40 7.69 10.91 10.19 0.48 3.43 6.06 Compound G 6.74 10.45 17.19 8.00 5.71 5.25 18.43 7.56 6.37 0.25 5.82 5.68 Compound I 16.19 10.09 10.47 8.31 16.46 3.40 10.08 8.87 10.15 0.20 3.16 6.05 Compound L 4.82 7.68 32.84 5.35 5.42 0.73 39.74 3.65 3.25 0.18 10.38 2.57 Example 18: In Vivo Studies of Radiopharmaceuticals Comprising Compounds of Formula I Using an in vivo model, overall survival and tumor growth regression in HSP90 expressing xenograft tumor-bearing mice was evaluated to determine the in vivo efficacy of the compounds of Formula I. Mice implanted with HSP90 expressing xenograft tumors were treated with various concentrations and doses of the compounds of Formula I to evaluate in vivo efficacy. To determine the most effective dose range, preclinical dose escalation studies were conducted. Average tumor growth suppression (n = 5 animals/group) in response to a dose escalation of 225Ac-Compound D in comparison to vehicle (buffer control) and non-radiolabeled Compound D is presented in Figure 1. It was observed that 225Ac-Compound D administered at 3 μCi was efficacious in significantly suppressing the tumor growth. OTHER EMBODIMENTS [158] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described herein. Such equivalents are intended to be encompassed by the following claims.
Claims
WHAT IS CLAIMED IS: 1. A compound of Formula I, or a pharmaceutically acceptable salt thereof: Z1 X N Y Z2 n W HO HN N O N N OH (I), wherein X is absent, C=O, or (C=O)NR1, R1 being H, alkyl, aryl, (C-CF3)R2 or (SO2)R2, R2 being alkyl or aryl; Y is each independently O or NR3, R3 being H, alkyl, aryl, or acyl; n is an integer of 0-5 (inclusive); Z1 and Z2 each are, independently, absent, an amino acid unit, (C=O)NR4(CH2CH2)O, or (C=O)NR4(CH2CH2)NR5, in which each of R4 and R5 independently is H or alkyl or (C-CF3)R6 or (SO2)R6, R6 being alkyl or aryl; and W is a chelator selected from the group consisting of DOTA, DOTAGA, NOTA, and NODAGA, wherein when W is DOTA, at least one of Z1 and Z2 is an amino acid unit, or each of Z1 and Z2 is absent and n is equal to or less than 4, wherein the compound binds to HSP90, wherein the compound optionally further comprises a radionuclide chelated by the chelator thereof.
2. The compound of claim 1, having the structure of Formula II: O HO O N N HO O Z1 OH X N N N Y Z2 n O O OH HO HN N O N N OH (II), wherein each of X, Y, n, Z1, and Z2 is as defined in claim 1.
3. The compound of claim 1 or 2, wherein at least one of Z1 and Z2 is an amino acid unit. 4. The compound of any one of claims 1-3, wherein the amino acid unit is formed from glycine (Gly), aspartic acid (Asp), glutamic acid (Glu), 2,
4-diaminobutyric acid (Dab), 2,3-diaminopropionic acid (Dap), lysine (Lys), arginine (Arg), or combination thereof.
5. The compound of any one of claims 1-4, wherein the amino acid unit comprises an organic moiety formed from Asp.
6. The compound of claim 1 or 2, wherein X is C=O.
7. The compound of claim 1 or 2, wherein n is 4 or 5.
8. The compound of claim 1 or 2, wherein each of Z1 and Z2 is absent.
9. The compound of claim 1 or 2, wherein X is absent, n is 0, Z1 is absent, and Z2 is an amino acid unit.
10. The compound of claim 1 or 2, wherein X is C=O, n is 4 or 5, Z1 is an amino acid unit, and Z2 is absent.
11. The compound of claim 1 or 2, wherein X is C=O, n is 4 or 5, Z1 is absent, and Z2 is an amino acid unit.
12. The compound of claim 1 or 2, wherein X is (C=O)NH, n is 4 or 5, each of Z1 and Z2 is absent.
13. The compound of claim 1 or 2, wherein X is C=O, n is 4 or 5, Z1 is absent, and Z2 is (C=O)NH(CH2CH2)NH.
14. The compound of claim 1 or 2, wherein X is absent, n is 0, each of Z1 and Z2 is absent.
15. The compound of claim 1 or 2, wherein the compound is one of the following: O HO O N N HO O O OH O O N N N O O N H O O OH HO HN N O N N OH ,
HO O O N N HO O H O OH (S) N O O N N N O N H O O CO2H O OH HO HN N O N N OH , HO O O N N HO O H O OH (S)N O O N N N O N H O O CO2 H HO HN N O N N OH , O HO O N N HO HO O 2 C O H OH O N N N N O O (S) N H O O O OH HO HN N O N N OH , O HO O N N H HO O O 2 C O H OH O N N N N O O (S) N H O O HO HN N O OH N N ,
O O OH H O O N O N N O O N N H O OH HO N N O HO O HO HN N O OH N N , O H O O O O O N N N H N N O OH HO N N O HO O HO HN N O OH N N , HO O O N N HO O H H O OH N O O N N N N O N O H O O OH HO HN N O OH N N , HO O O N N HO O H H O OH N N N N N O O O N O H O HO HN N O N N OH ,
O O OH H N O (S) N N N O OH CO2 H HO N N O HO O HO HN N O N N OH , O O H N OH (S) N N N O N CO2H HO N HO O O HO HN N O N N OH , O O HO HO O O N N N N HO HO O OH O OH N N N N N O N O O OH HO HN HO HN N N O O N N N N OH , and OH .
16. The compound of any one of claims 1-15, wherein the compound comprises a radionuclide selected from the group consisting of 43Sc, 44Sc, 47Sc, 55Co, 60Cu, 61Cu, 62Cu, 64Cu, 67Cu, 66Ga, 67Ga, 68Ga, 82Rb, 86Y, 87Y, 89Zr, 90Y, 97Ru, 99Tc, 99mTc, 105Rh, 109Pd, 111In, 117mSn, 133La, 134Ce, 149Pm, 149Tb, 153Sm, 152Tb, 155Tb, 161Tb, 166Ho, 177Lu, 186Re, 188Re, 198Au, 199Au, 201Tl, 203Pb, 211At, 212Pb, 212Bi, 213Bi, 223Ra, 225Ac, 227Th, and 229Th.
17. The compound of claim 16, wherein the radionuclide is selected from the group consisting of 68Ga, 89Zr, 90Y, 111In, 177Lu, and 225Ac.
18. The compound of claim 17, wherein the radionuclide is 177Lu or 225Ac.
19. The compound of any one of claims 1-18, wherein the compound bounds to extracellular HSP90 (eHSP90).
20. A pharmaceutical composition comprising a compound of any one of claims 1–19 and a pharmaceutically acceptable excipient.
21. A method of treating cancer, wherein the method comprises administering to a subject in need thereof a compound of any one of claims 1–19 or the composition of claim 20 in a therapeutically effective amount.
22. The method of claim 21, wherein the cancer is small-cell lung cancer, non- small-cell lung cancer, sarcoma, pancreatic cancer, breast cancer, or colon cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263401227P | 2022-08-26 | 2022-08-26 | |
US63/401,227 | 2022-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024044755A2 true WO2024044755A2 (en) | 2024-02-29 |
Family
ID=90014114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/072918 WO2024044755A2 (en) | 2022-08-26 | 2023-08-25 | Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024044755A2 (en) |
-
2023
- 2023-08-25 WO PCT/US2023/072918 patent/WO2024044755A2/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111263747A (en) | Bifunctional chelate pharmacokinetics enhancement and uses thereof | |
AU2018200419A1 (en) | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
CN111182927B (en) | PSMA ligands for imaging and intracavity radiation therapy | |
CN111741751A (en) | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents targeting prostate cancer | |
CN110891614A (en) | IGF-1R monoclonal antibody and application thereof | |
CN113474014A (en) | Combination therapy of radioimmunoconjugates with inhibitors of DNA damage and repair | |
JP2009500410A (en) | Hydrazide conjugates as imaging agents | |
JP5557425B2 (en) | Improved N4 chelator conjugate | |
TW202140432A (en) | Macrocyclic chelates and uses thereof | |
KR20230162589A (en) | Dual-mode radioactive tracers and -therapeutics | |
TWI381852B (en) | Biotin diaminoderivatives and their conjugates with macrocyclic chelating agents | |
WO2024044755A2 (en) | Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof | |
JP2024506700A (en) | CXCR4-ligands and their precursors for diagnostic and therapeutic use | |
TW202416974A (en) | Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof | |
JP2024517971A (en) | Radiopharmaceutical somatostatin receptor ligands and their precursors. | |
CN115315274A (en) | Radioimmunoconjugates targeting FGFR3 and uses thereof | |
TW200936169A (en) | N-alkoxyamide conjugates as imaging agents | |
WO2023164777A1 (en) | Gucy2c-targeted radiopharmaceuticals and use thereof | |
TW201919682A (en) | Novel compounds activating the Nrf2 pathway | |
RU2807076C2 (en) | Psma ligands for imaging and endoradiotherapy | |
WO2023141719A1 (en) | Psma-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy | |
WO2024064968A1 (en) | Fibroblast activation protein (fap) inhibitors, fap conjugates, and diagnostic and therapeutic uses thereof | |
WO2024023332A1 (en) | Silicon-based fluoride acceptor groups for radiopharmaceuticals | |
CN113557037A (en) | Radiopharmaceuticals for diagnostic/therapeutic use in nuclear medicine and radiation guided medicine | |
KR20230082178A (en) | Composition for photodynamic therapy for HER2-expressing cancer and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23858353 Country of ref document: EP Kind code of ref document: A2 |